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The opportunistic pathogen Clostridium difficile is the most common cause of antibiotic-associated 
diarrhoea, with severity of disease ranging from mild diarrhoea to fulminant pseudomembranous 
colitis and death. It poses a major burden on healthcare providers, costing millions of pounds each 
year due to ward closures, isolation measures and prolonged illness. The current antibiotic therapy 
for C. difficile infection is effective, but high rates of relapse lead to ongoing misery for patients 
and spiralling costs for healthcare providers. Novel therapeutics for C. difficile are therefore 
desperately sought, and the antibiotic-induced nature of the disease has led to interest in 
development of non-antibiotic therapies. 
Sortase enzymes are responsible for covalent anchoring of specific proteins to the peptidoglycan of 
the cell wall of gram-positive bacteria. Following the discovery that the Sortase A enzyme of 
Staphylococcus aureus is essential for pathogenesis, sortase inhibitors are under investigation as 
novel therapeutics. Being ubiquitous in gram-positive bacteria, it is likely that other gram-positive 
pathogens require sortase enzymes for their pathogenesis and may be targets for development of 
sortase inhibitors. 
This work describes a characterisation of the sortase enzyme of C. difficile. To provide evidence 
for a role of the sortase in the cell wall biogenesis, a C. difficile sortase knockout strain was 
constructed by intron mutagenesis. Characterisation of this mutant led to the discovery that the 
putative adhesin CD0386 is anchored to the peptidoglycan of C. difficile by the sortase SrtB. To 
provide structural insight into the catalytic mechanism of the C. difficile sortase, an active site 
mutant was crystallised and its structure solved to 2.55Å by X-ray diffraction. The wall-linked 
protein CD0386 was also crystallised and subject to successful test diffraction. Analyses of SrtB 
reaction products by chromatography and mass spectroscopy indicate that the enzyme cleaves an 
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Chapter 1 – Introduction to Clostridium difficile 
1.1.1 Introduction to Clostridium difficile 
Clostridium difficile is an obligately anaerobic Gram-positive bacterium that exhibits a rod-shaped 
vegetative cell morphology and forms cylindrical endospores (Figure 1.1.1).  It was first isolated 
from the faeces of healthy infants and originally named Bacillus difficilus due to difficulties that 
early investigators encountered in its isolation (Hall and O’Toole, 1935). The toxigenic nature of C. 
difficile was rapidly identified in initial studies - in guinea pigs, culture filtrates caused 
subcutaneous oedema, convulsions and death. Despite its apparent lethality, the newly discovered 
organism was isolated from healthy subjects and did not appear to be a human pathogen, so with 
the exception of sporadic reports of its isolation (Smith and King, 1962), the bacterium received 








Figure 1.1.1 – Clostridium difficile. (A) Transmission electron microscopy of C. difficile reveals a 
rod-like morphology with peritrichous flagella (B) Scanning electron micrograph of highly purified 
C. difficile endospores (Images courtesy of Electron Microscopy Unit, Public Health England 
(PHE) Porton). 
This period of relative obscurity came to an end in the mid-1970s, amidst anecdotal reports of 
pseudomembranous colitis (PMC) in patients undergoing therapy with clindamycin, a recently 
introduced lincosamide antibiotic (Fenton et al., 1974; Miller and Wheeler, 1975). These concerns 
led to Upjohn, the manufacturers of clindamycin, to fund a prospective study which found that of 
200 patients undergoing clindamycin therapy, 21% suffered diarrhoea and 10% suffered PMC 
(Tedesco et al., 1974).  
After establishing that clindamycin induced colitis was transferable in hamsters by passage of cecal 
contents even after removal of clindamycin, it was found that the agent causing disease could not 
B A 
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be filtered from the cecal contents with a 0.02µm filter but was successfully removed using a filter 
with a molecular weight limit of 10kDa (Bartlett et al., 1977). In addition, it was found that the 
cytopathic effect could be blocked by antiserum against Clostridium perfringens toxin. 
Concurrently, other groups examined the cytopathic effect of faecal extracts of clindamycin-
associated colitis patients, again implicating a heat labile toxin of >6 kDa which could be 
neutralised in vitro with antibodies against Clostridium sordellii toxin (Rifkin et al., 1977). Culture 
of Clostridium spp. from PMC patients resulted in isolation of several toxigenic Clostridium 
species, but C. difficile was the only species which produced the characteristic cytopathic effects in 
vitro (George et al., 1978). Thus, by the end of the 1970s, there was good evidence that antibiotic-
associated PMC was caused by a toxin or toxins secreted by C. difficile.  
1.1.2 Asymptomatic Carriage of C. difficile 
Carriage of C. difficile in infants and neonates is common, with estimates from single time point 
screening ranging from 2%  to 84% (Larson et al., 1982; Matsuki et al., 2005). In a longitudinal 
study of 10 healthy infants, all tested positive at some point during the one year study period, 
suggesting that colonisation with C. difficile may be a universal albeit transient phenomenon 
(Rousseau et al., 2012). Asymptomaticity is a notable characteristic of colonisation in early life 
despite detectable levels of toxin in the faeces (Stark et al., 1982). Carriage rate declines after the 
first year of life, but a small proportion (<10%) of adults are colonised (Loo et al., 2011; Miyajima 
et al., 2011), with much higher rates observed in certain populations such as those residing in long 
term elderly care facilities (Riggs et al., 2007). 
1.1.3 C. difficile disease and risk factors 
As an opportunistic pathogen, C. difficile can cause a wide spectrum of disease, ranging from mild 
diarrhoea and abdominal pain to pseudomembranous colitis (See Figure 1.1.2), bowel perforation, 
sepsis and toxic megacolon (Rupnik et al., 2009). Clostridium difficile Infection (CDI) is frequently 
fatal, with typically reported 30-day fatality rates in the range of 10-35% (Hota et al., 2012; Kotila 
et al., 2011). Definitive diagnosis of CDI is made by the detection of the presence of the classical 
C. difficile toxins TcdA and TcdB in the faeces. Historically this was performed by cytotoxicity 
testing, but is now routinely determined by imunosorbent assay (Kvach et al., 2010) or by detection 
of the tcdA and tcdB genes by nucleic acid amplification (De Jong et al., 2012). 
The transition of C. difficile from harmless commensal organism to lethal pathogen is thought to be 
due to changes in the normal colonic flora during antimicrobial chemotherapy, providing an 
ecological niche which is then exploited by C. difficile.  Although clindamycin was the antibiotic 










1998 meta-analysis of 49 studies, the third generation cephalosporins Cefotaxime, Ceftazidim, 
Cefoxitin and Cefuroxime all scored odds ratios for development of CDI higher than that of 
Clindamycin (Bignardi, 1998). An added difficulty with the use of cephalosporins is that in 
addition to disruption of the host gut flora, they have little effect on C. difficile itself, which appears 
to be universally resistant (Gerding, 2004). More recently, the use of fluoroquinolones, which was 
once considered low risk, has emerged as a risk factor of even greater significance than 
cephalosporins (McCusker et al., 2003). This  change in epidemiology has followed the emergence 
of strains with high levels of resistance to fluoroquinolones due to a single base substitution in the 
gyrA gene encoding DNA Topoisomerase IV, the target of quinolone antibiotics (Drudy et al., 
2007b) 
The effects of clindamycin treatment on the intestinal microbiota in mice and hamsters have been 
studied in depth with the use of metagenomic studies of 16S ribosomal RNA (16S rRNA) (Buffie et 
al., 2012; Peterfreund et al., 2012).  The overall 16S rRNA copy number observed in the ileum or 
cecum did not change after clindamycin administration in mice. Rather, there was a reduction in the 
number of unique 16S rRNA sequences, indicating a reduction in microbial diversity rather than a 
reduction in population. In particular, clindamycin treatment resulted in an almost complete 
obliteration of Bacteroides spp, Ruminococcus spp, and members of the Lachnospiraceae family. 
Expansions of population were observed in other bacterial species, reflected in the observation that 
overall 16S rRNA copy number was similar before and after clindamycin administration. Hence in 
mice, clindamycin causes changes in the intestinal microbiota rather than a reduction in numbers.  
Experiments in humans have demonstrated that clindamycin induces remarkably long-lasting 
changes in intestinal microbiota, with a reduction in Bacteriodes diversity even 24 months after 
treatment (Jernberg et al., 2007) 
Figure 1.1.2 - Gross and Microscopic Pathology of C. difficile Infection. A) Disruption of 
the epithelial layer resulting in ‘volcano-like’ microscopic lesions. B) Pseudomembranous 
lesions in the ascending colon visualised by colonoscopy (Rupnik et al., 2009). 
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Association of disease with advanced age is almost universal in epidemiological studies of CDI, 
with estimates of increased risk ranging from 2-4% per year after the age of 18 (Loo et al., 2011; 
Starr et al., 2003). The identification of gastric acid suppression by H2 receptor agonists or Proton 
Pump Inhibitors (PPIs) as a risk factor for CDI (Cunningham et al., 2003; Walker et al., 1993) has 
proven controversial, as some studies have found no statistically significant association (Pepin et 
al., 2005a). Meta analyses have, however, demonstrated that PPIs are likely to be a risk factor, with 
odds ratios ranging from 1.5 to 2.1 (Janarthanan et al., 2012; Kwok et al., 2012). C. difficile spores 
are capable of outgrowth in the gastric contents of patients undergoing therapy with PPIs, but only 
when supplemented with taurocholic acid and amino acids, so this is unlikely to occur in vivo 
(Nerandzic et al., 2009). In vitro, vegetative C. difficile cells are able to survive longer in the 
stomach contents of patients undergoing therapy with PPIs than those who are not – in some 
patients undergoing PPI treatment, the pH of the stomach contents was as high as pH7 and  survival 
of C. difficile in these conditions is not significantly different to survival in pH7 phosphate buffered 
saline (Jump et al., 2007).  Enhanced survival of vegetative cells in the stomach may therefore 
account for the increased risk of CDI due to acid suppression. 
1.1.4 Emergence of Hypervirulent/Epidemic C. difficile 
In the early 2000s, several retrospective studies uncovered significant changes in C. difficile 
epidemiology and worsening patient outcomes during the late 1990s (Dallal et al., 2002; Morris et 
al., 2002; Pepin et al., 2004). For example, in the study by Pepin et al. in Quebec, the proportion of 
patients who died within 30 days of diagnosis was 4.7% in 1991-92 but had risen to 13.8% in 2003. 
A detailed study of the Quebec outbreak identified the predominant strain as an 027 ribotype, and it 
was suggested that this strain may be a novel 'hypervirulent' type (Pepin et al., 2005b). Similar 
strains of ribotype 027 were isolated from patients in two prolonged and severe outbreaks of C. 
difficile at Stoke Mandeville hospital in the UK, where 498 people were infected and 117 died 
between April 2003 and March 2006 (Healthcare Commission, 2006). Surveillance in 2005 
revealed that 25% of cultures from symptomatic patients in England and Wales were ribotype 027, 
a figure which rose to 41% in 2007 (Brazier et al., 2008). As shown in Figure 1.1.3, a considerable 
increase in mortality from CDI was observed during this period. 
Although many authors frequently describe ribotype 027 strains as “hypervirulent” and state a link 
between ribotype 027 and increased severity of disease, not all of the evidence supports this 
assertion. For example, a retrospective case-matched study in the UK comparing 123 patients with 
027 or non-027 strains failed to find any association between 027 strains and increased severity 
(Morgan et al., 2008). Similar studies in the USA (Walk et al., 2012) and France (Sirard et al., 
2011) failed to find any association between disease severity and ribotype. Conversely, a study of 
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863 patients from across the Netherlands found that when compared with non-027 strains, ribotype 
027 were more likely to cause severe diarrhoea (22.4% vs. 13.9%)  and relapses were more 
common (20.6% vs. 14.9%) (Goorhuis et al., 2007). Given the undoubted success of ribotype 027 












Regardless of their in vivo virulence, 027 ribotype strains do exhibit in vitro characteristics which 
could account for hypervirulence. Most notable among these is increased toxin production, with 
epidemic 027 strains producing up to 16 times more toxin A and 23 times more toxin B than 
toxinotype 0 strains (Warny et al., 2005), a phenomenon discussed in Section 1.3.3. 
Several investigators have reported an increased rate of sporulation in epidemic 027 strains 
compared to non-027 (Akerlund et al., 2008; Merrigan et al., 2010). However, testing of a much 
larger sample of isolates found substantial variation in sporulation rate but no statistically 
significant association of high sporulation with epidemic 027 strains. Statistically significant 
diversity in sporulation rate was observed even within the group of epidemic 027 strains isolated 
within the UK (Burns et al., 2011, 2010) These results may indicate that previous findings of high 




Figure 1.1.3 – Deaths Attributed to C. difficile in England and Wales in 2001-2011.  
A significant peak in mortality was observed 2005-2010, concomitant with the 




1.2 – The C. difficile Cell Surface 
1.2.1 Overview of the C. difficile Cell Surface 
The surface of C. difficile is typical of a Gram-positive bacterium, composed of a lipid membrane, 
a substantial layer of peptidoglycan and an additional exterior proteinacous layer named the 
Surface or ‘S’ Layer (Figure 1.2.1). 
 
1.2.2 The Peptidoglycan of C. difficile 
A comprehensive analysis of the C. difficile peptidoglycan by mass spectroscopy of muramidase-
digested peptidoglycan fragments (Peltier et al., 2011), indicates the sequence of the tetrapeptide is  
L-Ala-D-Glu-A2pm-D-Ala, where A2pm is diaminopimelic acid (DAP). Of these tetrapeptides, 
41% are 3-3 linked (DAP to DAP, L,D transpeptidated) while 15% are 4-3 linked (D-ala to DAP 
D,D-transpeptidated). Diaminopimelic acid has two stereogenic centres and hence can exist in three 
stereoisomers, DD-, LL- and meso-. The chirality of the DAP in C. difficile peptidoglycan has not 
yet been determined empirically, but Peltier et al (2011) speculate that it likely to be meso- 
stereoisomer (mDap), based on the evidence that of the 32 Clostridium species previously 
examined, 28 contained the meso- stereoisomer (Schleifer and Kandler, 1972) including C. 
bifermentans and C. perfringens, which are considered the closest genetic relatives of C. difficile 
(Collins et al., 1994).  
 
Figure 1.2.1 – The C. difficile Cell 
Envelope. In common with many Gram 
Positive bacteria, C. difficile possesses 
an additional proteinaceous layer 
exterior to the peptidoglycan, named the 
surface layer (S layer), composed of a 
self-assembling paracrystalline array of 
high (HMW) and low (LMW) molecular 
weight SlpA interspersed with Cell Wall 




























A high level of N-deacetylation was observed in C. difficile peptidoglycan, specifically of N-
acetylglucosamine residues, with 93% of these bearing no acetyl group. Modification of sugars in 
this manner confers resistance to muramidases such as lysozyme and is generally considered a 
virulence factor (Boneca et al., 2007) 
1.2.3 The S-Layer of C. difficile 
In most species in which an S-layer has been characterised, the S-layer is composed of a single 
predominant protein. In some species, the S-layer is composed of two proteins but generally these 
proteins are encoded by separate genes. Bacillus anthracis for example, possesses two major SLPs 
named EA1 and Sap (Fouet et al., 1999). C. difficile is unusual in that it possesses two distinct S-
layer components, produced by the cleavage of a single precursor SlpA by the cysteine protease 
Cwp84 (Calabi et al., 2001; Kirby et al., 2009). The  SlpA cleavage products re-associate non-
covalently via the N terminus of the high molecular weight (HMW) fragment and the C terminus of 
the low molecular weight (LMW) fragment (Fagan et al., 2009), forming a crystalline array of 
equimolar quantities of the HWM and LWM proteins (Masuda et al., 1989). The HMW SlpA 
contains a predicted cell wall binding motif (Pfam motif PF04122), and it is therefore thought that 
the HMW component binds to the bacterial cell wall while the LMW SlpA forms the exterior of the 
array. This is confirmed by the observations that LMW SlpA is the immunodominant antigen 
recognised by convalescent sera so likely to be presented at the cell surface (Pantosti et al., 1989)  
Recombinant C. difficile SLPs bind to cultured human epithelial (HEP-2) cells, the epithelium and 
lamina propria of human colon tissues and several purified extracellular matrix components (Calabi 
et al., 2002). In addition, incubation of C. difficile cells with anti-HMW SLP antibodies results in a 
20-30% reduction in binding to HEP-2 cells. While this may indicate that the HMW is a 
physiologically relevant adhesin, the results must be interpreted with care as the surface of C. 
difficile is covered almost entirely in the HMW SLP and therefore binding of antibodies to HMW 
SLP may result in steric hindrance of other adhesins. 
1.2.4 The C. difficile Cell Wall Binding Domain (CWBD) Proteins 
The C. difficile genome encodes 28 proteins containing repeats of the Pfam motif PF04122, 
described as the cell wall binding domain (CWBD), a domain which is characteristic of the S-layer 
protein SlpA and is responsible for its surface localisation. 
Cwp84, the cysteine protease which cleaves SlpA, contains three repeats of the PF04122 motif and 
is expressed as a proenzyme and proteolytically processed to its active form (Chapetón Montes et 
al., 2011). It was originally thought that this cleavage may be an autocatalyic process similar to 
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other papain family enzymes, but mutation of the Cwp84 active site cysteine to alanine does not 
have any effect on its processing (de la Riva et al., 2011). Insertional inactivation of the closely 
homologous cwp19 gene, encoding another CWBD protein, does however result in a partial loss of 
Cwp84 processing. The residual processing of Cwp84 indicates that while Cwp19 may have a role 
in Cwp84 cleavage, either another protein must be involved or Cwp84 possesses catalytic activity 
independent of its putative papain-like active site. Cwp19 also exhibits some proteolytic activity 
towards SlpA, but this is insufficient to complement a cwp84 deficient mutant (de la Riva et al., 
2011) 
Several other CWBD proteins have been investigated experimentally and exhibit properties which 
may be linked to virulence. For example, the CWBD protein Cwp66 has been implicated in 
adhesion to mammalian cells (Waligora et al., 2001). The CWBD protein CwpV exhibits phase 
variable expression due to a genetic inversion (Emerson et al., 2009) and may therefore be 
involved in immune evasion, and although its function is currently unclear, it appears to promote 
aggregation in some C. difficile strains (Reynolds et al., 2011). 
1.3 – The C. difficile Toxins 
1.3.1 The Classical Toxins TcdA and TcdB 
The genes encoding the classical C. difficile toxins TcdA and TcdB are located in a 19kb element 
termed the pathogenicity locus (PaLoc). Both toxins have a domain structure comprising an N-
terminal glucosyltransferase domain, an autocatalytic cysteine protease domain, a translocation 
domain and a C-terminal receptor binding domain (Egerer et al., 2007).  
The binding domain of TcdA binds to gp96, a glycoprotein present on the surface of human 
colonocytes (Na et al., 2008), likely via a carbohydrate moiety (Teneberg et al., 1996). The 
receptor for TcdB remains unknown. Following cellular entry of TcdA and TcdB via clathrin 
mediated endocytosis (Papatheodorou et al., 2010) and in the low pH of the acidified endosome, 
structural changes within the translocation domain lead to the formation of channels in the 
membrane through which the glucosyltransferase and cysteine protease domains can pass (Barth et 
al., 2001; Giesemann et al., 2006). The cysteine protease domain is activated by binding of 
cytoplasmic inositol-6-phosphate (Egerer et al., 2009) and cleaves the toxin to release the 
glucosyltransferase domain into the cytoplasm while the binding and translocation domains remain 
membrane associated  (Pfeifer et al., 2003) 
Once in the cytoplasm, the glucosyltransferase domains of toxins TcdA and TcdB selectively O-
glucosylate threonine 37 of RhoA and the equivalent positions of the Rho family proteins Rac and 
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Cdc42, utilising UDP glucose as a cofactor. (Just et al., 1995a, 1995b). The resulting dysfunction in 
the cytoskeleton leads to cell death and disruption of the epithelium. Despite the structural 
homology of Toxins A and B, there are apparent differences in their activity and relative clinical 
importance, with disagreement between in vitro, in vivo and clinical data. The most definitive 
experiments investigating the relative effects of TcdA and TcdB have been enabled by the 
systematic generation of isogenic mutants which are either tcdA+ tcdB- or tcdA- tcdB+. In a 
hamster model, it was found that tcdA- tcdB+ mutants exhibited similar virulence to the tcdA+ 
tcdB+ wild type, whereas tcdA+ tcdB- mutants were significantly attenuated, with greater levels of 
survival and significantly longer time from colonisation to death in non survivors (Lyras et al., 
2009). That TcdB is not only essential but also sufficient for disease is supported by the observation 
that tcdA- tcdB+ strains are frequently isolated from CDI patients including in outbreaks (Alfa et 
al., 2000; Drudy et al., 2007a). However, an antibody protection study found that upon challenge 
with a tcdA+ tcdB+ strain, systemically delivered anti-TcdB antibodies did not offer any protection 
as would be expected if TcdB was essential for disease (Roberts et al., 2012). In conclusion, there 
remains conflicting evidence on the relative contributions to pathogenesis of the two classical 
toxins despite several investigations. 
1.3.2 The C. difficile Binary Toxin, Clostridium difficile Transferase 
The third C. difficile toxin, named Clostridium difficile Transferase (CDT) (Popoff et al., 1988) is a 
binary toxin encoded by the genes cdtA and cdtB, located outside of the PaLoc. CDT is a member 
of the family of binary actin ADP-ribosylating toxins including the C3 toxin from Clostridium 
botulinum, the iota toxin of Clostridium perfringens and the vegetative insecticide protein of 
Bacillus cereus. The proportion of strains which possess the cdtA and cdtB genes is relatively low -  
retrospective surveys of strain collections have revealed cdtAB gene carriage of between 6.4% and 
5.8% (Geric, 2004; Stubbs et al., 2000). Epidemic 027 strains are typically cdtAB
+
. (Stabler et al., 
2009) 
Assuming structural and functional homology with the other members of the family, CDTa is 
monomeric while CDTb forms heptamers on proteolytic activation (Barth et al., 2000). The 
holotoxin is endocytosed following binding of CDTb to the lipolysis stimulated lipoprotein 
receptor (Papatheodorou et al., 2011), following which acidification of the endosome induces 
conformational changes within the CDTb heptamer promoting membrane insertion and pore 
formation (Barth et al., 2000). The CDTa component then translocates through the pore and into 
the cytoplasm, where it ADP-ribosylates actin (Gülke et al., 2001) likely to be at arginine residue 
177 as is the case in C. botulinum C2 toxin and C. perfrignens iota toxin (Vandekerckhove et al., 
1988). ADP  ribosylation of this residue prevents incorporation of actin into actin filaments and 
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caps the barbed ends of actin filaments (Wegner and Aktories, 1988) leading to a shift in actin 
dynamics favouring depolymerisation. Application of CDT to cultured cells results in cell 
rounding, depolymerisation of actin and cell death (Perelle et al., 1997). In CaCo-2 colon 
carcinoma cells, disorder in microtubules has been observed, resulting in protrusions from the cell 
which increase the adherence of C. difficile in vitro (Schwan et al., 2009). 
The clinical relevance of CDT is still unclear. A small (n=26) case-control study (Barbut et al., 
2005) found that patients infected with cdtAB+ C. difficile strains suffered more severe disease 
than those with cdtAB 
-
 strains. A larger (n=131)  study (Barbut et al., 2007) also found association 
with greater severity and another (Goldenberg 2011, n = 207) found a significantly higher all-cause 
mortality at 30 days (31% vs 14%). However, none of these studies had sufficient sample size to 
conduct multivariate analysis – this is vital for a proper analysis because CDT carriage is clonal, 
requiring multivariate analysis to determine its independence from other strain dependent factors. 
1.3.3 Regulation of Toxin Production 
The PaLoc gene tcdR encodes a 22kDa lysine rich protein with homology to putative toxin 
regulators in C. botulinum and C. perfringens (Moncrief et al., 1997). Gel shift and in vitro 
transcription analysis revealed that TcdR does not bind directly to the PaLoc promoters , but is an 
alternate sigma factor, allowing the RNA polymerase complex to bind to and initiate transcription 
from the tcdA and tcdB promoters (Moncrief et al., 1997).  As a putative anti-sigma-factor, TcdC 
was suggested to be a negative regulator, antagonistic to TcdR. Accordingly, in C. perfringens, 
transcription of a fusion protein under the control of the C. difficile tcdA promoter is inhibited by 
the co-expression of TcdC. In the same work, in vitro expression experiments with E. coli RNA 
polymerase (RNAP) complexes confirmed that TcdC disrupts the interaction between the RNAP 
and TcdR, confirming its activity as an anti sigma factor (Matamouros et al., 2007). 
Early genomic characterisations of ribotype 027 strains revealed an 18bp deletion at position 330 of 
tcdC and a single base pair deletion at position 117, resulting in a frameshift and hence a truncation 
of TcdC (MacCannell et al., 2006). Based on the evidence of TcdC anti-sigma activity, it was 
therefore suggested that a deregulation of toxin production due to loss of functional TcdC was 
responsible for increased toxin production of epidemic 027 isolates. To investigate the role of the 
18bp deletion in tcdC observed in some strains, Carter and co-workers introduced a full length, 
functional tcdC from C. difficile VPI10463, a known high producer of toxin, into an 027 strain in 
trans (Carter et al., 2011). This resulted in a significant reduction in toxin titres and a reduction in 
virulence in a hamster model. 
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However, the restoration of functional tcdC in an 027 ribotype strain by allele exchange has no 
effect on toxin production (Cartman et al., 2012).  Similarly, when tcdC is inactivated in a non-027 
strain, only a modest increase in tcdRBEA transcription is observed, and there is no detectable 
increase in secreted toxins (Bakker et al., 2012).  While these results clearly cast doubt on the role 
of TcdC as a repressor of toxin production, it is possible that TcdC has a more specialised role in 
regulation, perhaps regulating toxin production in conditions not adequately replicated in the above 
experiments.   
Global regulation of the toxin production is linked to nutritional stress – transcription of toxin 
genes is low during exponential growth when nutrients are plentiful or when artificially repressed 
by glucose in vitro, and increases during the stationary phase as nutrients become scarce. This 
toxigenic response to nutritional stress is co-ordinated by the transcriptional regulator CodY, a 
transcriptional regulator whose affinity for its cognate promoters is modulated by the availability of 
branched chain amino acids, a proxy for nutritional sufficiency (Shivers and Sonenshein, 2004). In 
the absence of CodY, tcdRBEA transcription is increased between 51- and 174-fold (Dineen et al., 
2010).  
1.4 Current and Future Therapy of C. difficile disease 
1.4.1 Chemotherapeutics 
Vancomycin is considered the gold standard treatment for C. difficile. It is a glycopeptide produced 
by the bacterium Amycolatopsis orientalis and inhibits bacterial growth by binding to C-terminal 
D-ala-D-ala residues of peptidoglycan pentapeptides, preventing further transglycosylation or 
transpeptidation and thus preventing synthesis of functional peptidoglycan (Courvalin, 2006). Due 
to its negligible absorbance in the grastrointestinal tract, vancomycin concentrations of >2000mg/L 
are achievable in the colon (Gonzales et al., 2010), compared to a typical C. difficile minimum 
inhibitory concentration (MIC) of 0.5-2mg/L. (Aspevall et al., 2006). There are no reports of C. 
difficile isolates resistant to vancomycin. However, rates of CDI relapse after treatment with 
vancomycin are high, estimated at 15-25%, with many patients suffering multiple relapses (Louie 
et al., 2011; Wenisch et al., 1996)  or reinfection with another strain (Wilcox et al., 1998). This 
relapsing effect is generally ascribed to the continuing suppression of colonic flora by vancomycin, 
preserving the flora-depleted niche that led to C. difficile disease in the first instance. 
Despite its effectiveness, the use of vancomycin for treatment of CDI must be considered carefully 
due to its considerable cost and growing concerns about vancomycin resistance in Enterococcus 
spp. and Staphylococcus spp. For these reasons metronidazole is generally preferred as a first-line 
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treatment, with trials indicating that it is similarly effective as vancomycin in mild or moderate CDI 
(Zar et al., 2007). As with vancomycin, typical MICs for metronidazole are low, in the range of 
0.032-1.0 mg/L (Aspevall et al., 2006), although high levels of absorption from the gastrointestinal 
tract result in much lower (<50mg/g) concentrations in the colon (Bolton and Culshaw, 1986). 
Rates of relapse are similar to those seen with vancomycin therapy (Zar et al., 2007), and although 
reduced susceptibility to metronidazole is frequently observed it is not widespread and seems to be 
restricted to ribotypes 001 and 10 (Baines et al., 2008; Brazier, 2001)   
In 2011, the antibiotic fidaxomycin was licensed in Europe for treatment of CDI in light of 
randomised trials demonstrating non-inferiority to vancomycin (Louie et al., 2011). In fact, relapse 
rates were lower in patients treated with fidaxomycin (13%) than vancomycin (24%).  This 
protective effect may be due to the fact that Fidaxomycin has been demonstrated to have little 
effect on Bacteriodes spp. species which, as discussed in Section 1.1.3, is one of the groups of 
bacteria most depleted by antibiotics which predispose patients to CDI (Louie et al., 2012) 
1.4.2 Probiotics 
Probiotic strains investigated for prevention of CDI include Lactobacillus rhamnosus, 
Lactobacillus casei, Lactobacilli helveticus, Bifidobacterium longum, and formulations often 
include combinations of multiple strains (Allen et al., 2012; Gao et al., 2010; Rampelli et al., 
2013).  A recent meta-analysis of 23 trials with 4213 participants found that co-administration of 
probiotics reduced the rate of CDI of those undergoing antibiotic therapy by 64% (Goldenberg et 
al., 1996). A potential flaw exists in meta analysis of probiotic trials due to the significant 
heterogeneity of the compounds tested, but the above study did not find statistical evidence of 
subgroup effects, suggesting that all treatments were similarly effective.  
It is unlikely that the mode of action of these therapies is reconstitution of the gut flora, since the 
strains of bacteria administered (often from the Lactococcus spp) are not closely related to those 
which are absent from the CDI-predisposed colon (typically Bacteriodes spp, see section). A more 
likely hypothesis is inhibition of pathogen growth by acidic secondary metabolites such as lactate 
and acetate. This hypothesis is supported by the observation that in vitro inhibition of C. difficile 
growth by culture supernatants of 10 commonly used probiotic strains is lost when culture 





Where disease progresses to toxic megacolon, multiple organ failure, or fails to respond to 
chemotherapeutics, colectomy is a last resort treatment. Postoperative mortality is high, with a 30-
day mortality of 41% (Bhangu et al., 2012)  
1.4.4 Faecal Transplantation 
Faecal transplantation, the use of faeces from a healthy person to reconstitute the colonic flora, has 
been used to successfully treat CDI on a sporadic basis for some time, either via colonoscopy 
infusion or nasogastric tube (Aas et al., 2003; Rohlke et al., 2010). A recent meta-analysis which 
examined 273 patients from 11 studies found a rate of clinical resolution of 89% (Kassam et al., 
2013), which is comparable with the ~90% cure rate observed for vancomycin (Louie et al., 2011) 
In the studies reported above, recipients were encouraged to select donors from their immediate 
family, with the rationale that because people living together have similar faecal microbiota, it was 
more likely to be successful. However, Kassam et al (2013) found no significant difference in 
outcome between trials with volunteer donors and those with familial donors. Transmission of 
pathogens is clearly a concern in faecal transplantation, and although such concerns may limit the 
implementation of faecal transplant, these problems are likely to be surmountable with 
standardisation and evaluation of testing procedures as is the case for other common procedures 
such as blood transfusion. 
1.4.5  Active and Passive Immunotherapy 
There is good evidence that a C. difficile vaccine which induces a humoral response could prevent 
or improve outcomes of CDI patients. Poor anti-toxin antibody titres are significantly associated 
with a longer duration of disease and a higher risk of relapse (Warny et al., 1994) and patients with 
a high level of anti-TcdA IgM on day three of their first episode are less likely to experience a 
relapse (Kyne 2001). As the target population for a C. difficile vaccine is likely to include many 
elderly persons the phenomenon of immunosenesence, a reduction of immune responses in old age, 
must be considered. For example, poor responses to vaccines in the elderly has been noted for 
influenza vaccines (Bernstein et al., 1999).  A large phase I dose ranging trial of a toxoid A/B 
vaccine performed by Sanofi-Pasteur (Greenberg et al., 2012) examined this concern by comparing 
antibody response in an 18-55 age group with an >65 group. While seroconversion rates were 
similar in both groups after three doses (100% seroconversion for Toxin A, 75% for Toxin B), anti 
toxin A titres of the elderly age group were less than a third of those observed in the younger 
population. In addition, the younger population fully seroconverted after two doses - the third dose 
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was only strictly required for the elderly population. Results of Phase II trials must be awaited in 
order to determine whether these differences result in any significant in in vivo protection. 
The toxin-mediated, non-invasive nature of CDI and the aforementioned importance of humoral 
immunity make it an ideal target for an immunotherapeutic aimed at neutralising the toxins and 
preventing tissue damage. The prevention of CDI in animal models has been demonstrated with 
polyclonal ovine antibodies raised against TcdA and TcdB fragments (Roberts et al., 2012), by 
humanised murine IgG1 monoclonal antibodies raised against a range of TcdA and TcdA derived 
antigens (Davies et al., 2013) and fully human monoclonal antibodies raised against inactivated  
TcdA and TcdB (Babcock et al., 2006). The latter of these are currently undergoing Phase III 


















Chapter 2 - Introduction to The Sortase Enzyme Family 
2.1 Introduction to Sortase Enzymes 
2.1.1 The Sortase Enzyme Family 
Sortases are transpeptidase enzymes, ubiquitous in gram positive bacteria. They play a key role in 
assembly of the cell surface by covalently anchoring specific proteins to the cell wall peptidoglycan 
and by catalysing the assembly of pili (See Figure 2.1.1). Proteins destined for processing by 
sortases are initially secreted via the Sec apparatus of the general secretary pathway, following 
which sortase enzymes (which are often co-localised with the Sec apparatus (Kline et al., 2009)) 
recognise a pentapeptide cell wall sorting signal (CWSS) at the C-terminus of the protein. The 
sortase enzyme cleaves the protein at positions P4 and P5 of the CWSS (Navarre and Schneewind, 
1994), resulting in an acyl enzyme state. In wall-anchoring sortases, the acyl enzyme is resolved by 
nucleophilic attack by an amine group within the peptidoglycan, covalently anchoring the target 
protein to the cell wall. The identity of the nucleophile varies with the peptidoglycan structure – in 
species with pentaglycine cross links, it is the N-termini of cross-link precursors (Navarre, 1998), 
while species with diaminopimelic acid cross-links, it is the free amino group of diaminopimelic 
acid (Budzik et al., 2008b). In pilus-associated sortases which catalyse pilin-pilin polymerisation, 








Figure 2.1.1 Schematic of Wall Anchoring of Protein A (SpA) by S. aureus Sortase A.  
Following secretion by the Sec apparatus, the target protein is cleaved by Sortase A between 
the threonine and glycine of its ‘LPXTG’ cell wall sorting signal. The resulting acyl enzyme 
intermediate is attacked by the polyglycine moiety of a peptidoglycan crosslink precursor, 





Sortase family proteins can be classified into five subfamilies  (Dramsi et al., 2005) – Sortase A, B, 
C, D1 and D2 (SrtA, SrtB, SrtC and SrtD1 and SrtD2).  
2.1.2 The Cell Wall Sorting Signal 
Sortase substrates possess three key features (Figure 2.1.2). The most essential of these is a 
pentapeptide CWSS motif situated 20-30 amino acids from the C terminus. Following the CWSS is 
a predominantly hydrophobic region of ~20 amino acids in length, while the C-terminus often 
contains several lysine or arginine residues resulting in a positively charged ‘tail’. The purpose of 
the latter two features has not been investigated in depth, but there is evidence that the hydrophobic 
region facilitates transient membrane anchoring.  
The sequence of the CWSS follows a loose consensus in most species, but contains only one 
strictly conserved feature, a proline residue at position two (see Figure 2.1.2). In addition to 
varying between species, variation of the CWSS sequence of this motif in species with multiple 








Species/Protein    C-terminal Protein Sequence              Sortase Class 
 
S. aureus SpA       LPETGEENPFIGTTVFGGLSLALGAALLAGRRREL        (SrtA) 
S. aureus IsdC      NPQTNAGTPAYIYAIPVASLALLIAITLFVRKKSKGNVEQ   (SrtB) 
S. pneumoniae RrgA  YPRTGGIGMLLFYLIGCMMMGGVLLYTRKHP            (SrtC2) 
S. pneumoniae RrgB  IPQTGGIGTIIFAVAGAVIMGIAVYAYVKNNKDEDQLA     (SrtC1) 













Figure 2.1.2. The Cell Wall Sorting Signal. A) Pictographic representations of the consensus 
sorting signals of the four classes of sortase based on in silico analysis of 72 species (excerpt 
from Comfort and Clubb (2004)). Position variants are shown only if they occurred in >8% of 
substrates. B) Selection of C-termini from proteins processed by sortases, highlighting the 
CWSS (underlined) and their positively charged residues (red). 
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2.2 Microbiology of the Sortase Enzymes 
2.2.1 – The Class A Sortase Enzymes 
The Sortase A (SrtA) of S. aureus was the first to be identified and is considered the prototype 
sortase. It was discovered by investigators isolating random mutants deficient in surface display of 
Staphylococcal protein A (SpA) (Mazmanian et al., 1999). SpA is a virulence factor which binds to 
the Fc region of host antibodies, and hence facilitates evasion from phagocytosis and complement 
mediated killing (Kim et al., 2012; Palmqvist et al., 2002) Even before the discovery of SrtA, the 
anchoring of SpA to the cell surface was well understood. The feature responsible for the anchoring 
had been identified as an LPxTG C-terminal peptide motif, the CWSS, followed by a 20-30 
hydrophobic amino acids and a positively charged C-terminus (Schneewind et al., 1992). This C-
terminal signal is both essential and sufficient for wall-sorting – mutant SpA which lacks this signal 
is secreted into the growth medium while exogenous fusion proteins appended with the signal are 
anchored to the cell wall like SpA. In 1999, Mazmanian and coworkers reported a mutant deficient 
in SpA anchoring – the mutation responsible was mapped to a open reading frame encoding a 206 
amino acid protein with a predicted N-terminal secretion signal. 
There are several other S. aureus virulence factors which are wall anchored by SrtA, including the 
fibrinogen-binding clumping factors ClfA and ClfB (McDevitt et al., 1994) and the fibronectin 
binding proteins FnbA and FnbB (Flock et al., 1987). S. aureus mutants deficient in SrtA fail to 
bind IgG, fibronogen or fibrinonectin, and are severely attenuated in virulence (Mazmanian et al., 
2000). 
In Listeria monocytogenes, 13 SrtA substrates have been identified, including three internalins, 
three peptidoglycan hydrolases and a 5' nucelotidase (Pucciarelli et al., 2005). In Streptococcus 
gordonii, a human oral commensal, eight SrtA wall-sorted proteins have been identified (Davies et 
al., 2009) including the adhesins CshA, CshB, SspA, SspB, a putative 5' nucelotidase and several 
proteins of unknown function, one of which displays homology to the 'B' domains of the S. aureus 
collagen adhesin Cna. S. gordonii SrtA deletion mutants are deficient in binding to salivary 
pellicles (Davies et al., 2009). The S. pyogenes SrtA is responsible for cell wall anchoring of the M 
protein, a protease regulator, the fibronectin binding protein Protein F, and the ScpA protease which 
cleaves C5a of the compement cascade (Barnett and Scott, 2002)   
Despite the characterisation of SrtA as a housekeeping sortase, in some species which possess 
SrtC-assembled pili, such as Streptococcus agalactiae, it is the housekeeping SrtA which anchors 
the first pilus subunit to the peptidoglycan (Necchi et al., 2011). Indeed, the Corynebacterium 
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diptheriae SrtA catalyses assembly of an entire pilus. (Ton-That et al., 2004). 
2.2.2 – The Class B Sortase Enzymes 
The first class B sortase to be characterised was that of S. aureus, following identification of an 
open reading frame with homology to srtA within the iron-responsive surface determinant (isd).  
locus. Mutagenesis of the srtB gene resulted in loss of wall anchoring of the adjacently encoded 
IsdC protein, which contains an 'NPQTN' CWSS (Mazmanian et al., 2002), and a near iron 
transporter (NEAT) haemeoprotein binding domain (Dryla et al., 2003) 
Upstream of the isd locus promoter is a binding site for the ferrichrome uptake repressor (Fur). 
Consequently, growth of S. aureus in iron-limited medium increases expression of SrtB, as does 
deletion of the fur gene (Mazmanian et al., 2002). In this species, SrtB and SrtA appear to operate 
cooperatively in iron acquisition, as two of the genes encoded within the isd locus, IsdA and IsdB, 
contain 'LPXTG' SrtA CWSSs rather than 'NPQTN' SrtB sorting motifs.  
In addition to S. aureus, class B sortases have been characterised in Bacillus anthracis (Maresso et 
al., 2006), Listeria monocytogenes (Bierne et al., 2004) and Streptococcus pyogenes.  In L. 
monocytogenes, srtB is under the control of a fur box as is the case in S. aureus (Newton et al., 
2005) and proteomic analysis of a sortase knockout strain identified two sortase B substrates, 
Lmo2185 and Lmo2186 possessing CWSS motifs of ‘NAKTN’ and ‘NPKSS’ respectively 
(Mariscotti et al., 2009) These proteins are predicted to contain near-iron transporter (NEAT) 
domains, and L. monocytogenes SrtB mutants are deficient in uptake of 59Fe-labelled haemin 
(Xiao et al., 2011). B. anthracis SrtB is responsible for the anchoring of  a single haem binding 
protein IsdC (Maresso et al., 2006), and deletion of either srtB or isdC results in defective 
utilisation of haemin.  
Thus in the species so far characterised, SrtB fulfils a specialised role in iron acquisition systems, 
and particularly scavenging of iron from host proteins. Iron homeostasis is a critical function for 
any pathogen, since the concentration of free iron in human and animal tissues is virtually nil with 
most iron being bound to transporter proteins such as haemoglobin and transferrin.  
2.2.3 The Class C Sortase Enzymes 
Many Gram-positive bacteria possess pili, extracellular appendages constructed by polymerisation 
of multiple protein subunits, known as pilins. Pili are typically composed of major pilins, which 
form the main shaft, and minor or ‘accessory’ pilins, which often have virulence-associated effector 
functions. In several species, it has been demonstrated that the covalent linkage of these 
components is catalysed by sortases, particularly those of the class C. In sortase catalysed pilin 
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polymerisation, the sortase enzyme cleaves a C-terminal CWSS similar to that for SrtA, but rather 
than the acyl-enzyme intermediate being resolved by nucleophilic attack by a component of the 
peptidoglycan, the attack is from the epsilon amine of a lysine residue within a conserved motif of 
a second pilin at the terminus of the nascent pilus (Budzic 2008, Mandlik 2008). 
Unlike SrtA and SrtB, where only one gene copy is typically present per genome, it is common for 
bacteria to possess multiple SrtC genes (Dramsi et al., 2005), each encoding an enzyme with a 
specialised role in the pilin biogenesis pathway. For example, the S. pneumoniae pilus gene locus 
rlrA encodes three class C sortases (SrtC1, SrtC2, SrtC3), three pilins (RrgA, RrgB, RrgC) and a 
RofA-like transcription factor (Barocchi et al., 2006). In this system, the main fibre of the pilus is 
composed of RgrB and polymerised by SrtC1 (El Mortaji 2011). RgrA, a collagen adhesin (Izoré et 
al., 2010) which binds to epithelial cells in vivo, forms accessory fibres assembled by SrtC2 and 
anchored to the pilin fibre by SrtC3 (El Mortaji et al., 2011).  
Not all sortase-associated pili require multiple sortases. The pili of Corynebacterium diptheriae, for 
example, are composed of major pilin SpaA and the accessory pilins SpaB and SpaC, and are 
assembled by a single SrtC (Khare et al., 2011). In B. anthracis, SrtC (often termed SrtD due to 
genome annotation conventions) catalyses the transpeptidation reaction between the LPxTG sorting 
signal of the major pilin BcpA and the gamma amino group of lysine of an YPKN motif on an 
adjacent BcpA unit  (Budzik et al., 2008a). The B. anthracis SrtA is also capable of cleaving the 
LPxTG signal, and is responsible for anchoring of the first subunit of the pilus to the peptidoglycan 
(Budzik et al., 2007). The minor pilin BcpB is also cleaved by SrtD but because it lacks a YPKN 
motif, addition of this subunit to the pilus effectively terminates further pilus growth (Budzik et al., 
2008a).  
2.2.4 – The Class D Sortase Enzymes 
Class D sortases are the least investigated of all classes, with characterisation limited to the species 
B. anthracis. The CWSS recognised by B. anthracis SrtD (termed SrtC in the literature due to 
genome annotation conventions) is very similar to that of its SrtA, specifically an 'LPNTA' 
sequence as opposed to 'LPxTG' recognised by B. anthracis SrtA. The two proteins processed by B. 
anthracis SrtD are BasH and BasI (Marraffini and Schneewind, 2006), both of which are targeted 
to the diaminopimelic acid crosslinks of the peptidoglycan of cells undergoing sporulation 
(Marraffini and Schneewind, 2007). Their precise function is as yet unknown, but deletion of SrtD 




2.3 Biochemistry of the Sortase Transpeptidation Reaction 
2.3.1 Overview and Reaction Kinetics 
The sortase reaction is of the 'ping-pong bi-bi'  type (Huang et al., 2003), where 'bi-bi' describes 
that there are two substrates and two products while 'ping-pong' mechanisms are so named because 
the enzyme exists in one of two states, either free or in a substrate-modified state. Only the 
substrate-modified state is competent for binding of the second substrate, hence the overall reaction 
proceeds in a highly ordered manner. In the case of the sortase enzymes, this substrate-modified 
state is the acyl-enzyme complex formed by a nucleophilic attack of the enyzme upon the threonyl-
glycyl bond of the CWSS. 
Kinetic data for SrtA collected at a fixed concentration of substrate 2 (S2) and varying 
concentrations of substrate 1 (S1) do not fit the expected parameters for a ping pong bi bi 
mechanism – rather, they fit the parameters for a ping pong reaction incorporating a hydrolytic 
shunt (Frankel et al., 2005). In such a mechanism, water competes with substrate 2 in the second 
part of the reaction, so that at low concentrations of substrate 2, the enzyme is returned to its free 
state via hydrolysis reaction rather than transpeptidation (See Fig. 2.3.1).  Accordingly, in the 
absence of a suitable nucleophile to complete the transpeptidation reaction, hydrolysis of the 
























Figure 2.3.1 – Ping-Pong Transpeptidation by SrtA Incorporating a Hydrolytic Shunt. 
Cleavage of the LPxTG motif to generate the LPET-SrtA acyl enzyme releases a glycine 
residue. From this acyl state, the return of the enzyme to its free state can proceed via either 
transpeptidation with pentaglycine (GGGGG), producing an ‘LPETGGGGG’ peptide, or 
hydrolysis, releasing an ‘LPET’ peptide. 
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2.3.2 Mechanism of the Attack on the Threonyl-Glycyl Bond of the CWSS 
The rate limiting step in sortase transpeptidation is formation of the acyl-enzyme (Huang et al., 
2003). The mechanism of this reaction, so far only investigated in S. aureus SrtA, has been revised 
several times recently in light of new evidence from a variety of structural and biochemical 
experiments. 
The first structure of S. aureus sortase A (Ilangovan et al., 2001) revealed that the conserved and 
essential residues Histidine 120 (His120) and Cysteine 184 (Cys184) (Ton-That et al., 2002) were 
in close proximity (for detail, See Section 2.5.2). It was therefore initially proposed that SrtA 
operated in a mechanism analogous to that of the cysteine protease papain, via a thiolate-
imidazolium ion pair. There is, however, strong biochemical evidence against a thiolate 
imidazolium ion pair in SrtA. In papain, the ion pairing results in a pKa of the catalytic histidine 
residue as low as 3.3-4.0 (Lewis et al., 1981; Pinitglang et al., 1997), whereas in SrtA the pKa of 
His120 has been determined as 7.0 (Connolly et al., 2003), and hence does not allow for the low 
level of protonation as is required by a thiolate imidazolium pair model. Additionally, replacement 
of Cys184 with Ala has very little effect on the pKa of His120 in SrtA, whereas neutralisation of 
the papain catalytic cysteine by methylthiolation leads to a dramatic increase in the pKa of the 
paired His from 4 to 8.5 (Lewis et al., 1981). It therefore appears His120 and Cys184 of SrtA do 
not participate in an ion pair. 
An alternative mechanism for activation of Cys184 was therefore proposed, a general base 
activation mechanism whereby Cys184 exists in thiol form in the resting state, and is activated by 
abstraction of a proton by a base, proposed to be either Arg233 or His120. By determining kcat and 
kcat/KM values over a range of pH values, Frankel et al (2005) determined that enzyme activity was 
dependent upon two ionisable groups, with pKa values of 6.3 and 9.4, assigned to His120 and 
Cys184 respectively. Significantly, no effect was observed at or near that expected for an arginine 
residue as would be expected if Arg197 was acting as a general base. Additionally, mutation of 
Arg197 to either alanine or lysine does not change the pH-kcat curve (Frankel et al., 2007a), 
confirming that Arg197 does not act as general base to activate Cys184.  A variation on the general 
base mechanism is that of a Cys-His-Asp catalytic triad where protons abstracted by the histidine 
residue are shuttled by Asp. This proposition was based on structural evidence of a catalytic triad 
similar to that seen in serine and cysteine proteases (Zhang et al., 2004). However, mutation of 




Based on the above evidence, Frankel et al (2007) proposed a reverse protonation mechanism 
which does not implicate any special activation of Cys (Frankel et al., 2005). At pH7, a small 
proportion (estimated at less than 0.06%) of SrtA molecules are 'reverse protonated', ie. Cys is in 
the thiolate form while histidine is in the imidazolium form – a configuration which occurs, albeit 
rarely, due to overlaps in the protonation curves of histidine and cysteine at pH 7. The reverse 
protonation mechanism is compatible with pKa measurements, mutagenesis experiments, solvent 
isotope effects, and explains several unusual features such as the unusually low kcat of SrtA (Kruger 
et al., 2004b). The proposed role of His120 in this model is to donate a proton to the leaving amine 
group. 
2.3.3 Role of the Conserved Arginine Residue in Oxyanion Stabilisation 
The reverse protonation model for sortase catalysis does not directly implicate the conserved  
arginine residue, yet it is essential for optimal enzyme activity, with mutation of  Arg197 to alanine 
resulting in a 10
3
 decrease in kcat (Frankel et al., 2007b). It was therefore proposed that the role of 
Arg197 is to stabilise the oxyanion of the tetrahedral intermediate formed after the attack upon the 
threonyl glycyl bond. The calculated energetic contribution of Arg197 to oxyanion stabilisation is 
similar to that seen in other enzymes which employ oxyanion stabilisation, eg. carboxypeptidase A. 
Structural evidence from SrtB is compatible with Arg197 fulfilling an additional role in activating 
the nucleophile which attacks the acyl enzyme (see Section 2.5.4). 
2.3.4 Substrate Specificity 
The CWSS specificity of S. aureus SrtA has been comprehensively investigated by the use of a 
peptide mutant library (Kruger et al., 2004d). In an experiment examining initial reaction rates, 
only the canonical amino acids were tolerated at P1, P2, P4 and P5 (LPTG respectively), while P3 
was tolerant of any amino acid tested (ADEFGILMNPQSTYV). The relative rates of P3 variants 
do not appear to be correlated to side chain side size or polarity, suggesting that this residue 
undergoes minimal interaction with the enzyme. In an end-point experiment over a longer period of 
time, it was observed that SrtA is partially tolerant of methionine at P1, of alanine at P2, and of 
alanine, leucine, serine and valine at P4. However, glycine remained the only amino acid tolerated 
at P5. 
Because the acylation step of the reaction is rate limiting only in the presence of an appropriate 
nucleophile (Huang et al., 2003) specificity for the nucleophilic transpeptidation substrate can be 
assessed by comparison with hydrolysis rates. Of the pentaglycine crosslink precursor in the S. 
aureus peptidoglycan, diglycine is the minimum required unit for transpeptidation (Huang et al., 
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2003). SrtA is highly selective for glycine at P1, while positions P2 and P3 are more tolerant, with 
GlyVal and GlyAla both tolerated albeit with 5- and 10-fold increases in KM. Addition of 
GlyGlyHis and GlyGlyLeu resulted in reaction parameters very similar to those where tetraglycine 
is added. Addition of monomeric glycine does not result in transpeptidation, but glycinamide does, 
with reaction parameters similar to those of triglycine.   
2.3.5 Sortase Inhibitors 
Since the discovery of SrtA as an essential virulence factor in S. aureus (Mazmanian et al., 2000), 
the development of sortase inhibitors as an anti-infective treatment has received great interest, and 
several candidate inhibitors have been investigated. The first reported inhibitor of SrtA was 2-
(trimethylammonium) ethyl methanethiosulfonate (MTSET), a thiol reactive compound which 
reacts irreversibly with cysteine thiol of the sortase active site (Zong et al., 2004b). However, the 
short half-life and broad reactivity of this compound renders it useful only as an experimental in 
vitro inhibitor (Stauffer and Karlin, 1994). 
The CWSS substrate is relatively easy to mimic due to its peptide nature, and thus several substrate 
mimetic compounds have been developed. For example, two inhibitors of S. aureus SrtA with sub-
micromolar inhibition constants were developed by replacement of the C-terminal glycine with 
either a diazoketone or chloromethyl group (Scott et al., 2002), both of which have been found to 
alkylate active site cysteine residues in other enzymes. Of the two compounds tested, the 
chloromethyl-substituted peptide modified the enzyme at twice the rate of the diazoketone peptide 




. Replacement of the scissile Thr-Gly bond with a 
nonhydrolysible phosphinic bond also inhibited S. aureus SrtA but with a poor Ki of 11.4mM 
(Kruger et al., 2004a). 
In addition to substrate mimetics, several small molecule inhibitors have been identified. High 
throughput screening of sortase inhibition against a 135,635 small molecule library revealed 207 
specific inhibitors of B. anthracis SrtA (Maresso et al., 2007). Of these, several aryl (β-amino) 
ethyl ketones (AAEKs) were investigated further by X-ray crystallography of the inhibited enzyme, 
by which it was found that the inhibition was due to covalent adduction at the active site cysteine 
residue. 
To date, there is only one published report of in vivo testing of a sortase inhibitor, in which it was 
demonstrated that (Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile (DMMA) 
reduced mortality from S. aureus in mouse models of kidney and joint infection (Oh et al., 2010).  
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2.4 The Structure of the Sortase Family Enzymes 
2.4.1 Overview of Sortase Structures 
The first published sortase structure was that of S. aureus SrtA (Figure 2.4.1), determined by NMR 
spectroscopy (PDB 1IJA, Ilangovan et al. 2001). This revealed a novel structure composed of an 
eight stranded beta-barrel, flanked by one short alpha helix and one 310 helix. The unique sortase 
fold is formed by the interaction of two structural motifs, each composed of four strands. One 
strand from each motif (β4 and β7) interact along much of their lengths, while the remaining 
strands (β1,β2,β3 and β8,β6,β5) co-operatively form the remainder of the barrel which is completed 




Subsequent X-ray structures of S. aureus SrtA are in broad agreement with the NMR structure (eg. 
PDB 1T2P, Zong et al. 2004), and crystal structures of several other SrtA enzymes have been 
determined, including those of Bacillus anthracis (PDB 2KW8, Weiner et al. 2010), Streptococcus 
pyogenes (PDB 3FN7, Race et al. 2009) and Streptococcus agalactiae (PDB 3RCC, Khare et al. 
2011). 
The first structure of a class B sortase, again that of S. aureus, was determined by X-ray 
crystallography (See Fig 2.4.2). The core beta barrel structures of S. aureus SrtA and SrtB are very 
similar despite only sharing 40% sequence similarity. For the alpha carbon atoms of the β-strand 





Figure 2.4.1. Structure of S. aureus SrtA. (A) Cartoon rendering of the NMR structure 
of S. aureus SrtA (PDB 1IJA, Ilangovan et al, 2001) (B) Schematic representing the 























Despite the similarities between the core structures of S. aureus SrtA and SrtB, there are significant 
structural differences outside of the barrel region. Five helical regions are apparent in SrtB, most 
notably long alpha helices at the N-terminus and in the β6-β7 loop. Two further short alpha helices 
are present in the β4-β5 loop, and a short region following the N-terminal helix, separated from it 
by a turn motif. The presence of additional helices in SrtB relative to SrtA has the effect of placing 
the N-terminal membrane anchor proximally to the active site as opposed to SrtA where it is distal 
to the active site. This results in the SrtA active site being oriented away from the cell surface while 
the SrtB active site is oriented towards the surface. The significance of this difference has not been 
investigated, but may result in differences with respect to access to the peptidoglycan. 
Another significant difference between SrtA and SrtB is the configuration of the β7-β8 loop, which 
is much longer in SrtB than in SrtA. However, the relative positioning of the catalytic cysteine and 
conserved arginine residues at either end of this loop is well conserved. The structures of SrtB 
enzymes from two other species have been published, S. pyogenes (PDB 3PSQ, Kang 2011) and B. 
anthracis (PDB 1RZ2, Wu 2004). 
Figure 2.4.2. Structure of S. aureus SrtB.  
(A) Cartoon rendering of the crystal structure 
of S. aureus SrtB (PDB 1NG5, Zhang et al., 
2004) showing the two extended alpha helices 
flanking the core barrel structure (B) 
Schematic illustrating the secondary structure 


















Several class C Sortase structures have been determined by X-ray crystallography. Most notably, 
the structures of all three S. pneumoniae SrtCs have been solved (PDB 2W1J, 3G66, 2W1K, 
Manzano et al., 2008, Neiers et al., 2009) providing a complete structural overview of pilus 
biogenesis in this species. In common with SrtA and SrtB, the core SrtC structure is that of an 8 





The key distinguishing structural feature of class C sortases is a loop which forms a 'lid' occluding 
the active site. In crystal structures of the three S. pneumoniae  SrtCs, the lid region exhibited high 
B-factors compared to the remainder of the structures, suggesting a high level of flexibility, and 
similarly, in the case of SrtC2, the lid was observed in different conformations in two crystals 
grown in different conditions. In the Streptococcus agalactiae SrtC1, no electron density was 
observed in the loop region, again suggesting a high level of mobility (Khare et al., 2011). 
In S.pnuemoniae, the lid is anchored by a conserved salt bridge between Asparagine 73 within the 
lid and Arginine 215 within the β7-β8 loop (Manzano et al., 2008). Similar pairings are observed in 
other species eg Actinomyces oris and S. agalactiae  (Khare et al., 2011; Persson, 2011). This is 
particularly interesting given that this arginine residue is conserved in all sortase classes, and it has 
been suggested that the role of this interaction is not only to lock the lid in place, but also to 



























Active Site ‘Lid’ 
Active Site 
Figure 2.4.3. Structure of S. pneumoniae  SrtC1. (A) Cartoon rendering of S. pneumoniae  
SrtC1 (PDB 3G66, Neiers et al., 2009) showing the loop which forms a lid occluding the 










substrate access, or it may serve to protect against non-specific oxidation of the active site 
sulphydryl.  Despite its uniqueness to pilin-associated sortases, the role of the lid is clearly not 
specific to catalysis of pilin-pilin reactions, as S. pneumoniae SrtC3 possesses the lid despite only 
being able to catalyse pilin-peptidoglycan transpeptidation, and SrtC1 and SrtC2, both possessing 
the lid, can catalyse either pilin-peptidoglycan or pilin-pilin transpeptidation. 
Class D sortases are the least well characterised of the four classes and only one structure has been 
published, that of the B. anthracis SrtD determined by NMR spectroscopy (often named 'SrtC' due 
to naming conventions in the B. anthracis genome). B. anthracis SrtD is very closely related to 
SrtA, and can be superposed on the S. aureus, B. anthracis and S. pyogenes SrtA structures with 
carbon RMSD values of 2.4Ǻ, 1.9Ǻ and 2.0Ǻ respectively (Robson et al., 2012)  hence has not 
been illustrated here.  
2.5.2 Structure of the Sortase Active Site 
The active site of SrtA resides within a concave depression formed of β4 and β7, which provide the 
floor of the depression, and β2/β3, β3/β4 and β6/β7 which form the sides of the cleft (See Fig. 
2.4.4). Located at one end of this concave surface, within β7, is the conserved 'TLxTC' motif 
containing the catalytically essential cysteine residue. Flanking this residue on adjacent loops are 













Figure 2.4.4 - The Active Site of S. aureus SrtA (PDB 1IJA, Ilangovan et al, 
2001). The conserved and essential Cys184 residue at the C-terminus of β7 is 
flanked by conserved His120 and Arg197 residues on adjacent loops at distances 
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2.4.3 Structural Evidence for Recognition of the CWSS 
S. aureus SrtA binds the LPxTG CWSS via strands β4, β7 and the loops which flank them, 
particularly β6-β7 (Suree et al., 2009). Underlining the role of this loop in substrate recognition, 
targeted mutations within the β6-β7 loop can confer substrate promiscuity to SrtA (Piotukh et al., 
2011), while a loop swap mutant consisting of SrtA with the β6-β7 loop of SrtB confers SrtB-like 
substrate recognition (Bentley et al., 2007). Comparison of NMR spectra of apo SrtA and SrtA-
LPAT*  (SrtA modified with an irreversible inhibitor mimicking an LPETG sorting signal)  reveals 
chemical shift perturbations in β4 (A118), β7 (I182), β3-β4 (A104, E105), β6-β7 (L169, E171) and 
β7-β8 (V193, W194, R197) (Liew et al., 2004). Many of these interactions are depicted in Figure 
2.5.5.  
Further analysis of SrtA-LPAT* indicates that binding of the sorting motif to the β6-β7 loop may be 
via an induced fit mechanism. In the apo structure, loop β6-β7 is highly mobile and largely free of 
secondary structure (see Figure 2.4.6). Upon substrate binding, residues within β6-β7 (V166, V168, 
L169) rearrange to form a hydrophobic 310 helix which interacts extensively with the leucine and 
proline residue of the CWSS, providing a stronger hydrophobic interaction (Suree et al., 2009). 













Figure 2.4.5 – Structure of S. aureus SrtA with a Substrate Mimetic Adduct (PDB 
2KID, Suree et al., 2009). The proline and leucine residues of the LPxTG CWSS are 
placed to form extensive hydrophobic interactions (represented here by red dashed 











Underlining the importance of hydrophobic interactions in the active site, mutation of Thr180, 
Leu181 or Ile182 to alanine result in 14, 7.6 and 28-fold reduction in enzyme activity respectively, 
and mutation of Ile182 to serine, a more polar amino acid, results in a 74-fold reduction in activity 
(Frankel et al., 2007b). 
The solution structure of B. anthracis SrtA, despite being free of substrate, displays a helix within 
the β6-β7 loop, similar to that observed in S. aureus SrtA-LPAT* (see Fig. 2.4.6). The B. anthracis 
SrtA β6/β7 loop may not, therefore, require a transition to order upon substrate binding, as is the 
case in S. aureus SrtA. A similar pre-formed helix is observed in the S. pyogenes SrtA, although the 











In addition to the NMR structure of SrtA-LPAT*, a crystal structure of SrtA Cys184 to Alanine 
mutant complexed with an LPETG peptide is available (PDB 1T2W, Zong et al., 2004). However, 
this is quite different to the structure of SrtA-LPAT* presented by Suree et al and displays some 
features which suggest that the peptide is bound non-specifically. For example, the leucine side 
chain of the LPETG peptide is oriented away from the enzyme and towards the solvent, 
contradicting biochemical data which indicate that there are specific enzyme-substrate interactions 
at this position (Kruger et al., 2004d). Similarly, the SrtAC184-LPETG structure shows a hydrogen 
bond between Q172 and the backbone of the LPETG peptide, whereas biochemical data from 
Q172A mutants (Bentley et al., 2008) indicate that this residue is dispensable for catalysis so is 
unlikely to participate in such a strong interaction with the substrate. 
Figure 2.4.6. Superposition of Loop β6-β7 
from S. aureus and B. anthracis. In the 
absence of a CWSS substrate, the β6-β7 loop 
of S. aureus SrtA is disordered, but undergoes 
a transition upon substrate binding to form a 
short helix. This helix appears pre-formed in 
other apo SrtA enzymes eg. B. anthracis SrtA. 
N 
C S. aureus (apo-) SrtA 
S. aureus LPAT*-SrtA 




At present, there are no published structures of a class B sortase complexed with a sorting motif 
peptide. As discussed, the β6/β7 loop of S. aureus SrtA participates in significant hydrophobic 
interactions which anchor the 'LP' portion of the LPETG sorting signal. The analogous region in 
the β6/β7 loop of SrtB is more polar, reflecting the more polar nature of asparagine at P1 of the 
'NPQTN' S. aureus SrtB sorting motif. Residues which form key hydrophobic interactions with 
proline in SrtA-LPAT* structure do not appear to be conserved in S. aureus SrtB either, with 
isoleucine 182 replaced with a serine residue and alanine 118 with a tyrosine residue. The active 
site of S. aureus SrtB is therefore less hydrophobic and enzyme-substrate interactions are likely to 
bemore polar in nature. 
Neither the B. anthracis nor the S. aureus SrtB structures display a pre-formed helix within β6/β7, 
suggesting that they either undergo similar changes upon substrate binding as S. aureus SrtA or that 
such rearrangements are not necessary for binding of the SrtB CWSS. 
2.5.4 Interaction of Sortase Enzymes with the Peptidoglycan Nucleophile 
Although there are currently no published crystal structures of SrtA complexed with the 
polyglycine moiety which acts as a nucleophile in the transpeptidation reaction, this interaction has 
been partially investigated by NMR (Suree et al., 2009). In complexes of SrtA-LPAT* complexed 
with Gly3, perturbations were observed in residues within H1, β7/β8 and β4/H2. These regions 
form a surface which is exposed by a ~13Å displacement of the β7-β8 loop on the formation of an 
acyl intermediate. Furthermore, it was found that SrtA does not bind Gly3 at all in its apo state. For 
S. aureus SrtA, the displacement of the β7/β8 loop after formation of the acyl intermediate 
therefore appears to be the structural basis for the ordered binding of substrates observed in 
bisubstrate kinetic characterisations. 
A structure of S. aureus SrtB complexed with Gly3 has been obtained by X-ray crystallography 
(1QXA, Zong et al 2004) and in agreement with NMR data for SrtA, the Gly3 binding region is 
located within the β7-β8 loop (see Figure 2.5.7). Interestingly, in this structure Gly3 is bound to 
SrtB in the absence of a sorting motif substrate, contradictory to the findings of Suree et al (2009) 
that apo SrtA is not competent for binding of the second substrate. 
In order for the Gly3 peptide to participate in a nucleophilic attack upon the thioacyl intermediate 
form of enzyme, it must be activated by removal of a proton from its N-terminal amino group. The 
highly conserved residue Arg223 is observed within 4.5Å of the N terminal amino group of Gly3, 
suggesting that this is the most likely residue to fulfil the role of base activation. The suggestion 
that the conserved histidine is responsible for this role is not ruled out, but appears less likely as it 














2.5.5 Binding of Metal Ions by S. aureus SrtA 
Following the observation that S. aureus SrtA activity is stimulated eightfold by calcium ions, SrtA 
NMR spectra were recorded in the presence and absence of Ca
2+
. A  putative Ca
2+
 binding pocket 
was identified in loop β3-β4 comprising the residues Glu105, Glu108 and Asp112 (Ilangovan et al., 
2001). Ca
2+
 induced chemical shift changes were also observed in the adjacent β6-β7 loop, and 
further experiments confirm that E171 within β6/β7 interacts with Ca2+ bound within the β3/β4 
loop, confirmed by biochemical analysis in which an Glu171A mutation results in reduced Ca
2+
 
stimulation (Naik et al., 2006). It is therefore proposed that Ca
2+
 stimulates the S. aureus SrtA by 
stabilisation of the β6-β7 loop, a region which is a key for binding for the sorting motif, and which 
exhibits a high level of mobility in Ca
2+
-free structures (Zong et al., 2004a) 
However, stimulation by calcium ions is not universal in SrtA enzymes and S. aureus SrtA may 
indeed be an exceptional case. The Streptococcus pyogenes SrtA, is mildly inhibited by Ca
2+
, and 
correspondingly, the crystal structure of this enzyme does not display a calcium binding pocket 
within β3/β7, although an aspartic acid residue (D196) is present in the equivalent position to 
Glu171 within loop β6/β7 (Race et al., 2009). Similarly, the B. anthracis SrtA has a structurally 
conserved glutamic acid residue within β6/β7 but no binding pocket within β3/β4. The activity of 
S. agalactiae SrtA is also independent of Ca
2+ 
(Necchi et al., 2011). 
Figure 2.4.7. Interaction of SrtB with 
Gly3 Peptide. In the structure of a 
complex between S. aureus SrtB and a 
triglycine molecule (PDB 1QXA, Zong et 
al., 2004), Gly3 is observed within the β7-
β8 loop. Distances consistent with weak 
hydrogen bonding are observed between: 
1) The N-terminal amino group and the 
side chain of Glu224 and the 2) The 
carbonyl of the P1 Gly and the backbone 
amino group of Tyr227 located at the 
bottom of the loop. The distance between 
Arg233 and the N-terminus of the Gly3 
peptide is 4.5Å, consistent with its putative 
role in activation of Gly3 prior to 












2.6 Introduction to the C. difficile Sortase 
2.6.1 Current Knowledge of the C. difficile Sortase 
Annotation of the C. difficile 630 genome revealed two genes (CD2718 and CD3146) encoding 
proteins with homology to known sortases. The latter of these is a pseudogene, containing an in-
frame stop codon ; the stop codon in CD3146 occurs upstream of the nuceleotide sequence 
encoding the TLxTC active site motif, and the conserved arginine is also absent, meaning that any 
expressed fragment is very unlikely to be active. 
 
Based upon analysis of the C. difficile genome using consensus searches designed to identify wall-
sorted proteins, a C. difficile cell wall-sorting signal of SPxTG or PPxTG was initially suggested 
(Pallen et al., 2001). A  similar methodology employed within a larger scale search of bacterial 
genomes identified seven putative substrates in C. difficile, six of which contained SPxTG motif 
and one with a PPxTG motif (Comfort and Clubb, 2004, supplementary data - available in the form 
of a freely accessible database at http://nihserver.mbi.ucla.edu/Sortase/) 
 
At the time of writing, there are no literature reports of any in vitro investigation of the C. difficile 
sortase. However, a patent application has been made in which it is claimed that the sortase is an 
essential gene, a claim made upon the basis that the inventors could not isolate sortase mutants and 
therefore assumed it fulfils an essential function (Wren, 2011). Additionally, in a publication 
characterising a novel C. difficile collagen binding protein named CbpA, the authors observed an 
NVQTN motif at the C-terminus and suggested that this protein may be sortase anchored (Tulli et 
al., 2013), in spite of the in silico identification of SPKTG as the C. difficile sorting signal. 
2.6.2 Aims of the work 
The aims of the work are as follows: 
1. To elucidate the in vivo role of the C. difficile sortase by construction and  characterisation 
of a sortase gene knockout (Chapter  5) 
2. To provide structural information on the C. difficile sortase and its substrates by X-ray 
crystallography (Chapter 6 and 7)  
3. To determine the specificity and activity of the SrtB enzyme by biochemical assays and 
mass spectroscopy (Chapter 8), particularly with regard to the conflicting claims of Tulli et 
al (2013) and Comfort and Clubb (2004) regarding the identity of the CWSS. 
The general and preparative methods underpinning this work are detailed in Chapter 3 (General 
Methods) and Chapter 4 (Purification of Recombinant Proteins). 
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Chapter 3 - General Methods and Protein Purification 
 
3.1 General Microbiological Methods 
 
3.1.1 Chemical Reagents 
All chemicals were purchased from Sigma Aldrich unless otherwise stated. 
 
3.1.2 Bacterial Strains and Plasmids 
E. coli strains BL21 and 10β were purchased from New England Biolabs in a transformation-
competent state. Plasmid pEXP1 (Invitrogen) is an expression vector featuring a T7 promoter and 
encoding an N-terminal enterokinase-cleavable hexahistidine tag. pJ414 (DNA 2.0) is an 
expression vector featuring a pUC origin of replication, a multiple cloning site (MCS) downstream 
of a T7 promoter and an ampicillin resistance gene. pET28a (Novagen/Merck) is an expression 
vector featuring a pBR322 origin of replication, an MCS downstream of a T7 promoter and a 
kanamycin resistance gene. Its MCS is constructed such that cloned genes can be fused with 
sequences encoding either a thrombin cleavable N-terminal hexahistidine tag, or a non cleavable C-
terminal tag. 
 
3.1.3 Growth of Escherichia coli 
E. coli strains BL21 and 10β were routinely grown in Lysogeny Broth (LB, 10g/L tryptone, 5g/L 
yeast extract, 5g/L NaCl) or on LB Agar (LB + 1% agar). For expression of recombinant proteins, 
E. coli BL21 was grown in Terrific Broth (TB, 24g/L tryptone, 42g/L yeast extract, 17mM KH2PO4 
and 72mM K2HPO4) 
 
3.1.4 Transformation of E. coli 
Transformation-competent cells were thawed on ice, mixed with 1ng of plasmid DNA and 
incubated on ice for 30mins. Following heat shock for 10s at 42°C, 950μl of SOC broth was added 
and incubation continued for 1hr at 37°C with orbital agitation at 250rpm. Volumes of 10μl, 50μl 
and 200μl were spread onto LB agar plates supplemented with appropriate antibiotic – 100µg/ml 
ampicillin for pEXP1 and pJ414 or 50µg/ml kanamycin for pET28a.  
 
For transformation of E. coli CA343, electroporation was employed. Electrocompetent cells were 
mixed with 1ng of plasmid DNA within a pre-chilled electroporation cuvette and pulsed with 
2.5kV for 4 msec using a Bio-Rad Micropulser. After addition of 250μl of SOC broth, incubation 
and plating was performed as above. 
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3.1.5 Growth of Clostridium difficile 
C. difficile was grown within a Don Whitley MGW-1000 anaerobic chamber maintaining an 
atmosphere of 10% Hydrogen, 10% Carbon Dioxide, 80% Nitrogen, a temperature of 37°C and a 
relative humidity of 70%. Liquid cultures were grown in Supplemented Brain Heart Infusion broth 
(sBHI, 36g/L Brain Heart Infusion (Oxoid), 5g Yeast Extract (Oxoid), 0.5g/l L-cystiene 
hydrochloride). Plate cultures were grown on Facultative Anaerobe Agar (Oxoid). 
 
Archive and working stocks of C. difficile were generated by inoculating 80ml of sBHI with a 
single colony, growing to an optical density of 1.0, addition of dimethyl sulphoxide (DMSO) to a 
concentration of 10% and freezing of 1ml aliquots under liquid nitrogen. 
 
3.2 General Molecular Biology Methods 
 
3.2.1 Agarose Electrophoresis of DNA 
Plasmids, PCR products and restriction fragment solutions were mixed 6:1 with loading buffer 
(40% glycerol, 0.25% Orange G) and added to the wells of a 40mm x 60mm x 5mm 1% agarose 
gel made with tris-acetate EDTA  buffer (TAE, 40mM Tris, 20mM acetic acid, and 1mM 
Ethylenediaminetetraacetic acid). Electrophoresis was performed in TAE buffer for 60mins at 
120V. To estimate the size of DNA fragments, samples was electrophoresed alongside either a 
100bp or 1kb marker (NEB), as appropriate for the analysis. 
 
3.2.2 Plasmid and Genomic DNA Preparation 
Plasmid DNA preparation was performed with a Qiagen MiniPrep kit according to the 
manufacturers protocol. Genomic DNA preparation was performed using a Qiagen Blood and 
Tissue kit.  
 
3.2.3 Restriction Digests 
Analytical and preparative restriction digests were performed for 1hr at 37ºC in a thermostatic 
water bath with a concentration of restriction enzyme (New England Biolabs) according to the 
manufacturer’s guideline of 1 unit per 1µg of DNA. 
 
3.2.4 Restriction Cloning 
Vectors and inserts were digested as above and agarose electrophoresis of the entire reaction 
products performed. Inserts and vector backbones were excised from the gel and purified using a 
Qiagen Qiaquick kit. Purified digested vectors and inserts and were mixed in a range of ratios 
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between 1:3 and 1:1 in DNA Ligase Buffer (New England Biolabs) and incubated for 2hrs at room 
temperature with 1 unit of T4 DNA Ligase (New England Biolabs). Transformation of E. coli 10β 
with ligation products was performed as in Section 3.1.4 and plasmid stocks subsequently 
generated as in Section 3.2.2. Cloning of the insert was analysed by analytical digestion as in 
Section 3.2.3. 
 
3.2.5 Polymerase Chain Reaction (PCR) 
Polymerase chain reactions were assembled as in Table 3.2.1. Cycling was performed with a PTC-
200 DNA Engine (Bio-Rad) according to Table 3.2.2. Optimum annealing temperatures, detailed in 
Table 3.2.3, were determined means of an annealing temperature gradient of 5ºC either side of the 
calculated optima provided by Eurofins MWG. Extension time was calculated based on the 
manufacturer's guidelines of 1min per 1.5kb of amplified product. Where colony PCR was 
performed, template DNA was 1µl of a colony emulsion generated by resuspending a single colony 





12.5 Failsafe Buffer E (Epicentre Biotech) 
0.5 (1.75 Units) Expand HiFi DNA Polymerase blend (Roche) 
1 1ul Forward primer (1pM final concentration) 
1 1ul Reverse primer (1pM final concentration) 
1 1ul Template DNA 
9 9ul Molecular biology quality water 
 
      Table 3.2.1 – Assembly of Polymerase Chain Reactions (PCR). 
 
 
Step Temperature (ºC) Time 
Denaturation 94 3min 
Denaturation 94 15s 
Annealing See Table XX 15s 
Extension 72 1min per 1.5kb of amplicon 
Extension 74 3min 
 







3.2.6 Nucelotide Sequencing 
DNA sequencing, by the cycle sequencing/chain termination method, was performed by Eurofins 
MWG Operon using an ABI 3730XL sequencer (Applied Biosystems). 
 
3.2.7 Oligonucelotide PCR Primers 
Synthesis of oligonucleotides, by the phosphoramidite method, was performed by Eurofins MWG 
Operon. Primer sequences and properties are listed in Table 3.2.3. 
 






CD2718 Intern F AACCTTGAATGGAAAAGAAT 
50.0 
CD2718 Intern R GCATCATCAAATTCATAGGT 
rpoB F CAATAGAGACTCCAGAGGGAC 
59.8 
rpoB R AGGAACCATTTCAACAGCAC 
CD2718C26A F GTTACGCTGTCTACTGCTACTTACGAATTCG 
65 












       Table 3.2.3 – Sequence and Properties of PCR Primers. 
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3.2.8 Gene Synthesis 
Gene synthesis was performed by DNA 2.0 (Menlo Park, California USA), with the exception of 
the srtB gene, which was synthesised by Entelechon Gmbh. 
 
3.3 General Protein Methods 
 
3.3.1 Analysis of Proteins by Polyacrylamide Gel Electrophoresis 
Protein samples of 30μl were mixed with 10μl NuPAGE loading buffer (Invitrogen) and heated at 
90°C for 5mins. After cooling, 10μl of the prepared sample was loaded into the wells of a 4-12% 
bis-tris acrylamide gel measuring 80mm x 8mm x 10mm (Invitrogen). Electrophoresis was 
performed for 35mins within an X-cell Surelock chamber, in a buffer of 50 mM MES pH7.3, 50 
mM Tris Base, 0.1% SDS, 1 mM EDTA and at a voltage  of 200V. For estimation of protein 
molecular weights, all samples were run alongside SeeBlue Plus2 pre-stained standards 
(Invitrogen). 
 
Gels were coomassie stained by placing in 50ml of SimplyBlue stain (Invitrogen), heating for 
2mins in a 700W microwave oven then incubating for 15mins with rocking agitation. Stain was 
decanted from the tray and replaced with an equal volume of distilled water, microwaved for 2mins 
then incubated for 30mins with rocking agitation. Gels were rinsed once more in 50ml distilled 
water overnight to remove all stain. All gels were documented and analysed using a Bio-Rad GS-
800 densitometer and Quantity One analysis software (Bio-Rad). 
 
3.3.2 Protein Assays 
For routine determination of protein concentration, absorbance at 280nm was measured using a 
Nanovue small volume spectrophotometer (GE healthcare) and calculation of concentration based 
on molar extinction coefficient as provided by analysis of the protein sequence using the Protperam 
utility (http://web.expasy.org/protparam/) and as detailed in Appendix 1. 
 
Where noted in methods, a bicinchoninic acid BCA (Thermo) assay was utilised according to the 
manufacturer’s instructions, with a range of Bovine Serum Albumin (BSA) standards between 20-
2000μg/ml and ensuring dilution of the sample to fall within this range. 
 
3.3.3 Western Blotting 
For western blotting, SDS-PAGE was performed as above. Gels were washed briefly with distilled 
water, overlaid with a nitrocellulose membrane of 0.45µm pore size (Invitrogen) and placed within 
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filter paper sandwich in an Xcell II blot module (Invitrogen). Blotting was performed for 60mins at 
30V in NuPAGE transfer buffer (Invitrogen). 
 
Membrane was washed once in TBS-T (50mM Tris pH 7.5, 150mM NaCl, 1% Tween 20) and 
blocked by incubation at 4ºC overnight in 50ml of blocking buffer (TBS-T, 5% skimmed milk 
powder). Primary antibody was diluted to the appropriate concentration in 50ml blocking buffer 
and incubated at room temperature for 90mins with rocking agitation and then thrice washed for 
5mins in 50ml TBS-T before addition of an alkaline phosphatase conjugated secondary antibody 
diluted to the appropriate concentration in 50ml blocking buffer and then thrice washed for 5mins 
in 50ml TBS-T before addition of nitro-blue tetrazolium/5-bromo-4-chloro-3'-indolyphosphate 
(NBT/BCIP) reagent (Pierce). Development was halted after 10mins by extensive washing with 
distilled water. 
 
3.3.4 Recombinant Protein Expression Tests 
To select clones and conditions for optimal expression of recombinant proteins, 10ml of TB was 
inoculated with a single half colony picked from a plate of fresh transformants and incubated at 
37°C with orbital agitation at 180rpm. Upon the culture growing to an optical density of 0.6 at 
600nm, Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a concentration of 1mM. 
After incubation for a further 3hrs, aliquots of 1ml were taken and sonicated at for 30s. Lysates 
were centrifuged at 10,000g for 10mins. The supernatant, containing soluble protein, was decanted 
while the pellet containing insoluble protein was resuspended in 1ml of Phosphate Buffered Saline 
(PBS) and sonicated for 30s. 10μl of each fraction was analysed according to Section 3.3.1. For 
archiving of selected clones with maximal expression, the remaining half colony was picked from 
the plate, emulsified in the cryoprotectant fluid of a Cryobank bead stock tube (Copan 
Diagnostics), the fluid removed by pipetting and the vial stored at -80°C. 
 
3.3.5 Recombinant Protein Expression 
Archived bead stocks of E. coli BL21 were retrieved from storage at -80°C and a single bead used 
to inoculate 50ml of TB supplemented with the appropriate antibiotic as detailed in Section 3.1.4. 
After overnight incubation at 37°C with orbital shaking at 180rpm, a 5% subculture was made into 
1L of fresh broth and incubation continued while optical density at 600nm was monitored at hourly 
intervals. Upon the culture growing to an optical density of 0.6 at 600nm, IPTG was added to a 




Cell pellets were recovered by centrifugation for 30mins at 3,500g in a Sorvall RC3BP centrifuge 
with a H6000A rotor and resuspended 10% w/v in the chromatography 'Buffer A' as detailed. Cells 
were lysed by sonication on ice for 10 x 30s intervals and cell debris removed by centrifugation for 
30mins at 40,000g in a Sorvall RC5C with an SS-34 rotor. Supernatants were filtered with a 
0.22µm cellulose syringe filter (Sartorius) and processed as detailed in Section 4.2. All procedures 





























This chapter describes the expression and purification of four recombinant proteins originating in 
C. difficile which are utilised for various purposes throughout the remainder of the thesis. The 
proteins are briefly described below in Table 4.1, along with references to their use later in the 
work. 
 
Name Description/Function Purpose(s) Section Reference 
SrtB 
Putative C. difficile 
Sortase 








Site directed mutant of 
SrtB, Cys to Ala mutation 






A putative wall-sorted 
protein with homology to 
the S. aureus Cna 
collagen binding protein 
and the RrrA pilin of 
Streptococcus 
pneumoniae 
Raising of Antiserum Section 5.2 
CD0386N 
N-terminal Truncation 
mutant of CD0386 










Table 4.1 – Proteins Expressed and Purified in this Chapter – Section references 
correspond to to the methods section where the protein or its antiserum is predominantly 
used. 
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4.2 – Methods 
 
4.2.1 Purification of C. difficile SrtB 
A codon-optimised gene encoding C. difficile SrtB, devoid of its predicted signal peptide (See 
Appendix A for sequence), was synthesised by Entelechon Gmbh and supplied within the plasmid 
pEXP1. Protein was expressed as in Section 3.3.5, and the following buffers were prepared:  
 
Buffer A – 50mM HEPES pH 7.5, 500mM NaCl, 10mM imidazole 
Buffer B – 50mM HEPES pH 7.5, 500mM NaCl, 500mM imidazole 
Buffer C – 50mM HEPES pH 7.5, 1M  (NH4)2SO4 
Buffer D – 50mM HEPES pH 7.5 
 
A XK16 chromatography column (GE Healthcare) was packed with 20ml of Chelating Sepharose 
(GE Healthcare), charged with nickel as per the manufacturer’s instructions and equilibrated with 
10 column volumes (CV) of Buffer A. Lysate was applied at a rate of 2ml/min, following which the 
column was washed with Buffer A at 2ml/min until the measured absorbance at 280nm had 
returned to the baseline level. Flow rate was reduced to 1ml/min and a buffer gradient initiated 
from 100% Buffer A to 100% Buffer B over a period of 40mins, during which time 5ml fractions 
were collected. 
 
Fractions corresponding to absorbance peaks in the chromatograph were analysed by SDS-PAGE, 
and those containing the protein of interest were pooled and dialysed overnight in 5L of Buffer C at 
4ºC. A 5ml HiTrap Butyl HP column (GE healthcare) was equilibrated with 10CV of Buffer C after 
which the dialysed eluate from the nickel affinity step was applied at a rate of 1ml/min, following 
which Buffer D was applied at the same rate until the measured absorbance at 280nm had returned 
to the baseline level. 
 
SrtB was dialysed extensively in a storage buffer consisting of 25mM HEPES, 150mM NaCl, 
concentrated to a target concentration of 10mg/ml using a 20ml Vivaspin 10kDa centrifugal 
filtration unit and stored at -80°C . 
 
4.2.2 Site Directed Mutagenesis of pEXP1-SrtB to generate pEXP1-SrtB C226A 
Mutagenesis of srtB to replace the ‘TGT’ codon encoding cystiene 226 with ‘GCT’, encoding an 
alanine residue, was performed using a method based on the technique commercially known as 
'Quickchange PCR' (Weiner and Costa, 1994). The plasmid pEXP1-srtB was amplified in its 
entirety by PCR with primers complementary to the region for mutation, but incorporating the 
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desired nucleotide changes (Table 3.2.3,  CD2718C226A F and CD2718C226A R). Restriction 
digestion of PCR products was performed with the methylation sensitive restriction enzyme DpnI , 
in order to cleave the methylated template plasmid while leaving the newly synthesised PCR 
products intact. After analysis by agarose gel electrophoresis, NEB 10β cells were transformed with 
the DnpI digestion products. Plasmid was prepared from transformants and a restriction digest with 
RsaI performed to screen for mutants by the loss of an RsaI site which overlapped the codon 
encoding Cys226. Mutants were confirmed by sequencing PCR fragments amplified with primers 
designed to anneal within the T7 promoter and terminator. 
 
4.2.3 Purification of C. difficile SrtB C226A 
Expression and purification was performed as for SrtB. 
 
4.2.4 Purification of C. difficile CD0386 (C-terminal His Tag) 
A gene encoding CD0386 devoid of its signal peptide and incorporating a C-terminal thrombin-
cleavable hexahistidine tag was synthesised by DNA 2.0 and supplied within the plasmid pJ414 
(See Appendix A for sequences). Protein was expressed as in Section 3.3.5, and the following 
buffers were prepared: 
 
Buffer A – 50mM HEPES pH 7.5, 500mM NaCl, 10mM imidazole 
Buffer B – 50mM HEPES pH 7.5, 500mM NaCl, 500mM imidazole 
 
 An XK16 chromatography column (GE Healthcare) was packed with 20ml of chelating sepharose 
(GE Healthcare), charged with nickel according to the maufacturers instructions and equilibrated 
with 10 column volumes (CV) of Buffer A. Lysate was applied at a rate of 2ml min, following 
which the column was washed with Buffer A at the same rate until the measured absorbance at 
280nm had returned to the baseline level. Flow rate was reduced and a buffer gradient initiated 
from 100% Buffer A to 100% Buffer B over a period of 40mins, during which time 5ml fractions 
were collected. 
 
4.2.5 Cloning and Purification of CD0386 (N-terminal His Tag) 
To express CD0386 with an N-terminal affinity tag, restriction cloning via HindIII/KpnI was 
performed according to Section 3.2.4 in order to clone CD0386 into pTAC-MAT1 (Invitrogen) 
which encodes a metal affinity fusion tag of the sequence ‘MAHNHRKH’. Correct cloning of the 
gene was confirmed by analytical restriction digest with HindIII/KpnI as in Section 3.2.3. Protein 
was expressed as in Section 3.3.5 and the following buffers prepared: 
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Buffer A – 50 mM HEPES pH7.5, 500mM NaCl, 10mM imidazole 
Buffer B – 50mM HEPES pH 7.5, 500mM NaCl, 500mM imidazole 
Buffer C – 20mM Bis-Tris pH 5.5, 180mM NaCl   
Buffer D – 20mM Bis-Tris pH 5.5, 500mM NaCl 
 
A XK16 chromatography column (GE Healthcare) was packed with 20ml of chelating sepharose 
(GE Healthcare), charged with nickel according to the maufacturers instructions and equilibrated 
with 10 column volumes (CV) of Buffer A. Lysate was applied at a rate of 2ml min, following 
which the column was washed with Buffer A at the same rate until the measured absorbance at 
280nm had returned to the baseline level. Flow rate was reduced and a buffer gradient initiated 
from 100% Buffer A to 100% Buffer B over a period of 40mins, during which time 5ml fractions 
were collected. Fractions corresponding to absorbance peaks in the chromatograph were analysed 
by SDS-PAGE, and those containing the protein of interest were pooled and dialysed overnight in 
5L of Buffer C at 4ºC. 
 
A MonoQ 5/50 anion exchange column (GE Healthcare) was equilibrated with 5CV of Buffer C 
and the pooled dialysed fractions applied at a rate of 1 ml/min. The column was washed at the same 
rate with buffer C until absorbance at 280nm returned to the baseline level. A gradient to 25% 
Buffer D over 30mins was initated and 1ml fractions collected. 
 
CD0386 was dialysed extensively in a storage buffer consisting 25mM HEPES, 150mM NaCl, 
concentrated to a target concentration of 10mg/ml using a 20ml Vivaspin 10kDa centrifugal 
filtration unit and stored at -80°C 
 
4.2.6 Cloning and Purification of an N-terminal Fragment of CD0386 (CD0386N) 
For crystallographic studies, an N-terminal fragment of CD0386 was selected, encompassing a 
domain identified by Phyre2 as having predicted secondary structure homology to the RrgA pilin of 
Streptococcus pneumoniae  (Chapter 7 describes this fragment in detail, see Appendix A for 
sequence). The fragment was amplified from pJ414-CD0386 with primers incorporating restriction 
sites to allowing cloning into pET28a via NdeI and XhoI (Table 3.2.3, CD0386 pET28F and 
pET28R). Protein was expressed as in Section 3.3.5. For purification, the following buffers were 
prepared: 
 
Buffer A – 50mM HEPES pH 7.5, 500mM NaCl, 10mM imidazole 
Buffer B – 50mM HEPES pH 7.5, 500mM NaCl, 500mM imidazole 
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 A XK16 chromatography column (GE Healthcare) was packed with 20ml of Chelating Sepharose 
(GE Healthcare), charged with nickel as per the manufacturer’s instructions and equilibrated with 
10 column volumes of Buffer A. Lysate was applied at a rate of 2ml min, following which the 
column was washed with Buffer A at the same rate until the measured absorbance at 280nm had 
returned to the baseline level. Flow rate was reduced to 1ml/min and a buffer gradient initiated 
from 100% Buffer A to 100% Buffer B over a period of 40mins, during which time 5ml fractions 
were collected. 
 
After analysis of the nickel affinity purification by SDS-PAGE, fractions containing CD0386N 
were concentrated to a volume of 2ml and applied to a 16/60 Superdex 200 at a rate of 0.5ml/min 
with a running buffer of 50mM HEPES pH7.5, 250mM NaCl. After SDS-PAGE analysis, peak 
fractions were collected and concentrated to a target concentration of 10mg/ml using a 20ml 
Vivaspin 10kDa centrifugal filtration unit (Sartorius AG). 
 
4.2.7 Production and Titration of Rabbit Antiserum against SrtB and CD0386 
Production of rabbit antiserum was performed by Covalab S.A.S.  A 50μg dose of either SrtB or 
CD0386 was mixed with freund's incomplete adjuvant and injected subcutaneusly into duplicate 
New Zealand White rabbits. Immunisations were performed on days 0, 21 and 42. A terminal bleed 
was performed on day 53. 
 
To determine antibody titre, an Enzyme Linked Immunosorbent Assay (ELISA) was performed.  
The antigen to which the serum was raised was diluted to 5μg/ml in Phosphate Buffered Saline 
(PBS) and 100μl added to rows 1-6 of a 96 well ELISA plate (Corning) while 100μl of PBS was 
applied to the remaining wells. After overnight incubation at 4ºC, the plate was washed thrice with 
PBS + 0.1% Tween 20 (PBS-T) and blocked by incubation with blocking buffer (PBS-T + 5% 
foetal calf serum) for 2hrs at 37ºC.  The serum was diluted 1 in 2 in blocking buffer and 200µl of 
this dilution applied to wells in column 1. 120µL of blocking buffer was placed in the remaining 
wells in row A-C, and a 60µL serial dilution was performed across the plate resulting in 1 in 3 
dilution curve. The plate was incubated at 37°C for 2hrs followed by washing thrice with PBS-T 
and the application of the secondary antibody (Sigma goat anti-rabbit HRP conjugate) at a dilution 
of 1:10,000 in blocking buffer. Plate was incubated at 37°C for 2 hours followed by thrice washing 
with PBS-T and the application 100µL of 3,3’,5,5’-Tetramethylbenzidine (TMB). 100µL of TMB 
stop reagent was added after 5mins. Absorbance at 450nm was measured using a plate 
spectrophotometer (Tecan) using 620nm as a reference frequency. 
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4.2.8 – Analytical Gel Filtration of SrtB and SrtB C226A 
A Superdex 200 analytical gel filtration column (GE Healthcare) was washed with one column 
volume of filter sterilised water followed by one column volume of filter sterilised phosphate 
buffered saline (PBS) at a flow rate of 0.3ml/min. 40µg of SrtB or SrtB C226A was injected onto 
the column in a total volume of 200µl and isocratic elution with PBS continued at 0.3ml/min while 
absorbance was recorded at 280nm. Molecular weights estimation was performed by reference to a 
standard curve prepared by analysis of Blue Dextran 2000, Thyroglobulin, Ferritin, Aldolase, 




4.3.1 Purification of SrtB 
C. difficile SrtB was expressed in batch culture of E. coli BL21 from plasmid pEXP1-SrtB, which 
encodes a fusion protein comprising of an enterokinase cleavable hexahistidine tag. The 
purification method, detailed in Section 3.4.1, consisted of a nickel affinity chromatography 
followed by hydrophobic interaction chromatography (see Figure 4.3.1). Overall yield was 
typically 5mg per litre of culture. Mass spectroscopic analysis of the purified protein revealed a 
mass within 1 dalton of the theoretical mass of the protein (see Figure 4.3.3). 
 
4.3.2 Mutagenesis and Purification of SrtB C226A 
C. difficile SrtB C226A was expressed in batch culture of E. coli BL21 from plasmid pEXP1-SrtB 
C226A, generated by site directed mutagenesis of pEXP1-SrtB and hence encoding the same 
enterokinase cleavable hexahistidine tag. Purification methodology and typical yield was as for 
SrtB (See Figure 4.3.2). Mass spectroscopic analysis of the purified protein revealed a mass within 
1 dalton of the theoretical mass of the protein and with a loss of 32 Da relative to SrtB as expected 
due to the C226A mutation (see Figure 4.3.4) 
 
4.3.3 Attempted Removal of Hexahistidine tag from C. difficile SrtB 
C.difficle SrtB was incubated overnight at 4ºC with a varying range of concentration of 
enterokinase in an attempt to remove the hexahistidine tag. A multiple band pattern consisting of 
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Figure 4.3.3 – Mass Spectroscopic Analysis of Purified SrtB. The major peak of 28308 Da 
is in agreement with the theoretical mass of SrtB of 28307.6 Da. Minor contaminants are 
observed at 5, 11, 70 and 81kDa. 
 
Figure 4.3.4 – Mass Spectroscopic Analysis of Purified SrtB C226A. The major peak 
of 28276 Da is in agreement with the theoretical mass of SrtB C226A of 28275.5 Da. 






















4.3.4 Purification of CD0386 (C-terminal Polyhistidine tag) 
Pilot nickel affinity purification (see Figure 4.3.6) of CD0386 expressed in E. coli from plasmid 
pJ414 with the inclusion of a C-terminal hexahistidine tag resulted in poor yield and purity which 











Figure 4.3.5. Attempted Removal of the Polyhistidine Tag of SrtB. A) SDS-PAGE of 
cleavage products following incubation of SrtB with enterokinase overnight at 4°C B) 























Molar ratio of SrtB:Enterokinase 












































4.3.5 Cloning and Purification of CD0386 (N-terminal metal affinity tag) 
In order to improve yield and purity of CD0386, the gene was restriction cloned into pTAC-MAT1, 
a vector encoding a N-terminal metal affinity fusion tag. Expression of this construct and 
purification by nickel affinity resulted in much improved yield and purity (Figure  4.3.7 A). Lower 
molecular weight contaminants were substantially removed by a downstream ion exchange 
chromatography (Figure 4.3.7 B). 
 
Figure 4.3.6 – Purification of CD0386 (C-terminal polyhistidine tag).  
Chromatogram illustrating binding and imidazole gradient elution of C-terminally 
His-tagged CD0386 from a Ni
2+
 charged chelating sepharose. B) SDS-PAGE of the 
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4.3.6 Cloning and Purification of CD0386N 
A gene fragment encoding N-terminal domain of CD0386 (See Appendix A for sequence 
information) was cloned into pET28a in frame with an N-terminal thrombin cleavable 
hexahistidine tag and expressed in E. coli BL21. Purification consisted of nickel affinity 
chromatography (Figure 4.3.9 A), thrombin cleavage of the tag and recovery by nickel affinity 
chromatography followed by size exclusion chromatography to remove contaminating high 
molecular weight aggregates (Figure 4.3.9 B). Mass spectroscopic analysis of the purified protein 


























Figure 4.3.8 – Mass Spectroscopic analysis of purified CD0386N. The major peak of 
61114 Da is in agreement with the theoretical mass of thrombin-cleaved CD0386N of 
61111 Da. Minor contaminants are present at 12, 20, 30, 59 and 63kDa. No peak is 
observed for residual uncleaved CD0386 (mass 62630.9). 
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4.3.7 Production and Titration of Rabbit Antiserum Against CD2718 and CD0386 
Rabbits were immunised in duplicate and their serum titrated by ELISA on plates coated with the 
appropriate antigen (Figure 4.3.10). For both antigens, titres of ~10
-7
 were obtained with little 
difference between individual rabbits. Sacrifice of rabbits on Day 53 produced a terminal bleed of 


























Figure 4.3.10 – Titration of anti-SrtB and anti-CD0386 Serum. Duplicate rabbits 
were immunised with recombinant protein. Terminal bleeds on Day 53 were analysed 




4.3.8 – Analytical Gel Filtration of SrtB and SrtB C226A 
Analytical Gel Filtration of SrtB and SrtB C226A was performed as described in Section 4.2.8. 




























Ve = 15.9ml 
Ve = 15.9ml 
A 
Estimated Mr  
= 24.5 kDa 
Estimated Mr 
= 24.5 kDa 
Figure 4.3.11  - Analytical Gel Filtration of SrtB (A) and SrtB C226A (B). 
Estimated mass was determined by reference to a standard curve generated by 
analysis of six molecular weight standards.  
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4.4 Discussion on Purification of Recombinant Proteins 
 
4.4.1 Purification of C. difficile SrtB and SrtB C226A 
A good yield of SrtB was obtained following nickel affinity purification, with in excess of 20mg 
typically purified from a 4 litre batch culture. A negative chromatography step comprising a butyl 
sepharose hydrophobic interaction column increased the purity of nickel affinity purified SrtB to 
approaching 100% as determined by SDS-PAGE. Purification of the SrtB C226A mutant was 
essentially identical in both method and results with the exception of dimerisation as described 
below. Mass spectroscopic analysis indicates that both proteins are of the expected mass with the 
C226A substitution clearly apparent with mass difference of 32Da. 
 
Some dimerisation was observed in non-reducing SDS-PAGE analysis of SrtB (see Figure 4.3.1 B, 
~56kDa band). This dimerisation was not observed in reducing SDS-PAGE or in SDS-PAGE of the 
C226A mutant. As SrtB contains no cysteine other than Cys226, this dimerisation must be due to 
disulphide bonding between Cys226 residues of SrtB active site. Gel filtration experiments provide 
an estimated monodisperse mass of 24.5kDa, confirming that the protein is monomeric rather than 
dimeric in solution. It appears, therefore, that  disulphide formation is an artefact of preparation for 
SDS-PAGE, perhaps due to exposure of the buried active site sulphydryl during heating or 
denaturation. 
 
4.4.2 Removal of Polyhistidine tag from SrtB 
The plasmid from which SrtB was expressed, pEXP1, encodes a spacer peptide between the cloned 
gene and the polyhistidine tag which contains a canonical enterokinase cleavage site ‘DDDDK’ . 
However, despite its specificity for a pentapeptide site, enterokinase is known to cleave at non-
canonical sites (Shahravan et al., 2008). When removal of the tag from SrtB was attempted, a 
multiple band pattern was observed indicating that enterokinase cleaves SrtB at multiple sites. 
Shahavran et al describe methods to improve the specificity of enterokinase cleavage by 
denaturation of the tagged protein but this is not a desirable methodology for purification of an 
active enzyme. If it was deemed strictly necessary to remove the tag from this protein, cloning into 
a vector with a tag cleavable with a different protease (eg. Thrombin or Factor Xa) could be 
performed. 
 
4.4.3 Purification of CD0386  
Following nickel affinity chromatography, neither yield nor purity of CD0386 was satisfactory 
when expressed with an C-terminal hexahistidine tag. Blotting with an anti-his antibody did, 
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however, indicate expression of a protein of the expected mass. Poor affinity of the protein for 
nickel sepaharose was possibly due to inaccessibility of the tag due to inopportune protein folding. 
Affinity chromatography under denaturing conditions was attempted but did not improve yield, 
suggesting that the tag remained inaccessible even after the protein had been denatured. 
 
Cloning of the CD0386 into pTAC-MAT1 to allow expression of CD0386 with a N-terminal metal 
affinity tag significantly increased yield from metal affinity purification and when this was 
combined with a subsequent ion exchange chromatography step, a purity and yield was obtained 
which was considered satisfactory for the purposes of immunisation for raising of antiserum. 
However, significant contamination with higher molecular weight aggregates was observed, which 
could not be removed by size exclusion chromatography. 
 
4.4.4 Purification of CD0386N 
Due to the large size of CD0386 and the considerable difficulties in its purification, a smaller 
fragment was deemed necessary for crystallisation experiments. To this end, a gene fragment 
encoding a 61kDa N-terminal fragment of CD0386 was cloned into pET28a fused with an N-
terminal thrombin-cleavable hexahistidine tag. Purification of CD0386N by metal affinity 
chromatography resulted in much higher purity than was obtained with full-length CD0386. Also, 
unlike the full length protein, it was possible to remove the high molecular weight aggregates by 
size exclusion chromatography, resulting in a significantly more homogenous product. 
 
SDS-PAGE of CD0386N results in three bands, one at the expected mass of 61kDa and two bands 
at ~40kDa and ~20kDa. However, mass spectroscopy does not reveal major contaminants at these 
masses and the purified protein was obtained from a single, well-shaped peak, suggesting a 
monodisperse species. Given that the summed masses of the unexpected bands equal that of 
CD0386, it possible that these two bands correspond to breakdown products, and based on the 
above evidence that these contaminants are absent in the raw purified product, it is hypothesised 
that the protein is susceptible to breakdown during preparation for SDS-PAGE. This could be 
confirmed by excision of the unknown bands and mass spectroscopy of the excised protein. For the 
purpose of this purification it is satisfactory that both mass spectroscopy and size exclusion 





Chapter 5 – Characterisation of a C. difficile Sortase Knockout 
 
5.1 Introduction and Aims 
 
5.1.1 Introduction to Genetic Manipulation of C. difficile 
For many years, C. difficile was considered refractory to genetic manipulation. Early efforts 
focussed on transposon mutagenesis, with the demonstration that DNA within transposon Tn916 
could be inserted into the genome following conjugative transfer of a Tn916-bearing plasmid from 
B. subtilis (Mullany et al., 1994). Initial experiments in C. difficile CD37 indicated that insertion of 
Tn916 occurs at defined hotspots (Mullany et al., 1991) which would make it of limited use for 
mutagenesis, and although later experiments in C. difficile 630 and R20291 resulted in a random 
and multiple insertion pattern (Hussain, 2005; Mullany et al., 2012) it remains of limited use for 
mutagenesis experiments. 
 
A major obstacle to the development of genetic manipulation in C. difficile was the lack of a 
suitable vector system. In C. difficile, as in many species, introduction of exogenous plasmid 
vectors is hindered by the presence a restriction/methylation system which protects the host by 
selectively cleaving exogenous DNA. By characterising the restriction/methylation system of C. 
difficile and engineering a plasmid without recognition sites for its restriction enzyme CdiI (Purdy 
et al., 2002), it has become possible to efficiently transfer shuttle vectors from E. coli to several 
strains of C. difficile.  
 
With plasmid vectors now readily available, the most common genetic manipulation technique 
currently utilised in C. difficile is insertional mutagenesis with mobile bacterial introns. Self-
splicing mobile introns are present in many bacterial, plant and mitochondrial genomes, and of 
particular interest are the mobile group II introns. These encode an intron encoded protein (IEP) 
and a ribozymic RNA component. The IEP binds to the RNA to form a ribonucleoprotein complex 
(RNP), activating ribozymatic activity by which the RNA splices itself into the sense strand of the 
target DNA (Cousineau et al., 1998). The IEP then cleaves the antisense strand and reverse 
transcribes the integrated RNA to generate a single stranded DNA (Zimmerly et al., 1995). The 
process by which the sense strand is synthesed to repair the site is dependent on host DNA 
polymerases rather than any activity of the IEP  (Smith et al., 2005). 
 
The overall process activity is known as 'retrohoming' (See Figure 5.1.1), and because target 
sequence recongition is co-operative between the protein and RNA components, the sequence of 
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the RNA component can be engineered to promote integration of the intron at specific sites (Mohr 
et al., 2000). In addition, genetic elements can be introduced into the intron without affecting 
mobility (Smith et al., 2005), allowing selectable markers to be employed. Of particular utility are 
Retrotransposition Activated Markers (RAMs), consisting of an antibiotic resistance gene 
interrupted by a group I intron. Splicing out of the group I intron occurs only when the RAM is 
integrated into chromosomal DNA, so acquisition of antibiotic resistance can be used to select 



















The use of retargeted Lactococcus lactis Ll.LtrB intron for targeted mutagenesis became 
widespread after commercialisation by Sigma Aldrich under the name of ‘Targetron’, and an 
adaptation of the system for use in C. difficile was published in 2007 (Heap et al., 2007).  The 
system employs the Ll.LtrB intron within a conjugative shuttle vector pMTL007 which is capable 
of independent replication in either E. coli or C. difficile and is competent for conjugation between 
the two. Thus retargeting of the plasmid-borne intron can be performed in E. coli before transfer 
into C. difficile by conjugation. The intron encoded by pMTL007 includes an erythromycin 
resistance RAM, so an erythromycin sensitive strain must be used. In the case of C. difficile, an 
erythromycin sensitive mutant of strain 630 (C. difficile 630Δerm) is typically employed.  
 
Figure 5.1.1 – Schematic of Retrohoming by a Group II Intron. Following 
recognition of the target DNA by the intron ribonuceloprotein, the intron RNA splices 
itself into the target. The Intron Encoded Protein reverse transcribes the intron sequence 





The aims of the work described in this chapter were to investigate the C. difficile sortase by the 
following means: 
 
1. Analysis of the C. difficile genome to identify predicted proteins with characteristics of 
sortase-anchored proteins and to provide a putative summary of their functions. 
 
2. Construction of a a C. difficile sortase (srtB) gene mutant by intron mutagenesis and 
confirmation of a loss of SrtB from the cell surface. 
 
3. Characterisation of the sortase mutant with particular regard to the localisation of the 




5.2.1 In Silico Analysis of The Putative C. difficile Class B Sortase 
For placement of the putative C. difficile srtB gene (gene locus CD2718) within a phylogenetic tree 
of sortases, five representative sortase genes were chosen from each class and a distance tree drawn 
using a maximum likelihood method using the online pipeline provided by the Centre National de 
la Recherche Scientifique, France (www.phylogeny.fr,  Dereeper et al. 2008). For identification of 
conserved amino acids within the sequence of SrtB, amino acid sequence alignments were 
performed using an  implementation of ClustalW algorithm hosted by the European Bioinformatics 
Institute (www.ebi.ac.uk/Tools/msa/clustalw2/,  Larkin et al. 2007). 
 
5.2.2 Identification and Analysis of Putative Sortase Substrates 
The genome of C. difficile 630 was searched for proteins containing an [SP]PxTG motif using the 
Basic Local Alignment Search Tool (BLAST) of the National Centre for Biotechnology 
Information (http://blast.ncbi.nlm.nih.gov/,  Altschul et al. 1990). The resulting list of [SP]PxTG-
containing proteins was further refined by removal of proteins which did not contain N-terminal 
secretion signal as predicted by the SignalP 4.0  program (www.cbs.dtu.dk/services/SignalP, 
Petersen et al. 2011), or those in which the [SP]PxTG motif was not within 50 amino acids of the 
C- terminus. To ascribe putative functions to the products of the identified genes, conserved 
domains were identified using the NCBI Conserved Domain Search (Marchler-Bauer and Bryant, 
2004) and secondary structure prediction and secondary structure homology searches were 
performed using the Phyre2 server (www.sbg.bio.ic.ac.uk/~phyre/, Kelley & Sternberg 2009) 
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5.2.3 Generation of Targeted Insertion Knockout Mutants 
Targets for insertion within the srtB gene (gene locus CD2718) were chosen using the online tool 
provided by Sigma for the targetron system (http://www.sigma-genosys.com/targetron/). The 














pMTL007 plasmids were retargeted for the sites listed in Table 5.2.1 and synthesised by DNA2.0 
on supply of the sequence for the retargeting region, generated by replacing the retargeting 
sequences of the intron with the sequences as provided by the Sigma targetron tool. E. coli CA343 
was transformed with retargeted pMTL007 plasmids by electroporation. 
 
A culture of E. coli CA343 pMTL007 harbouring the retargeted intron was grown overnight in LB 
to an optical density of 0.6 at 600nm. Cells were harvested from 1ml of broth by centrifugation at 
3,000g for 30mins and resuspended in 100μl of a culture of C. difficile 630Δerm grown to an 
optical density of 0.6 at 600nm, resulting in a 100:1 ratio of E. coli to C. difficile. The culture 
mixture was spread on a 22μm nitrocellulose filter paper (Sartorius AG) placed in the centre of an 
FAA plate. After 3 days of incubation, filter papers were removed, washed with sterile pre-reduced 
phosphate buffered saline and transconjugants selected by spreading of the resulting suspension 
spread on C. difficile selective agar plates (E&O Laboratories, Bonnybridge UK) supplemented 
with 15µg/ml thiamphenicol. 
 
Integrants were selected by restreaking transconjugant colonies onto BHI agar supplemented with 
5µg/ml erythromycin. Colonies were picked and colony PCR performed with primers flanking the 
group I intron (Table 3.2.3 ErmR and ErmF) to confirm that the erythromycin resistant phenotype 
was due to splicing out of the group I intron within the ErmRAM. To confirm specific integration 
Insertion site Sequence 5' exon Sequence 3' Exon Score 
354/255a CTTTCTGTTGAGAATACAAATATAAATTAT CCAGTTGTACAATCT 8.3 
510|511s   GTAGAATCTGATTATGATTATCTAAAAACA AATTTTAATAATGAA 8.19 
514|515a TGTAATTTTGATAATCAGATTCATTATTAA AATTTGTTTTTAGAT 8.07 
206|207a TTATCTTTAGATTGTACAACTGGATAATTT             ATATTTGTATTCTCA 7.13 
213|214s   ATTTAGGTTGTTGAACATAGTTTTATTTTT CATATTATGTCCATA 6.32 
Table 5.2.1 Hypothetical Ll.LtrB intron insertion sites within CD2718 (srtB) as 
predicted by the Sigma Targetron Tool. Insertion site loci are expressed as base 
pairs from the start of the open reading frame. Sense or antisense insertion is indicated 
by ‘s’ or ‘a’ respectively after the site locus. 
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of the intron into the intended site, PCR was performed with primers flanking the gene of interest 
(Table 3.2.3, CD2718FlankF and CD2718FlankR) and the products sequenced. 
 
5.2.4 Determination of Growth Rate and Toxin Production of C. difficile 630 srtB::erm 
Intracellular and extracellular toxin titres were determined by an Enzyme Linked Immunosorbent 
Assay (ELISA) employing sheep antitoxin polyclonal antibodies as a capture step. Growth rate data 
were collected simultaneously with toxin sampling in order to ensure equivalence of growth 
between strains. 
 
Two 14ml aliquots of reduced BHI were inoculated with either C. difficile 630 or C. difficile 
srtB::erm and grown overnight. Three 1ml aliquots were taken from each, centrifuged at 4,000g for 
15mins and the pellets resuspended in 1ml fresh BHI, a step neccesary to remove any toxin 
produced in the overnight culture. The resuspended culture was then used to inoculate 25ml of 
fresh BHI. At time points 0h, 8h, 24h, 30h, and 48h, 2ml samples were taken from each culture. 
Following measurement of optical density at 600nm, culture samples were centrifuged at 10,000g 
for 10mins and the supernatant decanted and frozen at -80°C. Pellets were resuspended in 1ml BHI, 
sonicated on ice for 20s then stored at -80°C until analysis by ELISA.  
 
Sheep polyclonal anti-TcdA or anti-TcdB antibodies were diluted to a concentration of 5µg/ml and 
a volume of 100µl applied to a high binding 96 well plates (Corning). Plates were incubated at 
37°C for 90mins, then washed thrice in PBS-T (1x PBS, 0.1% Tween). Plates were blocked by 
incubating with with 150µl blocking buffer (PBS-T + 5% foetal calf serum) for 1hr at 37°C and 
then washed thrice with PBS-T. Dilution series of standards and samples were assembled in non-
binding 96-well plates (Corning) Standard preparations of TcdA or TcdB were diluted to 1μg/ml in 
blocking buffer and 300μl applied to wells 1A and 1B of the plate. Samples for analysis were 
applied in triplicate to the remaining wells of column 1 in a volume of 300μl.  The remainder of the 
wells on the plate were filled with 150µl of blocking buffer. A multichannel pipette was used to 
perform a 1 in 2 serial dilution series across the plate. From this dilution plate, 100µl of was 
transferred to the assay plate and incubated for 1hr at 37°C before washing thrice with PBS-T. 
 
Biotinylated sheep anti-TcdA or anti-TcdB polyclonal antibodies were diluted in blocking buffer to 
either 1µg/ml for TcdA or 10µg/ml for the TcdB. 100µl added to all wells of the appropriate plate 
and incubated for 1hr at 37°C before washing thrice with PBS-T. A streptavidin horseradish 
peroxidase conjuagate was diluted 1/1000 in blocking buffer and 100µl added to all wells and 
incubated for 10mins, followed by washing 3x with PBS-T. 100µl of 3,3’,5,5’-
Tetramethylbenzidinem (TMB) substrate was added to each well, incubated at 37°C for 10mins. 
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100µl of TMB stop reagent was added to each well and absorbence at 450nm measured with a plate 
spectrophotometer (Tecan), with reference readings taken at 620nm. All washing steps were 
performed using a 12-head automated microplate washer (Thermo) 
 
5.2.5 Immunofluorescence with anti-CD0386 antibodies 
Unless otherwise noted, centrifugation steps described below were for 10mins at 5,000g and where 
washing consisted of is described, this consisted of three resuspensions in 1ml PBS followed by 
three centrifugation steps at 5000g.. 
 
C. difficile was grown to an optical density of 1.0 at 600nm. Aliquots of 1.5ml culture were 
centrifuged and washed. The pellet was resuspended in 100μl sterile water, added to 900μl ice cold 
methanol, incubated for 10mins at room temperature with rotational incubation and then washed 
thrice. Cells were resuspended in PBS supplemented with 1mg/ml Bovine Serum Albumin (BSA), 
either with or without 10μg/ml of purified primary antibody, and incubated with rotation for 1hr at 
room temperature. After washing with PBS, cells were resuspended in 1ml PBS 1mg/ml BSA, with 
10μg/ml anti-rabbit Alexa 488 conjugated antibody (Thermo), incubated with rotation for 1hr. After 
washing in PBS, cells were resuspended in distilled water. The suspension was spotted onto a glass 
slide and air dried in darkness before inspection with an MWG EVOS fluorescence microscope 
using either visible light or UV light with the manufacturer's GFP filter (transmission peak 
525/550nm). 
 
5.2.6 Automated Counting of Fluorescent Cells 
Samples of C. difficile 630 and 630 srtB::erm were prepared as in Section 4.2.5. To ensure blind 
counting of fluorescent cells, the CellC image analysis program was utilised (Selinummi et al., 
2005). Fields were selected blind from three biological replicates and images were taken in 
duplicate visible/UV. The software was configured to run in batch mode and to count cells as 
fluorescent when appearing in both the visible and UV images. The mean number of fluorescent 









5.2.7 Fractionation of C. difficile 
Cells were fractionated using a method adapted from previous reports of proteomic analysis of C. 
difficile (Wright et al., 2005). 1ml aliquots of C. difficile 630 and 630 srtB::erm were retrieved 
from storage at -80°C and used to inoculate 14ml of BHI and incubated anaerobically overnight at 
37°C. Four sets of 3% subcultures were made (ie. four cultures of each knockout) in 50ml of fresh 
BHI and incubated anaerobically at 37°C At 5hrs, 24hrs and 48hrs, the following fractionation 
protocol was performed on both the wild type and knockout.   
 
Culture aliquots of 1ml were pelleted by centrifugation at 3,000g for 10mins, resuspended in 20ml 
Tris Sucrose Buffer (TS – 100mM Tris pH6.9, 10mM MgCl2, 0.5M Sucrose) and centrifuged once 
again at 3,000g for 10mins. Pellets were resuspended in 2.4ml of digestion buffer (DB – TS Buffer 
+ 1mg/ml lysozyme and 60μg/ml mutanolysin) and incubated at 37°C for 60mins with rotational 
agitation. Protoplasts were recovered by centrifugation at 10,000g for 10mins. The supernantant, 
composed of the wall fraction, was decanted and frozen at -80ºC. 
 
The protoplast pellet was resuspended in 1ml protoplast lysis buffer (10mM Tris pH7.4, 100mM 
NaCl, 10mM MgCl2), incubated for 60mins on ice and freeze-thawed twice at in a dry ice/ethanol 
bath. Membrane fraction was recovered by centrifugation at 10,000g for 10mins. The supernatant, 
composed of the cytoplasmic fraction, was decantedand frozen at -80ºC . The pellet was 
resuspended in 1ml of TS buffer and sonicated 3 x 10s until homogenous. To ensure equivalence 
between samples, protein concentration was determined by BCA assay. Analysis by SDS PAGE and 
western blotting was performed as detailed in Section 3.3. 
 
5.2.8 Immunoprecipitation of CD0386 from C. difficile wall fraction 
Immunoglobulin G (IgG) was purified from anti-CD0386 rabbit serum using a Protein A sepharose 
column (GE healthcare) according to the manufacturers instructions. 20µg of IgG was coupled to a 
direct immunoprecipitation column as supplied in Pierce Direct Immunoprecipitation kit, following 
which the column was incubated at 4ºC overnight with either 600µl of wall fraction, 60µl of wall 
fraction diluted to a volume of 600µl with the Pierce immunoprecipitation buffer or 20µg of 







5.2.9 Preparation of purified C. difficile peptidoglycan 
Peptidoglycan purification was attempted by the ‘boiling SDS’ method, whereby culture was added 
dropwise to an aqueous solution of 8% SDS at 95ºC. After heating for 2hrs at 95ºC, insoluble 
material was recovered by centrifugation at 10,000g and resuspended in a volume of water equal 
that that of the original culture volume before being added dropwise to a fresh solution of 8% SDS. 
This washing process was repeated thrice. Fractions were collected throughout and analysed by 
SDS-PAGE. 
 
5.2.10 Challenge of Hamsters with C. difficile 630 srtB::erm 
The animal procedures described in this study were perfomed by staff of Public Health England, 
Porton Down. Procedures were approved by a local ethical committee and carried out under a UK 
Home Office-approved Project Licence and in full compliance with the UK Animals (Scientific 
Procedures) Act 1986. 
 
To prepare spores for challenge experiments, 12 Facultative Anaerobe Agar (FAA) plates were 
inoculated with overnight growth of either C. difficile 630 or C. difficile 630 srtB::erm in 5ml 
sBHI. After 14 days of anaerobic incubation at 37°C, colonial growth was scraped with a sterile 
swab and resuspended in 15ml Dulbecco’s Modified Eagle’s Medium (DMEM). The resuspension 
was heat-shocked at 62°C for 40mins to kill vegetative cells, aliquoted and stored at -80°C. Spore 
counts were determined by plating of tenfold serial dilutions on FAA agar.  
 
Female syrian hamsters (80-100g) were housed in pairs in isolator cages with filter lids to minimise 
contamination between groups. Clindamycin was administered to all groups at a dose of 2mg in 
0.2ml sterile H2O two days prior to challenge. Group 1 (n=10) was challenged orally with 10
3
 C. 
difficile 630 spores, Group 2 (n=10) was challenged with 10
3
 C. difficile 630 srtB::erm spores 
while Group 3 (n=6) remained unchallenged.  
 
All animals were weighed daily and monitored six times per day throughout the experiment. 
Hamsters were scored (0-3) on diarrhoea, weight loss, lethargy, and tender abdomen. Hamsters 









5.3.1 In Silico Analysis of The Putative C. difficile Sortase 
A maximum likelihood phylogenetic tree (Figure 5.3.1) places the gene locus CD2718 (srtB), 

















Multiple sequence alignment (Figure 5.3.2) reveals several motifs which are conserved in the class 
B sortases, including a TLxTC motif which is characteristic of sortase enzymes containing the 
active site cysteine residue equivalent to Cys184 in S. aureus SrtA, a conserved arginine 
downstream of the TLxTC motif in a similar position to Arg233 of S. aureus SrtA and a ‘YGH’ 
motif containing the structural equivalent of the S. aureus SrtA His120 (Zhang et al., 2004) 
 
 
Figure 5.3.1 – Phylogeny of C. difficile CD2178 (srtB). Phylogram showing 
placement of the C. difficile CD2718 (srtB) gene (boxed) within a tree of selected 

















































































































































5.3.2 In Silico Identification of the Putative C. difficile Sortase Substrates 
A BLAST search to identify hypothetical C. difficile 630 proteins containing an [SP]PxTG motif 
led to a preliminary list of 25 proteins. Of these, 15 were eliminated because they did not contain 
an N-terminal secretion signal peptide as determined by the SignalP program. The remaining 
proteins were examined manually, and a further 3 eliminated either because the [SP]PxTG motif 
was too far (<50aa) from the C terminus or because the C-terminus was not rich in positively 
charged amino acids. The remaining seven proteins, containing all of the characteristics of sortase 
substrates, are listed in Table 5.3.1 accompanied by gene annotations and results of conserved 

























CD0183 37.0 Cell Wall Hydrolase Pfam 877 (Unknown Function) 
Pfam08239 (Bacterial SH3 domain) 




CD0386 111.6 Putative collagen-
binding surface 
protein 














CD2768 24.9 Cell Wall Hydrolase Pfam 877 (Unknown Function) 
Pfam08239 (Bacterial SH3 domain) 




CD2831 107.7 Putative Adhesin Pfam05738 (Cna B Domain) 
CL05349 (Collagen Binding Domain) 
2.33e-06 
3.79e-03 
CD3246 79.9 Surface Protein Pfam06346 (Phormin Homology Region) 5.39e-05 









Fig 5.3.3. Alignment of the C-termini of the Seven Putative C. difficile Sortase 
Subtrates. The C-termini of the proteins listed in Table 5.3.1 are shown. The [SP]PxTG 
motif has been underlined and positively charged residues are highlighted in red. 
Table 5.3.1 – The Putative C. difficile sortase substrates. Identification of C. difficile 
proteins fulfilling the criteria for sortase substrates, containing a C-terminal [SP]PxTG 
motif and a N-terminal secretion signal. 
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5.3.3 Phyre2 Analysis of Putative C. difficile Sortase Substrates 
To aid in ascribing putative functions to the putative sortase substrates, their sequences were 
submitted to the Phyre2 server, which performs secondary structure prediction followed by 
searching of PDB entries to predict structural homologues. With the exception of CD3246, for 
which Phyre2 predicted very low secondary structure, alignment hits with >98% confidence were 
obtained for all proteins. The results of the Phyre2 search are tabulated in Table 5.3.2. 
 
   CD0386: 
Template Description Species %ID Coverage 
3kptA  BcpA Pilin B. cereus 22 37% 
2ww8A  RgrA Pilin S. pneumoniae 21 50% 
2xicB  Pilus Adhesin S. pyogenes 22 33% 
 
   CD2768: 
Template Description Species %ID Coverage 
3npfB Dipeptidyl peptidase vi Bacteroides ovatus 35 80% 
2fg0B γ-d-glytamyl-diamino 
acid endopeptidase 
Nostoc punctiforme 27 80% 
3h41A Nlp/p60 family protein B. cereus 25 82% 
 
   CD2537: 
Template Description Species %ID Coverage 
2wdfA Sulfur oxidation SoxB Thermus thermophilus 23 79% 
2z1aA 5’ nucelotidase Thermus thermophilus 30 78% 
3ivdA Put. 5’ nucelotidase E. coli 28 78% 
 
   CD3392: 
Template Description Species %ID Coverage 
3kptA  BcpA Pilin B. cereus 21 36% 
2ww8A  RgrA Pilin S. pneumoniae 23 50% 
2xicB  Pilus Adhesin S. pyogenes 20 36% 
 
   CD0183: 
Template Description Species %ID Coverage 
3h41A Nlp/p60 family protein B. cereus 30 85% 
3npfB Put. Dipeptidyl 
peptidase vi 
B. ovatus 26 82% 
2fg0B γ-d-glytamyl-diamino 
acid endopeptidase 
N. punctiforme 26  65% 
 
   CD2831: 
Template Description Species %ID Coverage 





2xtlB Major pilin Streptococcus 
agalacticae 
14 49% 
3kptA BcpA Major pilin Bacillus cereus 21 18% 
 
Table 5.3.2 Phyre2 Analysis of Putative C. difficile Sortase Substrates. Details of the three 
highest ranking predicted secondary structure alignments are shown for each protein.  CD3246 is 
omitted due to lack of significant predicted secondary structure. 
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5.3.3 Generation of C. difficile SrtB Gene Knockout 
A total of five retargeted introns were introduced into C. difficile 630Δerm by conjugation from E. 
coli CA343. In all cases, colonies were isolated on thiamphenicol supplemented plates, indicating 
that conjugation of the plasmid had been successful. For introns retargeted at sites 354, 510, 514, 
and 206, no colonies were isolated on erythromycin-supplemented plates, indicating that 
integration of the intron had not occurred. The entire protocol was repeated twice with each intron 
before unsuccessfully retargeted introns were abandoned. 
 
At site 213, several colonies were isolated on erythromycin supplemented plates. PCR 
amplification of gDNA from these integrants was performed with primers flanking the srtB gene. 
This revealed a characteristic ~1.9kb insertion within the srtB gene (Figure 4.3.4A). The insertion 
was then fully characterised by sequencing of the intron junctions (Figure 5.3.5). To confirm lack 
of SrtB protein in the knockout strain, western blots of cell fractions was performed as in Section 
4.2.7 and probed with rabbit serum raised against recombinant SrtB (Figure 5.3.4B).  The knockout 





















Fig 5.3.4 Confirmation of Interruption of srtB by Intron Mutagenesis. A) DNA fragments 
generated by PCR amplification utilising primers flanking the srtB gene, demonstrating an 
insertion of ~1.9kb in strain 630 srtB::erm corresponding to the size of the Ll.LtrB intron. B) 

































































































































5’ of CD2718 (srtB) 








3’ of CD2718 (srtB) 













5.3.4 Growth and Toxin Production of C. difficile 630 srtB::erm 
Growth  curves were plotted for C. difficile 630 and 630 srtB::erm (Figure 5.3.6). No significant 



















Figure 5.3.5 Sequencing of the Interrupted srtB gene of C. difficile 630 srtB::erm. The 
sequence of the wild type is shown for reference. Underlining indicates Ll.LtrB intron DNA. 
Figure 5.3.6 – Growth of C. difficile 630 and 630 srtB::erm over 30hrs. Triplicate culture 
samples were taken over 30hrs and absorbance at 600nm measured. Mean values (n=3) are 





Toxin titres, both intracellular and extracellular, were determined by a TcdA and TcdB capture 
ELISA as detailed in Section 4.2.4. Toxin A titres of 630 srtB::erm were statistically significantly 
higher (p<0.05) at 7, 24 and 50hrs intracellularly and at 24hrs extracellularly. Intracellular toxin B 
was higher in 630 srtB::erm at 7, 24 and 50hrs, of which 7hrs and 50hrs were statistically 




































5.3.5 Localisation of Sortase Substrate CD0386 in C. difficile 630 srtB::erm 
By muramidase digestion of C. difficile cells and subsequent lysis and centrifugation of the resulting 
protoplasts, wall, membrane and cytoplasm fractions were obtained. Fractions were analysed by SDS-
PAGE, blotted and probed with anti-CD0386 rabbit serum (Figures 5.3.8 and 5.3.9) 
Figure 5.3.7. Intracellular and extracellular Toxin A and Toxin B titres of C. difficile 
630 and C. difficile srtB::erm. Toxin Titres were determined by capture ELISA. Error bars 
display standard deviation (n=3). (*) indicates a difference in toxin titre statistically 
























































































































7h    12h   24h             7h    12h    24h    
C. difficile 630 
C. difficile 630 
srtB::erm 
7h   12h  24h            7h   12h   24h    
C. difficile 630 
C. difficile 630 
srtB::erm 
Coomassie Stained SDS-PAGE Anti-CD0386 Blot 
C. difficile 630 
srtB::erm 
C. difficile 630 
srtB::erm 
7h     12h  24h           7h    12h   24h    
C. difficile 630 
7h     12h   24h           7h    12h    24h    
C. difficile 630 
Coomassie Stained SDS-PAGE Anti-CD0386 Blot 
Figure 5.3.8 Cell Fractionation and Localisation of CD0386 (Cytoplasm and Membrane). 
Cytoplasmic and membrane fractions from C. difficile 630 and 630 srtB::erm after 7, 12 or 
24hrs of growth were analysed by SDS-PAGE and either stained with coomassie or 

































































































An unambiguous immunoreactive band corresponding to the approximate molecular weight of 
CD0386 is observed in the wildtype wall fraction, but is absent in the sortase knockout wall 
fraction.  A fainter band of a slightly higher molecular weight is present in both the wild type and 
the sortase knockout. Anti-CD0386 reactive bands were observed in membrane and cytoplasmic 
fractions of both strains. 
 
Coomassie Stained SDS-PAGE Anti-CD0386 Blot 
C. difficile 630 
srtB::erm 
C. difficile 630 
srtB::erm 
 7h  12h   24h             7h    12h   24h    
C. difficile 630 
 7h   12h    24h          7h    12h   24h    
C. difficile 630 
Figure 5.3.9 Cell Fractionation and Localisation of CD0386 (Wall). A) Wall fractions from 
C. difficile 630 and 630 srtB::erm after 7, 12 or 24hrs of growth were analysed by SDS-PAGE 
and either stained with Coomassie or transferred to a nitrocellulose membrane and blotted 
with anti-CD0386 serum B) Enlarged detail of the anti-CD0386 blotted membrane. 
A 
B 
 7h             12h          24h                            7h              12h            24h    
C. difficile 630 srtB::erm C. difficile 630 
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5.3.6 Immunofluorescent Staining of C. difficile with anti-CD0386 serum 
 
Methanol-fixed C. difficile cells were incubated with anti-CD0386 antibodies and a fluorescent 
secondary antibody according to Section 3.2.5. Upon visualisation by UV microscopy, a small 
population of fluorescent cells was observed (Figure 5.3.10). Where no primary antibody was 
added, no fluorescence was observed, indicating that fluorescence was due to specific interactions 
of the CD0386 antibodies. The proportion of fluorescent cells in both C. difficile 630 and 630 
srtB::erm samples was quantified by automated counting using the CellC software as described in 
Section 4.2.6. Significance testing using Students t test revealed no statistically significant 





















Figure 5.3.10 – Immunostaining of C. 
difficile with anti-CD0386 serum. C. difficile 
630 cells were immunostained with anti-
CD0386 rabbit serum rabbit followed by  an 
Alexa488 conjugated anti-rabbit antibody. A) 
Visible light transmission B) UV illumination 
with a 525/550nm filter C) UV illuminated 
cells stained with secondary antibody only.  
A B 
C 
(Scale Bar = 200µm)  
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C.difficile  630:
Total Cells Fluorescent Cells % of Cells Fluorescent
Set 1 1381 36 2.61%
Set 2 1931 30 1.55%
Set 3 1759 45 2.56%
Mean 1690 37 2.24%
C.difficile  630 srtB::erm:
Total Cells Fluorescent Cells % of Cells Fluorescent
Set 1 3017 51 1.69%
Set 2 2249 40 1.78%
Set 3 1958 52 2.66%










5.3.7 Immunoprecipitation of CD0386 from C. difficile 630  
When anti-CD0386 IgG coupled resin was incubated overnight at 4°C with recombinant CD0386, 
the protein was successfully recovered, indicating that the coupling reaction was successful and 
that coupled anti-CD0386 antibodies were presented in a functional manner. However, when the 
resin was incubated with C. difficile 630 wall fraction, no protein was recovered (Figure 5.3.11) 
 
5.3.8 Purification of C. difficile 630 Peptidoglycan 
Despite three extended washes of insoluble cell debris with a solution of 4% SDS at 95ºC, SDS-









Table 5.3.3 – Proportion of fluorescent cells after anti-CD0386 Immunostaining. 
Students t test was used to test the hypothesis that there was no difference between 






































Figure 5.3.12 – Purification of C. difficile Peptidoglycan. SDS-PAGE analysis of 
supernatants following centrifugation of insoluble matter after washing with detergent. 
Insoluble material was resuspended in equal volume of loading buffer for analysis. 
Figure 5.3.11 – Attempted Immunoprecipitation of CD0386 from C. difficile 
630.  Cell Wall fractions or recombinant CD0386 was incubated overnight at 4ºC 
with a resin conjugated to anti-CD0386 antibodies. Proteins were eluted by lowering 
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5.3.9 – Challenge of Hamsters with C. difficile 630 srtB::erm 
Syrian hamsters were challenged with either C. difficile 630 or 630 srtB::erm as described in 



























Analysis by the Log-Rank test did not find any statistically significant difference between the 
















Figure 5.3.13 – Kaplan Meier Plot of Hamster Challenge with C. difficile 630 
and C. difficile 630 srtB::erm. Plotted points indicate the day on which hamsters 




5.4.1 - Introduction 
Since sortase enzymes have no function other than to anchor other proteins to the cell surface, the 
phenotype of a sortase mutant is determined entirely by the functions of the cell wall anchored 
proteins.  
 
The first aim of investigating a sortase mutant must, therefore, be to determine which surface 
proteins are anchored to the cell surface by the sortase and to confirm that their anchoring is absent 
in the sortase deficient strain. Following this, the wider phenotype of the sortase deficient organism 
can be investigated with the knowledge of the functions of its substrate proteins. In this chapter, the 
cellular distribution of one putative sortase substrate, CD0386 was examined in a sortase deficient 
mutant. 
 
5.4.2 In silico Analysis of the C. difficile ORF CD2718 (Putative Sortase B) 
Phylogenetic analysis of the open reading frame CD2718 (srtB) encoding the putative C. difficile 
sortase places it within the SrtB class. Of  the small panel of species chosen for analysis, C. 
perfringens SrtB was the closest relative of CD2718. 
 
Alignment of the translated C. difficile CD2718 with a selection of class B sortases reveals several 
conserved motifs. The most notable of these is the TLxTC motif near the C-terminus which is 
highly characteristic of sortase enzymes and contains the equivalent of the catalytic Cys184 in S. 
aureus SrtA. A conserved arginine is observed 8-10 amino acids towards the C-terminal of this 
motif, the equivalent of Arg233 in S. aureus SrtA. The intervening sequence forms the loop β7-β8 
which is known to be variable in length in other species and indeed the alignment contains a gap of 
two amino acids in the C. difficile and C. perfringens sequences. Also of interest is the 'YGH' motif 
at position 114, in which the histidine residue is the conserved equivalent of His120 in the S. 
aureus SrtA. The functions of these conserved residues is described in detail in Section 2.3. 
 
Considering the above observations, it appears that the C. difficile open reading frame CD2718 
(srtB) encodes a complete sortase enzyme which most likely is of the class B. 
 
5.4.3 The Putative Sortase Substrates and their Putative Functions 
Based upon the possession of CWSS-like characteristics including an SPxTG or PPxTG sorting 
motif as proposed by Pallen et al (2001), seven putative C. difficile putative substrates were 
identified - 6 SPxTG proteins and one PPxTG protein. The set of proteins identified in this work 
concurs with the seven proteins identified by Comfort and Clubb (2004, supplementary data).  
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The proteins identified as putative sortase substrates consist of two putative cell wall hydrolases 
(CD0183 and CD2768), a putative 5' nucleotidase (CD2537), one protein of unknown function 
(CD3246) and three proteins (CD0386, CD2831, CD3382) with sequence homology with the S. 
aureus collagen binding protein, Cna and secondary structure homology with pilins from various 
species. In light of the classification of the C. difficile sortase as a class B enzyme, it is noteworthy 
that the proteins identified as its putative substrates are typical of the sortase repertoire observed for 
class A sortases rather than class B. Notably absent are typical iron-associated class B sortase 
associated proteins such as haem binding proteins reflecting the specialised role of SrtB in iron 
homeostasis. Based upon the above list of proteins, it would appear that although the C. difficile 
sortase is of the class B, it may fulfil a general ‘housekeeping’ role more akin to a class A sortase. 
 
Proteins CD0183 and CD2768 are putatively identified as peptidoglycan hydrolases. Such enzymes 
are essential for processes such as cell growth, remodelling and turnover of peptidoglycan and 
more specialised roles such as creation of space for secretion systems (Vollmer et al., 2008).  
Localisation of peptidoglycan hydrolases to the cell surface is a common adaptation, presumably in 
order to allow efficient access to substrates - for example, the peptidoglycan hydrolase InlB of L. 
monocytogenes contains glycine tryptophan rich repeat regions which mediate interaction with the 
lipoteichoic acid of the cell wall (Jonquières et al., 1999). Sortase anchoring of peptidoglycan 
hydrolases would simply represent another method of localisation. 
 
Protein CD2753 is putatively identified as a 5’-nucelotidase. Dephosphorylation of nucleotides by 
this protein may simply form part of a nucleotide scavenging pathway, as C. difficile contains 
several genes annotated as encoding members of the NCS1 nucleotide transporter family. However, 
there is evidence in other species that surface-localised nucleotidases may be virulence factors in 
their own right. For example, the AdsA protein of S. aureus is a putative 5’ nucleotidase which 
produces adenosine by cleavage of the adenosine monophosphate found at elevated concentrations 
at the site of infection. AdsA is essential for virulence in a mouse sepsis model, a phenomenon 
thought to be due to inhibition of neutrophil activity by adenosine (Thammavongsa et al., 2009). A 
similar virulence associated nucelotidase has been partially investigated in Streptococcus sanguis 
(Fan et al., 2012). In both of the above examples, the nucleotidases in question are sortase 
substrates, containing LPxTG cell wall sorting motifs. 
 
With respect to virulence, the proteins of most interest are those which display homology to 
adhesins of other species, namely CD0386, CD2831 and CD3392. There is evidence from an in 
vivo model that these proteins are virulence associated - in a porcine ligated loop model, 
transcription of CD0386 is upregulated 1.9- and 2.5-fold at 8hrs and 12hrs respectively and 
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CD3392 and CD2831 are upregulated 2.7-fold and 2.4-fold respectively, but only at 12hrs (Scaria 
et al. 2011, supplementary data). 
 
CD2831 and CD3382 possess conserved domains identified as 'Cna B' domains. Cna is a two 
domain collagen binding protein from S. aureus - domain A possesses collagen binding activity 
while the B domain forms a stalk which projects the binding domain away from the cell surface. 
These proteins therefore only share homology with the structural domain of a collagen binding 
protein and their annotation as ‘collagen binding protein’ may therefore be premature. 
 
Secondary structure prediction and homology analysis of CD0386, CD2831 and CD3382 suggests 
that all three possess homology with various bacterial pilins. They do not, however, possess the 
‘YPKN’ motifs which are characteristic of sortase-associated pili and act as acceptors in the 
transpeptidation reaction. It is also notable that in western blots of cell extracts, CD0386 appears 
monomeric (see Fig. 5.3.9) with a single band rather than the polymeric, ladder-like pattern 
expected for a covalently polymerised pilin. CD0386 may, therefore, possess a pilin-like domain, 
but it is monomeric in vivo. 
 
Perhaps the most intriguing of all the predicted sortase substrates is CD3246. Sequence analysis by 
Phyre2 predicted a very low level of secondary structure, resulting in a failure to produce any 
reliable secondary structure homology results. Similarly, a BLAST search results in no proteins 
with significant homology outside of low complexity regions at the C and N termini. In spite of the 
lack of homologous proteins, some clues to the function of CD3246 have been uncovered by 
workers investigating riboswitches. Lee and co-workers (2010) discovered a self splicing ribozyme 
upstream from the start codon of the CD3246 open reading frame. By monitoring cleavage of 
radiolabelled transcript, they discovered that the riboswitch is regulated by the presence of cyclic-
di-guanidine monophosphate (c-di-GMP). The native transcript contains a stem loop which is 
likely to sterically hinder ribosome access to the start codon and a ribosome binding site which is 
distant from the start codon - splicing of the transcript in the presence of c-di-GMP results in a 
much more favourable transcript by removing the stem loop and creating a ribosome binding site 
which is an optimum distance from the start codon (Lee et al., 2010). The importance of c-di-GMP 
in regulation of bacterial virulence has only recently been recognised, and encompasses twitching 
motility in Pseudomonas aeruginosa, flagellar motility in Salmonella Typhimurium and Vibrio 
cholera and biofilm formation in all of the aforementioned species as well as Yersina pestis 
(Tamayo et al., 2007). In these examples, c-di-GMP  modulates virulence via direct effects on 
effector proteins rather than by the translational regulation described for CD3246. 
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5.4.4 Generation of C. difficile 630 srtB::erm 
A total of five sites provided by the Sigma Targetron tool were chosen and retargeted introns 
synthesised (see Table 5.2.1) of which the successful knockout at site 213 was the last to be 
attempted. At all other sites, failure occurred at the integration stage of the protocol - after streaking 
of transconjugants on agar supplemented with erythromycin, no colonies were obtained. Genetic 
confirmation of gene interruption was obtained by sequencing of the intron/exon junctions.  
 
Although examination of transcripts from the interrupted gene was not performed in this work, 
results previously obtained suggest that insertion of the intron abolishes all transcription of the 
target gene, as evidenced by a lack of mRNA for the targeted gene (Kirby, 2011). The lack of 
reactivity when fractions of C. difficile 630 srtB:erm are probed with anti-SrtB rabbit serum 
(Figure 5.3.4B) provides good evidence that all expression of SrtB has been entirely abolished. The 
successful generation of a srtB mutant knockout clearly contradicts previous reports of that sortase 
is essential, reports which were based solely on the failure of the authors to isolate mutants of the 
srtB gene (Wren, 2011). 
 
The major disadvantage of intron mutagenesis for gene inactivation, aside from its low rate of 
success, is that it is an insertional rather than a deletional method, resulting in a large genomic 
insertion into the gene of interest and the persistent introduction of an antibiotic resistance gene. 
More satisfactory methods such as double crossover allele exchange techniques are commonly used 
in other species but were described in C. difficile only recently (Cartman et al., 2012). Using this 
technique, whole portions of the chromosome can be replaced by homologous recombination 
leaving no trace of manipulation aside from a ‘watermark’ element. The region of homology is 
placed on a replication defective 'suicide' vector flanked by two selection markers, one positive and 
one negative. Two crossover events are required – the first crossover results in integration of the 
entire vector into the chromosome, at which point integrants can be isolated using the positive 
selection system. The second crossover liberates the vector backbone from the chromosome leaving 
just the DNA between the regions of homology – mutants which have undergone double crossover 
can be isolated by the application of the counterselection agent, which will kill remaining single 
crossover mutants still harbouring the negative selection gene.  
 
Another method which avoids large insertions while providing the additional benefit of allowing 
control of the mutant phenotype is inducible antisense RNA, an example of which in C. difficile has 
been described (Fagan and Fairweather, 2011). In this system, a sequence encoding a RNA 
complementary to the mRNA of the gene of interest was placed on a plasmid under the control of 
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tetracycline promoters. In strains transformed with these plasmids, effective silencing of the 
relevant genes could be achieved by addition of a non-toxic tetracycline analog to the growth 
medium. 
 
5.4.5 Growth and Toxin Production  
C. difficile 630 srtB::erm does not exhibit a growth deficit compared to the wild type. It grows at a 
similar rate and to a similar optical density during a logarithmic growth and maintains a similar 
optical density during stationary phase. This suggests that the C. difficile sortase does not have a 
role in cell nutrition - where sortases are involved in fulfilling nutritional requirements such as in 
the case of the iron-responsive SrtB enzymes, sortase knockout can lead to attenuated growth 
(Maresso et al., 2006). 
 
C. difficile 630 srtB::erm does, however, exhibit an aberrant toxin production profile. Intracellular 
TcdA concentrations were higher and significantly different (p <0.05) at 7h, 24h and 50h. Mean 
extracellular TcdA concentrations were also higher, although this was only statistically significant 
at 24hrs. Altered toxin secretion is not necessarily an expected characteristic of a C. difficile sortase 
mutant, as none of the predicted sortase substrates have predicted functions related to toxin 
secretion, either directly or indirectly. 
 
However, previous surface protein knockout strains have exhibited similar characteristics. In 
previous investigation of surface proteins utilising the ClosTron system (Kirby, 2011), increased 
toxin production was noted in 6 of 8 surface protein mutants. As increased toxin production appears 
to be a common artefact in surface protein mutants and therefore likely to be due to non-specific 
factors, it was not investigated further in this instance. A speculative explanation of the 
phenomenon relates to the toxin secretion apparatus - the classical C. difficile toxin secretion 
system is poorly characterised and may involve pores formed by the holin-like protein TcdE, 
(Govind and Dupuy, 2012; Olling et al., 2012). Even subtle changes at the cell surface may disrupt 









5.4.6 Localisation of Putative Sortase Substrate CD0386 in C. difficile 630 srtB::erm 
To obtain cell fractions representing the cell wall, cell membrane and cytoplasm, a fractionation 
method was employed based upon digestion of the peptidoglycan by muramidases. Equivalent 
fractions collected from the two strains did not exhibit gross differences in protein profile, 
indicating that the fractionation method was similarly effective in both strains. As expected, most 
of the visible proteins in the wall fraction are SLPs (eg. the HMW and LMW products of SlpA 
cleavage), released as the peptidoglycan to which they are bound is digested by lysozyme and 
mutanolysin.  As expected, cytoplasm and membrane fractions contained much greater numbers of 
proteins. 
 
Wall, membrane and cytoplasm fractions of C. difficile 630 and C. difficile 630 srtB::erm were 
separated by SDS-PAGE, blotted onto membranes and probed with polyclonal rabbit serum raised 
against a recombinant version of the putative adhesin and putative sortase substrate CD0386. 
Probing with anti-CD0386 rabbit serum revealed that in wild type cells, CD0386 is present in the 
wall, membrane and cytoplasmic fractions in roughly equal amounts. In C. difficile srtB::erm, 
however, there is a dramatic loss of CD0386 from the cell wall fraction. This would be the 
expected effect of sortase inactivation if CD0386 is a sortase substrate. It is unlikely that this 
observation is due to changes in CD0386 expression since the relative proportion of CD0386 in the 
cytoplasmic fractions of the two strains is unchanged, and is unlikely to be due to differences in 
loading masses because protein concentrations were controlled by BCA protein assay to ensure that 
equivalent masses of total protein were loaded. 
 
A faint immunoreactive band at a molecular weight slightly higher than that of the major reactive 
species is present in both the wildtype and sortase knockout strains. Given that cleavage of the cell 
wall sorting signal results in a loss in mass of 3.7kDa corresponding to the hydrophobic region 
downstream of the scissile bond, it is tempting to speculate whether this higher band corresponds to 
unprocessed CD0386. Unfortunately, as detailed in Section 5.4.7, preparation of native CD0386 for 
mass spectroscopy was not successful, so this hypothesis could not be tested. Fluorescence imaging 
of cells stained with anti-CD0386 rabbit serum followed by a fluorescent anti-rabbit conjugate 
indicates that CD0386 is expressed by only 1-3% of wild type C. difficile 630 cells at any one time. 
Counting the proportion of cells which were fluorescent did not find a statistically significant 
difference between the number of fluorescent cells in C. difficile 630 and C. difficile 630 srtB::erm. 
Further investigation into the phenomenon of the variable expression of CD0386 would be 
worthwhile to determine whether its expression is an example of true phase variation as is seen in 
the C. difficile surface protein CwpV (Reynolds et al., 2011), or whether its expression is 
associated with a particular phase of growth. 
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In summary, the results presented above indicate that CD0386 is associated with the peptidoglycan 
of the cell wall in C. difficile, and that this association is lost in a sortase deficient mutant. It does, 
however, remain surface localised and can be visualised at the surface by immunofluorescence. 
There are several literature reports of sortase wall-anchored proteins which remain surface 
localised even in the absence of sortase activity. For example, Aucher et al (2011) investigated the 
sorting signals of several B. anthracis wall anchored proteins by fusing their C termini with GamR, 
a receptor for the B. anthracis gamma phage. Cells lacking SrtA were still susceptible to phage 
infection, indicating that GamR was surface associated even in the absence of sortase activity. In 
this case, it appears that the association, most likely via the hydrophobic region, was sufficient to 
render GamR functional and facilitate phage infection.  
 
Evidence in other species suggests that even when surface localised sortase substrates are present at 
the cell surface, they may not be functional – deletion of srtA in S. gordonii results in a 97% 
reduction in binding to salivary agglutinin despite robust levels of non-anchored LPxTG-containing 
adhesins SspA and SspB detectable at the surface (Nobbs et al., 2007). In this case, the surface 
presentation of the sortase substrate occurred but was clearly inappropriate for its function.  
 
5.4.7 Immunoprecipitation 
Attempts were made to immunoprecipitate CD0386 from cell extracts using anti-CD0386 
antibodies with the intention to perform mass spectroscopy and determine whether a mass change 
was observed consistent with cleavage of the putative CWSS and loss of the hydrophobic region 
downstream of it – unfortunately sufficient yields were not obtained even from large volumes of 
culture, presumably due the low levels of expression of CD0386. 
 
5.4.8 Preparation of Purified C. difficile Peptidoglycan 
C. difficile peptidoglycan was prepared with the intention of digesting it with muramidases and 
hence producing a stringent fraction of proteins covalently attached to the peptidoglycan. This 
subset of proteins could then be analysed by proteomic methods and comparisons made between 
the wild type and the sortase mutant. The purification method employed is based upon the principle 
that proteins, DNA and lipid membranes (ie. the majority of cell components) are all soluble in a 
strong detergent solution, while SDS-insoluble by so can be recovered from SDS-solubilised lysate 
by centrifugation. Despite extensive optimisation of conditions and washing cycles, significant 
protein contamination of the peptidoglycan was observed. The SDS-PAGE band pattern of the 
contaminants is similar to that of fractions collected early during the procedure, suggesting that 
proteins are trapped within the peptidoglycan matrix and released upon preparation for SDS-PAGE. 
As such, purity of the peptidoglycan was judged as unsatisfactory for the intended purpose. 
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5.4.9 – Challenge of Hamsters with C. difficile 630 srtB::erm 
The Syrian hamster is the longest established and most widely used animal model for C. difficile 
infection (Best et al., 2012). Hamsters are exquisitely sensitive to C. difficile and typically die 
several days after infection. However, while diseased hamsters exhibit many of the 
histopathological features observed in human infection (Goulding et al., 2009), they do not exhibit 
profuse watery diarrhoea that occurs in humans, and the rapid progression  to fulminant disease is a 
poor representation of the usual progression of disease in humans. The extreme sensitivity of the 
hamster model may paradoxically render it insensitive to more subtle differences in colonisation 
and pathogenicity factors which may have real effects on the disease in humans. 
Recent advances have seen the development of mouse models of CDI. Several groups have 
described a mouse model which models human disease more faithfully than the hamster model, 
with animals devloping diarrhoea and fulminant disease only occurring after challenge with high 
doses (Chen et al., 2008). Relapse models have also been developed, closely mimicking the 
relapsing phoenomenon in humans (Sun et al., 2011). It is also possible to induce a 'carrier' state in 
mice, whereby animals are persistently but asymptomatically infected, which again is a close 
mimic of human infection and has the potential to offer insight into how the disease spreads, how 
infection is established, and how outbreaks can be prevented (Lawley et al., 2009). While it is 
likely that hamster models will remain the gold standard animal model for the foreseeable future 
while mouse models are refined and validated, it is likely that mouse models will offer a more 
accurate model of human disease in the long term. 
In Bacillus anthracis, the sortase enzymes SrtA and SrtB have been found to be required for 
efficient survival in macrophages in vitro (alveolar macrophages being the primary site of infection 
in pulmonary anthrax), but in mouse model of cutaneous anthrax, srtA deletion mutants are fully 
virulent (Gaspar et al., 2005; Zink and Burns, 2005). This may reflect different contributions of the 
sortases to disease in the two modes of infection, and given that pulmonary anthrax is the most 
serious form of the disease in humans, it is unfortunate that the sortase mutant was not tested in a 
pulmonary model. Similarly, in L. monocytogenes, there is disparity between in vivo and in vitro 
evidence – deletion of the srtA gene results in a loss of anchoring of proteins known to be essential 
for virulence, but in a mouse model, virulence is only moderately attenuated (Garandeau et al., 
2002). In. S. aureus, srtA is unequivocally essential for full virulence in animal models 
(Mazmanian et al., 2000). 
When hamsters are challenged with C. difficile 630 srtB::erm, mortality is indistinguishable from 
hamsters challenged with the wild type C. difficile 630. Two of the six uninfected control animals 
became symptomatic after several days  -  this does not indicate that the hamsters were 
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endogenously infected, since this would have resulted in control animals becoming ill ~2 days 
before challenged animals. More likely it reflects accidental cross-contamination, especially as the 
two were housed in the same box. Importantly, partial failure of the control group does not affect 
interpretation of the test groups since it occurred late in the experiment, long after the test groups 
became symptomatic. 
While taking into account the limitations of the model, the results of hamster challenge indicate 
that SrtB is not required for pathogenesis of C. difficile in hamsters. 
5.4.10 Further Work 
The lack of a genetically complemented srtB mutant is a significant weakness of the work 
presented in this chapter. This omission was initially due to difficulties obtaining a suitable vector 
for the purpose. A vector with suitable replicons, derived from pMTL9301 (Purdy et al., 2002) was 
eventually sourced and a plan was developed to modify it for complementation. Approval for this 
procedure was granted from the local genetic modification safety committee and the necessary 
notification was made, but time constraints ultimately prevented the work from being carried out. 
 
In order to definitively confirm CD0386 as a C. difficile sortase substrate, it is essential to provide 
evidence of a mass change as would be associated with the transpeptidation reaction, ie. a loss of 
the cell wall sorting signal and replacement with a peptidoglycan fragment. Furthermore, tandem 
mass spectroscopy of recovered CD0386 could allow elucidation of the exact structure of the 
peptidoglycan anchor, as has been performed in B. anthracis (Budzik et al., 2008b).  Recovery of 
sufficient CD0386 is likely to be major obstacle to this experiment, and although expression of 
CD0386 from a plasmid under the control of a strong promoter may provide sufficient yield, C. 
difficile 630 is a non-attenuated clinical strain and CD0386 is a putative virulence associated 
protein, so it unlikely that such a plan could be executed. A more satisfactory approach would be 
the overexpression of a recombinant marker protein as a surrogate for CD0386, by fusing the 
marker protein to the C-terminus of CD0386 and therefore determining if the C-terminal CWSS is 
sufficient for surface anchoring. Such an approach was taken in S. aureus by fusing the C-terminus 
of SpA to the Staphylococcal Enterotoxin B protein (Mazmanian et al., 1999) and in B. subtilis by 
fusion of the CWSS of the sortase substrate YchS to either a β-lactamase reporter protein or green 
fluorescent protein (Liew et al., 2011). 
 
Regarding investigation of the remaining six sortase substrates, piecemeal analysis by systematic 
raising of antisera as described in this work is feasible, but time-consuming and expensive.  A more 
serious disadvantage of this approach is the severe bias encountered, because only proteins 
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suggested by bioinformatic analysis are investigated, leading to the risk that important unidentified 
sortase substrates could be overlooked. A more rigourous, non-assumptive approach would be to 
compare the peptidoglycan-linked proteomes of the wild type and sortase knockout. Methods such 
as surface shaving or biotinylation which have been very successful in general cell surface 
proteomics (Hempel et al., 2011) are not suited to analysis of sortase mutants because, as has been 
discussed, sortase substrates often remain surface localised (albeit often non-functional) even in the 
absence of anchoring to the peptidoglycan. The focus of efforts should, therefore, be on developing 




Following in silico analysis of the putative C. difficile sortase and its putative substrates, a sortase 
deficient mutant of C. difficile 630 was generated by insertion of a bacterial intron into the srtB 
gene. Inactivation of the gene was confirmed by DNA sequencing and western blotting – the 
mutant exhibits normal growth and slightly aberrant toxin production. One of the seven predicted 
sortase substrates, the putative adhesin CD0386 exhibits a loss of anchoring to the cell wall in the 
sortase mutant. Efforts to recover CD0386 for mass spectroscopic confirmation of its processing by 
the C. difficile sortase were unsuccessful due to its low levels of expression under standard culture 












Chapter 6 – Structural Characterisation of the C. difficile 
Sortase Enzyme 
6.1. Introduction 
6.1.1 Methods for Determination of Macromolecular Structures 
One of the major driving forces behind the rapidly expanding knowledge of biology is the ability to 
visualise biological molecules, allowing researchers to directly examine the molecular basis of 
biological processes. As of 2013, the international Protein Data Bank (PDB) contains over 93,000 
biological structures of proteins and nucleic acids, with its rate of growth increasing year on year. 
The most commonly used techniques for determination of macromolecular structures are Nuclear 
Magnetic Resonance (NMR) spectroscopy, X-ray crystallography and Electron Microscopy (EM). 
Other techniques such as neutron diffraction and Small Angle X-Ray Scattering (SAXS) are more 
specialist in nature and account for very few published structures. Historically, NMR spectroscopy 
has been more suited to small molecules and smaller macromolecules, but its use for protein 
structure is increasing due to the development of improved techniques for larger proteins. 
Conversely, EM is more suited to very large macromolecules because its resolution is ultimately 
limited by the wavelength of electrons. Although X-ray crystallography remains the most popular 
methodology employed by structural biologists (see Figure 6.1.1), diversity of techniques has 
somewhat increased in recent decades and many proteins have now been characterised using 








X-ray crystallography is suitable for characterisation of molecules over a wide range of molecular 
mass, from small molecules to complex proteinaceous assemblies such as viral capsids. It is also by 
far the most popular method of structure determination, with over 88% of the structures currently in 
Figure 6.1.1 – Protein Data Bank 
Entries by Experimental 
Technique. Figures are shown as a 
percentage of PDB entries as of 
September 2013 The ‘Other’ 
classification includes Neutron 
diffraction, Powder Diffraction, 
Electron Crystallography  and SAXS 
(www.rcsb.org/pdb/statistics/).   
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the PDB having been determined by this method. The major disadvantage of the technique is that it 
requires that the sample be crystallised, and because little is known about the mechanisms of 
crystallisation, conditions favourable for crystallisation must be determined empirically for each 
molecule, representing a major bottleneck in X-ray structure determination. 
6.1.2 Crystallisation of Macromolecules 
The first step in crystallisation is a nucleation event whereby two molecules in solution form a 
nucleus of crystallisation. Dependent upon the stability of these nuclei, growth of a crystal can then 
follow by ordered packing of subsequent molecules onto the nuclei. To encourage these processes, 
it is helpful to progressively increase the concentration of the molecule to be crystallised close its 
solubility limits to achieve a supersaturated state (see Figure 6.1.2).  In protein crystallography, the 
most frequently utilised method to achieve supersaturation is vapour diffusion, whereby a drop is 
sealed within a chamber containing a reservoir of the crystallisation solution. Diffusion of water 
between the drop and the reservoir increases precipitant concentration in the drop, hence increasing 
the effective protein concentration. The drop may be placed on a pedestal within the sealed 













Figure 6.1.2 – A Hypothetical Crystallisation Phase Diagram. As the concentration of 
precipitant and/or protein concentration is increased, the state of the protein can pass 
through various several zones. Crystallisation experiments aim to place proteins in 













To determine favourable conditions for crystallisation of a particular molecule, a large number of 
screening experiments must be performed, typically facilitated by high-throughput robotic systems 
which allow thousands of conditions to be tested rapidly and using a minimum of sample volume. 
Such screens frequently produce crystals of suitable size and quality for X-ray diffraction, but 
manual optimisation of conditions is generally required to optimal produce crystals. 
Whilst nucleation is a prerequisite for crystal growth, the processes of nucleation and growth can 
be uncoupled experimentally so that crystals can be grown in conditions under which they do not 
readily nucleate  (Chayen, 2005). The most common method to achieve this is known as ‘seeding’, 
whereby whole crystals or crystal fragments are transplanted into conditions more favourable for 
growth than for nucleation, often within the metastable zone. This can result in crystals of an 
entirely different morphology via epitaxial growth. Alternatively, seeding into conditions with a 
precipitant concentration lower than that required for spontaneous nucleation may yield larger 
crystals than would be obtained in the original condition. 
6.1.3 The Properties of Crystals 
Many crystalline substances display unusual physical properties, typically due to the arrangement 
of their constituent molecules in a highly ordered and regular manner. This regularity naturally 
gives rise to symmetry, and due to the number of symmetry operations possible in three 
dimensional space, there are a huge number of potential arrangements of molecules in a crystal – 
these arrangements are described in the 230 space groups listed in the Tables for Crystallography 
published by the International Union of Crystallography. With respect to protein crystals, the 
chirality inherent in proteins precludes mirror and inversion symmetry operations, reducing the 
number of potential space groups to 65. The majority of protein crystals fall into an even smaller 
set of the most common space groups. 
6.1.4 X-Rays and Diffraction by Crystals 
The unique usefulness of X-rays for molecular structure determination lies with their short 
wavelength which, at the lower range of 0.5 Å to 1.5 Å, overlaps the typical lengths of intra-atomic 
bonds (eg. 1.54Å for a C-C bond and 0.96Å for a O-H bond (Haynes and Lide, 2010)). Equally 
importantly, the interaction of X-rays with matter is sufficient to result in significant scattering of 
energy, while still readily passing through air.  
The ordered crystal can be described in terms of a series of lattices. When a wave is diffracted by 
planes of atoms as exists in a crystal lattice, there are two potential outcomes. If the refracted 
waves are in phase with those from an adjacent lattice, the waves are said to interfere coherently.  
Bragg’s law (see Figure 6.1.3) states that coherent diffraction occurs when the planes of diffracting 
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molecules are separated by a distance equal to an integer multiple of the wavelength. It is these 
peaks of coherent diffraction which are observed when a crystal is subjected to X-ray diffraction. 
 
The mathematical description of waves, especially complex waves such as those produced by X-
ray diffraction, is often achieved by use of Fourier transforms. There are two forms of Fourier 
transform of interest to the crystallogapher. The forward Fourier transform is effectively a 
mathematical representation of the diffraction experiment, generating structure factors (amplitude 
and phase) from the electron density in the crystal. The reverse Fourier transform reconstructs the 
electron density in the crystal based upon the phase and amplitude of the waves. It is this operation 
which allows crystal structures to be determined from diffraction data. However, phases must be 
known - this is the so-called ‘phase problem’ which poses a major obstacle to structure 











Figure 6.1.3. Illustration of Bragg’s Law. X-rays diffract coherently where the 
distance between the two diffracting planes (d) is an integer multiple of the wavelength 
(λ). The additional path length of the lower wave is 2dsinθ. 
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6.1.5 The Phase Problem 
The intensities of diffracted X-rays are easily recorded by use of photographic film or a charge 
coupled detector (CCD), but it is not possible to record the phase of the waves. This is a major 
obstacle to structure solution, since extracting information encoded in waves by Fourier analysis 
requires their phase to be known.  
For many years, the predominant methodology for determining phases was Multiple Isomorphous 
Replacement (MIR), developed by Max Perutz during the 1950s (Perutz et al., 1960). Compounds 
containing heavy metal atoms such as mercury or uranium are soaked into crystals where they bind 
at well-defined sites within the protein, such as thiol side chains in the case of mercury or 
carboxylic side chains in the case of uranium. Phase information is calculated by comparison of 
Patterson difference maps of the native and isomorphous heavy-atom soaked derivitaves. 
The method of Multiple-wavelength Anomalous Dispersion (MAD), developed by Wayne 
Hendrickson and Jerome Karle, has become increasingly popular due partly to the widespread 
availability of tuneable wavelength beamlines at synchrotron facilities (Hendrickson et al., 1988). 
This method, along with its predecessor Single-wavelength Anomalous Dispersion (SAD), takes 
advantage of the phenomenon of anomalous scattering at wavelengths close to the absorbance 
edges of atoms. Conveniently, the absorbance edge wavelengths of several heavy metals are close 
to the typical wavelengths used for protein crystallography. MAD does not require comparison of 
diffraction from apo and heavy metal derivative crystals – diffraction is instead recorded from the 
same crystal at different wavelengths. Selenium is a popular heavy atom for MAD because it can 
be consistently and accurately incorporated into proteins by recombinant expression in a 
methionine auxotroph organism grown in a selenomethionine substituted medium (Hendrickson et 
al., 1990). 
In addition to the experimental phasing techniques described above, several wholly computational 
methods are available. Increasing computing power has enabled the use of direct methods for 
structure solution using ‘Shake and Bake’ algorithms (Weeks et al., 1999), but use of such 
techniques is still limited to data of atomic resolution. The most widely used purely computational 
phasing method for data of moderate resolution is ‘molecular replacement’ (Rossman and Blow, 
1962), a technique which infers phase information from a previously solved homologous structure. 
The search model is placed within the unit cell and subjected to three-dimensional rotation and 
translation functions. A Patterson map is calculated from the test solution after each manipulation 
and compared to the experimental map.  Convergence between the two maps will indicate a 
potentially correct solution from which phases can be calculated.  
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6.1.6 Refinement of Protein Structures 
The aim of structure refinement is to improve the molecular model initially obtained by structure 
solution, doing so in such a way that the refined model better fits the experimental data. The fit 
between experimental structure factor amplitudes (Fobs) and those predicted by the model (Fcalc) is 
assessed during refinement using statistical measures such as residual maximum likelihood or least 
square residual.  
The simplest form of model refinement is rigid body refinement, whereby a whole model is moved 
rigidly – this is often performed at the very beginning of refinement to correct gross inaccuracies in 
the initial solution, following which more sophisticated techniques can be applied, whereby 
individual atoms or groups of atoms are moved in three dimensions. In most cases, refinement is 
restrained using known physical parameters such as bond lengths and angles. Not only does this 
ensure that the resultant structures are geometrically plausible, it increases the observation to 
parameter ratio and reduces computational demands. Unrestrained refinement is only appropriate 
when data is at or near atomic resolution, where experimental observations are of sufficiently high 
quality to produce a model of excellent geometry without restraint. 
Residual based refinement has a disadvantage of risking the model becoming trapped in local 
minima – to overcome this, simulated annealing steps can be introduced, whereby the molecule is 
‘heated’ to high temperature and slowly cooled. As the simulation is cooled, convergence between 
Fobs and Fcalc is obtained with lower risk of the model being distorted by entrapment in local 
likelihood minima. Where non-crystallographic symmetry is present, restraints based upon NCS 
operators can be used, which again increases the observation to parameter ratio and can lead to 
significant improvements in the model. 
6.1.7 Validation of Protein Structures 
Several statistics are available to monitor the progress of refinement and to validate finished 
models. The most widely used is the crystallographic residual or, Rcryst, calculated by comparing an 
inverse reverse Fourier transform of the model to the experimental electron density map, thus 
providing a measure of how well the model explains the observed density.  
However, reliance on Rcryst can lead to serious errors, because the atoms used for validation are also 
part of the refinement process, leading to a cyclical process whereby low R factors are easily  
achievable by over-fitting of the model to the data. This problem was addressed by the 
development of RFree, a statistic which is independent of refinement, being calculated using a subset 
of reflections, generally 5-10%, set aside before refinement (Brünger, 1992). While some 
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difference between Rcryst and Rfree is expected, especially at low resolution, inappropriate overfitting 
of a structure will produce an unusually large gap.  
The geometric correctness of the model must also be assessed. A common method is to calculate 
root mean square deviation (RMSD) values for parameters such as bond lengths and angles. Local 
adherence to the ideal geometry of peptides can be assessed by examination of a Ramachandran 
plot, a graphical representation of the dihedral angles of carbon atoms in the peptide backbone 
(Ramachandran and Sasisekharan, 1968). Discrete areas within the plot represent the secondary 
structure of the peptide,  encompassing regions of ‘preferred’ and ‘allowable’ combinations of phi 
and psi angle – amino acids which fall out of these regions are either incorrect or require 
justification by recourse to clear electron density.  
Programs such as Molprobity (Davis et al., 2007) perform more advanced geometric validation by 
assessing such parameters as dihedral angles, torsion angles and Cβ deviations alongside 
comprehensive analysis of van der Waal’s contacts and hydrogen bonding. Ultimately, human 
interpretation of electron density is essential throughout model building and refinement to 















6.2.1 Protein Purification 
C. difficile SrtB and SrtB C226A were purified as described in Section 4.2.1. 
6.2.2 High-Throughput Crystallisation Screening 
Initial crystallisation conditions for C. difficile SrtB C226A were determined by high-throughput 
screening using a Phoenix robotic crystallisation system (Art Robbins Industries). Reservoir 
volumes of 50µl were dispensed into Intelliplate crystallisation plates (Art Robbins Industries) and 
sitting drops of 200nl assembled by dispensing protein and reservoir solution in ratios of 1:2, 1:1 
and 2:1. Plates were sealed, incubated at 16°C and drops inspected microscopically weekly for one 
month, then monthly. Seven commercially available screens were tested - Structure Screen I and II, 
Clear Strategy Screen I, Clear Strategy Screen II, PACT Premier, Heavy and Light,  JCSGplus and 
Morpheus (all obtained from Molecular Dimensions) . 
6.2.3 Optimisation of Crystallisation Conditions 
Manual optimisation of the condition 0.1M Phos/cit buffer pH4.2, 40% PEG300 was performed by 
the hanging drop method in a 16 well tissue culture plate with a reservoir volume of 1mL, sealed 
with greased 20mm siliconised glass cover slips. Variables optimised were pH of crystallisation 
solution (pH4-9), protein concentration (11.6-2.9mg/ml), PEG300 concentration (5-40%) drop 
volume (2-10µL) and ratio of protein to reservoir (1:3-3:1).  
Microseeding was performed in parallel with optimisation of protein and precipitant concentration. 
A 1µL drop of small needles grown in the initial conditions was pipetted from its cover slip and 
resuspended in 50µl of 50% PEG 300, 100mM Phos-Cit pH7.2. This seed stock was then diluted in 
mother liqor in a range of 1 x 10
-1
 to 1 x10
-5
 and 1µL added to fully assembled drops which had 
been allowed to equilibrate for 1hr. 
Attempted crystallisation of SrtB under reducing conditions was performed as above but with the 
addition of tris(2-carboxyethyl)phosphine (TCEP) to protein stock and reservoir solutions at a 
concentration of 1mM. Attempted crystallisation of covalently inhibited SrtB was performed as 
above but with the addition of (2-(trimethylammonium)ethyl methanethiosulfonate (MTSET) to 




6.2.4 Diffraction Data Collection and Processing 
X-ray diffraction experiments with SrtB C226A crystals were performed at beamline I-04 of the 
Diamond Light Source, Didcot, Oxon. and diffraction recorded using a Pilatus 2M CCD detector. 
Due to the 40% PEG300 concentration in the crystallisation conditions, no additional 
cryoprotectant was added prior to diffraction data collectin. Crystals were mounted within a 
cryoloop directly prior to data collection and frozen to 100K by placement within liquid nitrogen 
stream. Diffraction images were processed in space group P212121 using the Xia2 pipeline (Winter 
et al., 2013) at the Diamond Light Source and merged using Scala, a component of the CCP4 
software suite (Winn et al., 2011). 
6.2.5 Structure Solution, Refinement and Validation 
Initial phases were obtained by molecular replacement with Phaser-MR (McCoy et al., 2007) using 
a homology model of C. difficile SrtB. The search model was produced by SWISS-Modeller 
(Arnold et al., 2006) using the X-ray structure of B. anthracis sortase B (Zong et al., 2004b) which 
exhibits 37% sequence identity and 63% sequence similarity to C. difficile SrtB. Refinement was 
performed using REFMAC (Murshudov et al., 1997), each round of refinement consisting of three 
cycles of restrained refinement (XYZ, real space, B-factors, occupancies and torsion angle NCS) 
followed by manual refinement and rebuilding within Coot where required (Emsley et al., 2010). 
The quality of the structure was evaluated throughout using Molprobity (Davis et al., 2007). 
6.2.6 Modelling of The Cysteine 226 Residue 
In order to appropriately model the conformation of a modelled Cys226 residue, a superposition 
was assembled consisting of C. difficile SrtB C226A, S. aureus SrtB, and B. anthracis SrtB (Zhang 
et al., 2004). The alanine 226 residue was mutated to cysteine and the chi (χ1) angles of the mutated 
residue were adjusted to match the conformation of the template structures.  
6.2.7 Structural Analysis 
Superpositions were performed using the Secondary Structure Matching utility of Coot. Secondary 
structure assignments were performed using the Define Secondary Structure of Proteins (DSSP) 
program (Kabsch and Sander, 1983) 
To identify structural homologues and analyse their relationship to the SrtB C226A structure, the 
PDB was queried using the PDBeFold program hosted by the European Bioinformatics Institute 
(EBI) (Krissinel and Henrick, 2004). Calculation of protein-protein interfaces and assembly surface 
area was performed using PDBePISA, also hosted by the EBI (Krissinel and Henrick, 2007).  
 
All figures were prepared and rendered using Pymol (Schrödinger LLC). 
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6.3 Results 
6.3.1 Crystallisation of SrtB C226A 
Initial high-throughput screening experiments yielded clusters of needle crystals (Figure 6.3.1 A) in 
the condition C6 of the JCSGplus HT96 screen (0.1M Phosphate/Citrate pH4.2, 40% PEG300). 
Optimisation of protein concentration and precipitant concentration yielded thicker crystals (Figure 
5.3.1 B), with the optimum parameters being a drop volume of 2µl, a protein stock to reservoir 
ratio of 1:1, 40-34% PEG300 and a protein concentration of 2.9mg/mL. Even larger crystals 
(Figure 6.3.1 C) were obtained by microseeding, the optimum parameters being 32% PEG300, a 
protein concentration of 2.5mg/mL and a seed dilution factor of 1 x10
-5
. 
Crystallisation of wild type SrtB was not successful, either by high throughput screening or 
optimisation of conditions under which SrtB C226A was crystallised, including the addition of 













Figure 6.3.1 – Crystallisation of SrtB C226A. (A) Crystals grown in 0.1M Phos/Cit buffer 
pH4.2, 40% PEG300 with 10mg/ml SrtBC226A (B) Larger crystals grown after optimisation of 
protein concentration to 2.9mg/ml (C) Crystals grown by microseeding into pre-equilibrated 




6.3.2 X-Ray Diffraction with SrtB C226A Crystals 
Diffraction of X-rays with crystals of C. difficile SrtB was performed on 3
rd
 May 2012 at beamline 
















Three sets of diffraction images were collected, a summary of which is shown in Table 5.3.1. A 
summary of data collection statistics is displayed in Table 6.3.2. 








Cd2718_1_M3S5_1 60 0-60 2.31, 29.41 66.0 
Cd2718_1_M3S5_2 120 140-260 2.47, 29.45 90.2 
Cd2718_1_M3S5_3 100 260-360 2.28, 29.13 84.6 
 
 
Figure 6.3.2 – X-Ray Diffraction by Crystals of C. difficile SrtB C226A. An example  
diffraction image is shown with a diffraction limit of 2.5Å, represented by the blue 
hatched area. Inset is an image of the mounted crystal at the beamline. 
Table 6.3.1 – Summary of images collected by diffraction of SrtB C226A 
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6.3.3 Diffraction Data Processing 
Data reduction, indexing, integration and scaling in P212121 was performed by the automated Xia2 
pipeline (Winter et al., 2013). Merging of the three datasets was later performed manually using 
Scala. Due to the low completeness of Set 1, only Sets 2 and 3 were merged. A resolution limit of 
2.55Å was applied as the Rmerge above this resolution was unacceptably high. Processing statistics 
for these datasets are shown in Table 6.3.2.  
 
 
Data Collection and Processing  
Statistics 
SrtB C226A 
Space Group P212121 
Number of protein molecules per 
asymmetric unit 
2 
Cell dimensions a = 38.25Å, b = 90.27Å,     
c = 134.74Å 
α = β = γ = 90o 
Resolution range (Å) 29.37 – 2.55 
Rsymm (outer shell) 0.151 (0.506) 
I/σI (outer shell) 11.8 (4.2) 
Completeness (outer shell) % 98.8 (100.0) 
Total no. of reflections 122009 
Unique no. of reflections 15902 
Redundancy (outer shell) 7.7 (8.0) 
 
 
6.3.4 Solution of SrtB C226A Structure by Molecular Replacement 
Determination of initial phases was performed by molecular replacement using Phaser-MR 
(McCoy et al., 2007). The search model was a homology model of C. difficile SrtB based upon the 
B. anthracis SrtB, which exhibits a 37% sequence identity and 63% sequence similarity to C. 
difficile SrtB. Based upon the Matthews coefficient calculation, Phaser-MR predicted an 
asymmetric unit containing ~54kDa of protein, relative to SrtB theoretical mass of~28kDa. The 
program therefore searched for two molecules in the asymmetric unit. Molecular Replacement 
Statistics are shown in Table 6.3.3. The >4-fold increase in LLG upon the addition of the second 
molecule is strongly suggestive of a correct solution, as is the TFZ of >8.0. 
 
Table 6.3.2 – Summary of Data Collection and Processing Statistics 
for SrtB C226A. 
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 RFZ TFZ PAK LLG 
Molecule 1 6.8 7.8 0 75 




6.3.5 Refinement and Validation of SrtB C226A 
Refinement was performed iteratively across the whole assembly using Refmac for automated 
refinement and Coot for real space refinement following inspection of electron density. The model 
exhibited severe discordance with the electron density in two regions – the helical regions from the 
N-terminus to β1 and the tight loop between β5 and β6. Here, the modelled amino acids were 
deleted and replaced with a polyalanine chain, allowing the main chain atoms to be fitted before 
addition and refinement of side chains.  A summary of refinement and validation statistics is shown 
in Table 6.3.4. 






























(Rcryst = Σh |Fo − Fc|/ΣhFo, where Fo and Fc are the observed and 
calculated structure factor amplitudes of reflection h, respectively. 
Rfree is as for Rcryst for a randomly selected 5.0% subset of 
reflections not used in refinement) 
 
 
Table 6.3.3 – Molecular Replacement Statistics for SrtB C226A. Where RFZ = Rotation 
Function Z-Score, TFZ = Translation Function Z-Score, PAK = Packing Clashes, LLG = 
Log Likelihood Gain. 
 



























Figure 6.3.3 -  Ramachandran Plots for SrtB C226A. Ramachandran plots of SrtB C226A 
generated for (A) All non-Proline/Glycine residues (B) Glycine residues and (C) trans-proline 





6.4.1 Crystallisation of the C. difficile SrtB C226A and Solution of its Structure 
The C. difficile sortase SrtB with a cysteine to alanine substitution at position 226 was crystallised 
in phosphate/citrate buffer at pH4.2 and with 40% PEG300, conditions determined by high 
throughput screening. Microseeding into the metastable zone (< 40% PEG300) was required to 
grow crystals of sufficient size for X-ray diffraction. Crystals diffracted X-rays to 2.28Å and data 
were processed in P212121 with a 2.55Å resolution limit. The structure was solved by molecular 
replacement using a homology model based upon the Bacillus anthracis sortase B as a search 
model, the intention of homology modelling step being to use the most closely related extant 
structure while minimising model bias in the final structure. 
The model of SrtB C226A contains two molecules of SrtB C226A, with the modelled dimer 
including 115 water molecules and 7 diethylene glycol molecules derived from the PEG300 present 
in the crystallisation solution. The two SrtB molecules exhibit a high level of similarity, and can be 









The refinement statistics show in Table 6.3.4 are considered to be acceptable for a structure of this 
resolution, with an Rcryst of 0.19 and an Rfree of 0.24. The Rcryst – Rfree interval of 0.05 is considered 
acceptable, although indicates a slight overfitting of the model. No Ramachandran outliers are 
present, and although 4.44% of residues are in non-favoured regions of the plot, this is for the 
entire dimer, so equates to only 2.22% per protein chain. Bond lengths and angles are also within 
the acceptable range for a structure of this resolution and analysis by Molprobity did not reveal any 
dihedral angle outliers or rotamer probability outliers.  
Figure 6.4.1 - One SrtB C226A 
Crystallographic Dimer Shown 
Within the Unit Cell. The model is 
composed of two monomers of SrtB 
C226A (blue and orange) and includes 
115 water molecules (red spheres) and 
7 diethylene glycol molecules (green 
sticks). 
 SrtB C226A Chain A 
SrtB C226A Chain B 
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6.4.2 The Structure of C. difficile SrtB 
The arrangement of secondary structure elements and overall fold of C. difficile SrtB (Figures 6.4.2 
and 6.4.3) is typical of a class B sortase. The N-terminus is characterised by a substantial alpha 
helix of 18aa followed by a short loop incorporating a three residue 310 helix. Strands β1 and β2 are 
arranged in an antiparallel manner, separated by a turn motif. A long loop places β3 (which is the 
shortest of the beta sheet regions) parallel to β2, while β4 is antiparallel to β3.  
Following β4, another 310 helix of 7 residues is followed immediately by a shorter alpha helix of 4 
residues. This breaks the continuity of the barrel by placing β5 adjacent to β1 rather than β4. The 
longest extended beta sheet region of 13aa, β6, lies antiparallel to β5 for around a third of its length 
and forms a striking curved backbone of the barrel. The long sequence separating β6 from β7 
features an alpha helix of 12 residues in length. β7 runs parallel to β4, with β8 completing the 
















Helix 1 (α) 
Figure 6.4.2 – C. difficile SrtB C226A Coloured by Secondary Structure. The structure 
of C. difficile SrtB incorporates three α helices, two 310 helices and eight β strands. 






















There are several regions of C. difficile SrtB C226A which exhibit B factors significantly higher 
than the structure average, indicating high mobility (Figure 6.4.4). These include the β3-β4 loop 
which has been implicated in metal binding in other species (see Section 6.4.5) and the β6-H5 loop 












Figure 6.4.3 – Schematic of C. difficile SrtB C226A coloured by Secondary 
Structure. A schematic of secondary structure elements clearly shows the non-









Figure 6.4.4 – Structure of C. difficile SrtB C226A coloured by B-Factor. B-factors 
higher than the structure average of 25Å
2






6.4.3 General Comparison of C. difficile SrtB with Other Sortase Enzyme Structures 
To provide a comparison of C. difficile SrtB with structures of related proteins, secondary structure 
analysis and three-dimensional alignment was performed using the PDBeFold program, results of 
which are shown in Table 6.4.1. The structure of B. anthracis SrtB is the closest homologue, with 
the two other SrtB structures ranking second and third. Secondary structure matching scores were 
lower for the class A and C sortases although the RMSD of matched atoms was similar, 






PDB Code Reference 
SrtB B. anthracis 1.19 77 1RZ2 (Zhang et al., 2004) 
SrtB S. aureus 1.41 85 1NG5 (Zhang et al., 2004) 
SrtB S. pyogenes 1.62 77 3PSQ N/A 
SrtC A. oris 1.88 62 2XWG (Persson, 2011) 
SrtA S. pyogenes 1.97 54 3FN6 (Race et al., 2009) 
SrtA S. aureus 1.99 54 1T2O (Zong et al., 2004a) 
SrtC S. agalactiae 2.00 62 4G1H (Khare et al., 2011) 
 
 
Figure 6.4.5 shows a superposition of C. difficile SrtB (Cd.SrtB) with those of S. aureus, B. 
anthracis and Streptococcus pyogenes (Sa.SrtB, Ba.SrtB and Sp.SrtB respectively). The barrel 









Table 6.4.1 – PDBeFold Analysis of C. difficile SrtB C226A. Results from PDBeFold 
analysis, sorted by ascending RMSD (*SSE = ‘Secondary Structure Element’). 
ooo 
Figure 6.4.5 – C. difficile SrtB C226A 
superposed with three other SrtB 
structures. Superposition of Cd.SrtB, 
Sa.SrtB, Ba.SrtB and Sp.SrtB.  
Note that for clarity, loops have been 
smoothed - loop conformations are 







As shown in Figure 6.4.6, the most striking structural differences between the four molecules lie at 
their N-termini. In Sa.SrtB and Ba.SrtB, this region features two alpha helices (H1 and H2) 
arranged in an inverted ‘V’ and where H1 lies roughly parallel to the axis of the barrel. Ba.SrtB 
possesses 13aa loop between these helices which projects a three residue long 310 helix away from 
the core structure of the enzyme, while in Sa.SrtB the helices are connected by a much shorter loop 
of 4 residues. The N-terminus of Sp.SrtB is different to all three, possessing a single helix at 90° to 











The structure of this region in Cd.SrtB is most similar to that of Sa.SrtB, but with a significantly 
shorter H2, resulting in H1 being placed lower relative to the side of the barrel. Reflecting their 
novel arrangement in Cd.SrtB, these two helices were placed incorrectly in the initial solution 
produced by molecular replacement and significant manual rebuilding of the entire N-terminus was 
required. Nothing is known of the functions of the N-terminal helices, which are a unique feature of 
the class B sortases, although it has been suggested that their purpose is to project the enzyme away 
from the cell surface (Zong et al., 2004b). Differences in this region may reflect differences in 
bacterial physiology as well as function, which would explain the radically different conformation 







Figure 6.4.6 – N-terminus of C. 
difficile SrtB C226A superposed 
with three SrtB structures.  
The N-termini of B. anthracis S. 
aureus, S. pyogenes and C. difficile 
SrtB enzymes adopt three different 






6.4.4 The Clostridium difficile SrtB Active Site 
C. difficile SrtB features the characteristic conserved sortase triad of histidine, cysteine and 
arginine centred upon Cys226 at the C-terminal end of strand β7 (Figure 6.4.8). Cys226 and 
Arg224 reside in a deep depression on the surface of the enzyme, while the conserved His133 is 




















Figure 5.4.8 – The Modelled Active Site of C. difficile SrtB. Selected electron density 
(blue mesh) is shown contoured to 1.0 Sigma. Clear and continuous electron density is 
visible for His133 and Arg234. Electron density is clearly absent for the modelled Cys266. 
Figure 6.4.7 – Surface Representation of the C. difficile SrtB Active Site. The conserved 
cysteine and arginine residues form the floor of a deep depression at the C-terminus of β7. The 






β4 β7 β8 
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The 5.8Å distance between Cys226 and His133 in C. difficile SrtB is greater than B. anthracis and 
S. aureus SrtB enzymes (4.2Å and 4.6Å respectively), but is similar to that observed in S. aureus 
SrtA (5.7Å). The increased distance relative to the other class B sortases is due partly to a slightly 
different histidine conformation but mostly due to a torsional displacement of the β7-β8 loop. It is 
not possible to exclude that distortion of the loop is an artefact of the Cys to Ala mutation. 
Of the three SrtB active site residues, the conserved arginine appears the least strictly conserved 
with respect to its side chain conformation. In the B. anthracis structure it is clearly projected 
towards the conserved cysteine residue. In the S. aureus structure it points downwards, towards the 
β7-β8 loop. In the C. difficile SrtB it appears directed upwards, away from the loop. Nevertheless, 
the distance between Cys226 and Arg234 in Cd.SrtB is similar to that of Ba.SrtB due to 




Figure 6.4.9 – Superposition of Three SrtB Active Sites.  Superposition of the 










6.4.5 The Putative CWSS Substrate Binding Site of C. difficile SrtB 
As there are no published structures of a SrtB complexed with a Cell Wall Sorting Signal (CWSS) 
peptide, analysis of the putative substrate binding region of C. difficile SrtB must be based on 
comparison with the S. aureus SrtA-CWSS structure (Suree et al., 2009). As described in Section 
2.5.3 the β6-β7 loop of S. aureus SrtA undergoes structural rearrangements to produce a 310 helix 
which contributes to an enveloping hydrophobic environment for the hydrophobic ‘LP’ portion of 
the LPxTG S. aureus SrtA CWSS. Such rearrangements are not thought to be universal to sortase 
enzymes, as the structures of several SrtA enzymes exhibit such a helix in apo form (See Figure 






In contrast to the exclusively hydrophobic interactions of Sa.SrtA with its LPxTG substrate, the 
Cd.SrtB, Sa.SrtB and Ba.SrtB sorting signals of SPKTG, NPQTN and NPKTG respectively require 
a more polar environment for the P1 residue - serine and asparagine are capable of acting as both 
donators and acceptors in hydrogen bonding interactions. The β6-H5 loop adjacent to the Cd.SrtB 




























Figure 6.4.10 – The Putative CWSS Peptide Binding Loop of C. difficile SrtB. (A) The β6-H5 
loop analogous to the peptide binding region of S. aureus SrtA contains polar residues with one 
conserved hydrophobic residue, Leu185. Selected electron density (blue mesh) is shown 
contoured to 1.0 Sigma. Examination of the floor of the binding cleft (B) reveals several residues 
(Ile129, Tyr131, Thr222 and Val226) which could provide hydrophobic contacts with the proline 
of the SPKTG motif. 
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residue, Leu185. This residue and its Leu/Ile homologues in the other two SrtB enzymes may be 
analogous to Leu169 of Sa.SrtA which is located at the top of the 310 helix and interacts 
hydrophobically with the P2 proline (see Fig 2.4.5 for comparison). Hydrophobic contacts with the 
invariant  P2 proline are likely to be the similar in all sortase enzymes, and residues capable of such 
contacts are present in Cd.SrtB (Fig 6.4.10 B). 
All three SrtB enzymes contain at least one tyrosine residue in the sequence preceding the 
conserved Ile/Leu (Figure 6.4.11 B), with Ba.SrtB and Cd.SrtB possessing two. Of particular 
interest is Cd.SrtB Tyr182 which is conserved in the primary sequence of Ba.SrtB, while in 
Sa.SrtB, the side chain of an adjacent tyrosine residue is placed only ~3Å away from that of 
Cd.SrtB (Figure 6.4.11 A) suggesting this may be a structurally conserved feature although further 
SrtB structures are required to confirm this. This residue is a good candidate to form a polar contact 







Figure 6.4.11 – The Putative 
CWSS Peptide Binding Loop of 
Three Superposed SrtB 
Enzymes. (A) The β6-H5 loop of 
C. difficile SrtB, S. aureus SrtB 
and B. anthracis SrtB all contain 
a conserved Leu/Ile residue  and 
a structurally semi-conserved 
Tyrosine residue. (B) The 
conserved polar nature of the 
amino acids preceding the 
conserved Leu/Ile is clear in the 
primary sequence of the region. 
C. difficile  VESDYDYL 
S. aureus     TTTKDNYI 








6.4.6 Structure of the C. difficile SrtB Putative Transpeptidation Substrate Binding Site 
The structure of S. aureus SrtB/GlyGlyGly revealed a binding site for the transpeptidation substrate 
within the β7-β8 loop (Zong et al., 2004b), confirmed by NMR experiments in S. aureus SrtA 
(Suree et al., 2009). The analagous region in C. difficile SrtB is shown in Figure 6.4.12.  
The loop contains two prominent aromatic residues which project upwards towards the barrel and 
shield the sides of the area between the loop and the active site. Within this shielded area is the side 
chain of Arg233, which is thought to be responsible for activating the transpeptidation substrate for 
nucleophilic attack by abstraction of a proton from its N-terminus (See Section 2.5.4). Unlike in 
Sa.SrtB where the GlyGlyGly peptide hydrogen bonds with backbone as well as with the side chain 
of glutamic acid residue directly adjacent to the cysteine, no side Cd.SrtB chains project into the 
space between the loop and the active site. Any hydrogen bonding interactions between Cd.SrtB 










Figure 6.4.12 – The β7-β8 Loop of C. difficile SrtB C226. The loop contains two 
aromatic amino acids, the side chains of which shield the putative substrate binding 
region between the loop and the active site. The conserved arginine residue, 
responsible for activating the transpeptidation nucleophile, is also observed projecting 
into this space. 
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As measured from the conserved cysteine at the end of β7 to the conserved arginine within β8, 
Cd.SrtB features a loop of 7 amino acids, which is the same length as the Sp.SrtB but two amino 
acids shorter than those of Sa.SrtB and Ba.SrtB. The structural implications of this can be seen in 
Figure 6.4.13. The loop adopts a similar conformation in all three despite differences in sequence 





















Figure 6.4.13 – β7-β8 Loop of C. difficile 
SrtB C226A Superposed with two SrtB 
Structures.  
The β7-β8 loop of Cd.SrtB adopts a similar 
conformation to that of Sa.SrtB, but its 
shorter length results in a shorter extension, 
~3.5Å closer to the barrel region relative to 
Sa.SrtB 
Ba.SrtB β7-β8 was omitted from the 
















Figure 6.4.14 - Metal Independent 
Stabilisation of the β6-β7 Loop in C. 
difficile SrtB. (A) Distances consistent with 
hydrogen bonding are observed between 
Asn188 of loop β6-β7, and the backbone 
amide and side chain of Asp125 within loop 
β3-β4. The β3-β4 loop itself is stabilised by 
hydrogen bonding of Asp125 with backbone 
amides of Lys121 and Ser122. Two 
additional stabilising hydrogen bonds are 
observed between Leu185, Arg119 and 
Asn127. This is contrasted with the S. aureus 































5.4.7 Structure of the C. difficile SrtB loop β3-β4  
In S. aureus SrtA, which is dependent upon calcium for activity, a Ca
2+
 ion resides in a pocket 
formed by three glutamic acid residues in loop β3-β4 (Figure 6.4.14 B). The ion also engages a 
fourth glutamic acid within β6-β7, hence stabilising the substrate binding loop and thus exerting its 
stimulatory effect. In the C.difficle sortase, this region exhibits an extensive network of hydrogen 





















6.4.8 Analysis of Non-Crystallographic Dimerisation of SrtB C226A 
The non-crystallographic symmetry within SrtB C226A crystals results from dimerisation of two 
SrtB C226A molecules. As can be seen in Figure 6.4.15 A, these interactions are extensive in 
nature, with the N-terminus of each chain projecting into the active site depression of the other 
subunit (see Figure 6.4.2 B). These interactions are not thought to be biologically relevant, as size 
exclusion chromatography experiments indicate that SrtB is monomeric in solution. Crystal 
structure of sortase enzymes frequently exhibit crystallographic polymers, although no such 
structures exhibit interfaces similar to those observed in C. difficile SrtB.  
Analysis with PISA reveals 13 intermolecular hydrogen bonds. There are two interfaces: 1) 
Between the N-terminus and the loops surrounding the active site (β6-β7/β2-β3) and 2) Between 
loop β7-β8 and β6-H5. The assembly surface area is calculated to be 19580 Å2, with a buried 
surface area of 4150 Å
2
. The interface is not symmetrical – 5 of the 13 hydrogen bonds occur in 














Figure 6.4.15 - Interaction 
Between SrtB C226A 
Molecules. (A) 
Crystallographic dimers of SrtB 
C226A with (B) Interaction of 
the N-termini with the loops 
forming the active site 
depression. 
SrtB C226A Chain A 
 
SrtB C226A Chain B 
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Bond Distance (Å) Chain A Residue [Atom] 
 
Chain B Residue [Atom] 
 
1 2.42 Asp 183[OD2] Lys  40[HZ3] 
  2* 2.37 Asn  96[O] Gly  42[H] 
3 2.28 Ser  97[OG] Gly  42[H] 
  4* 2.14 Lys  39[O] Asn  96[HD22] 
  5* 1.88 Thr 227[O] Lys 136[HZ2] 
  6* 2.04 Asn 134[O] Phe 230[H] 
 7* 2.34 Gly  42[H] Asn  96[O] 
8 2.47 Ala  44[H] Ser  97[OG] 
  9* 2.08 Asn  96[HD22] Lys  39[O] 
10 2.48 Lys 136[H] Tyr 228[O] 
 11* 1.65 Lys 136[HZ3] Thr 227[O ] 
12 3.37 Thr 227[OG1] Glu 229[OE1] 
  13* 2.07 Phe 230[H] Asn 134[O] 
 
 
6.5 - Discussion 
6.5.1 General Discussion 
The C. difficile sortase enzyme adopts a fold similar to other class B sortases, being composed of 
the 8-stranded non-contiguous β-barrel which forms the core of all sortase classes, decorated on its 
exterior surfaces with the multiple helices which are characteristic of the class B and C sortases. 
Compared to other class B enzymes, it features a more compact arrangement of helices at the N-
terminus. Little is known about the function of these helices, but being located proximally to the 
membrane anchor region it is likely that they are involved in enzyme localisation and hence 
variation in this area is likely to reflect differences in either enzyme function or bacterial cell 
surface physiology.  
By analogy with Sa.SrtA, the putative CWSS binding site of Cd.SrtB has been identified within the 
β6-H5 loop and contains several polar residues which could form contacts with the P1 serine of the 
SPKTG sorting signal together with a semi-conserved hydrophobic residue which could form 
contact with the P2 proline. Analysis of this region was unfortunately limited by poor electron 
density, presumably due to high mobility of the loop as indicated by the high B-factors of the Cα 
backbone atoms (which nevertheless exhibited continuous density even where side chain density 
was lacking). In the absence of a substrate complex structure, it is clearly not possible to determine 
whether β6-H5 undergoes a transition to a more ordered state upon substrate binding in a manner 
similar to formation of the 310 helix in Sa.SrtA β6-β7. However, it is notable that in Cd.SrtB 
Table 6.4.2 – Hydrogen Bonds between SrtB C226A molecules. Entries with an 
asterisk indicate the presence an equivalent bond in the other chain. 
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C226A, higher than structure average B factors are observed in this region, indicating that in its 
apo form, this loop is relatively disordered.  
The β7-β8 loop, which forms the putative binding site of the transpeptidation substrate (meso-
DAPA in the case of Cd.SrtB) is of a similar overall shape to that observed in the SrtB enzymes of 
other species, while being slightly less extended than that of Sa.SrtB. Differences in this region are 
more likely to reflect differences in function rather than bacterial physiology, since the S. aureus 
SrtA enzyme has a significantly more extended β7-β8 loop than Sa.SrtB despite sharing the same 
polyglycine transpeptidation substrate. Given the role of Sp.SrtB in pilus biogenesis, it is therefore 
hardly surprising that its β7-β8 loop is radically different in shape to Sp.SrtA – its transpeptidation 
substrate, a pilin rather than a peptidoglycan cross-link, is likely to be more bulky and require more 
clearance. It is unfortunate that the B. anthracis structure did not exhibit electron density in this 
area since this species has a similar cell wall composition to C. difficile, having mDAP cross links; 
comparison between the species may have revealed specific features potentially involved in 
recognition of mDAP as distinct from S. aureus SrtB which is specific for polyglycine cross links. 
In agreement with cleavage assay results indicating a lack of metal dependence presented in 
Chapter 8, the crystal structure of SrtB C226A did not include any bound metal ions. Furthermore, 
examination of the Cd.SrtB β3-β4 loop, equivalent to the Sa.SrtA metal binding site, revealed an 
extensive network of hydrogen bonding in place of metal co-ordination. Since stabilisation of the 
region is clearly achievable in the absence of metal binding, it seems likely that metal binding by S. 
aureus SrtA is a regulatory adaptation rather than a biological necessity, although metal binding 
may afford more robust stabilisation. 
6.5.2 Failure to Crystallise Wild Type C. difficile SrtB 
Extensive but ultimately unsuccessful efforts were made to crystallise wild type C. difficile SrtB. 
As confirmed by mass spectroscopy data, the only difference between SrtB and SrtB C226A is the 
intended single substitution from cysteine to alanine at position 226. Prior to solution of the SrtB 
C226A structure, efforts to improve crystallisation of SrtB therefore focussed on biochemical and 
biophysical changes which could be accounted for by the substitution.  
In the low pH conditions in which SrtB C226A crystallised it is likely that the cysteine residue 
(with its side chain pKa of ~8.0) would be effectively entirely protonated, so charge contributions 
from the cysteine side chain are unlikely to interfere with crystallisation. It is quite possible, 
however, that Cys226 engages in thiol exchange reactions to form disulphide complexes. As was 
discussed in Section 4.1.1, size exclusion chromatography of SrtB indicates that SrtB is monomeric 
when in a buffer with neutral pH and moderate ionic strength, but conversely, results from SDS-
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PAGE analysis demonstrate that that when placed in appropriate conditions SrtB is indeed capable 
of forming disulphide dimers, presumably due to exposure of the active site sulphydryl Cys 226 by 
denaturing. Crystallisation screens feature a diverse set of conditions, and it is quite possible that 
some of these may promote exposure of the cysteine residue and allow disulphide mediated dimers 
to form.  
The usual method of preventing disulphide formation is by addition of reducing agents. Production 
of reducing conditions in crystallisation experiments is challenging due to the instability of 
dithiothreitol (DTT) and the volatility of 2-mercaptoethanol. In the case of Cd.SrtB it was achieved 
by addition of the reducing reagent TCEP. Irreversible inactivation of the cysteine residue by 
adduction by the known sortase inhibitor  MTSET was also performed. Neither of these 
modifications improved crystallisation.  
Failure to crystallise proteins is a common problem in X-ray crystallography, and there are many 
approaches to overcoming such an obstacle. Most commonly, a suitable condition can eventually 
be identified by continued and optimised high-throughput screening. Improving protein purity is 
also advised – a survey of 229 crystallisation experiments (Geerlof et al., 2006) showed that 
proteins of  >95% purity crystallise in 59% of cases wheras proteins of <95% purity only yielded 
37% of cases . However, purity is unlikely to be the limiting factor in the case of Cd.SrtB as its 
purity is not only very high, it is essentially identical to that of SrtB C226A which crystallises 
readily. 
Once the structure of Cd.SrtB C226A was available, it was clear that there was additional structural 
evidence which may help explain the failure to crystallise wild type Cd.SrtB. Specifically, the 
loops surrounding the active site are a key interface within crystallographic dimers of SrtB C226A. 
It is plausible that in the wild type enzyme, the additional bulk of the cysteine residue prevents 
these interactions and hence prevents dimerisation which is presumably essential for crystallisation 
under these conditions. Alternatively, the cysteine may prevent dimerisation by exerting effects on 
the general electrostatic environment of the active site. 
In light of the failure of exhaustive efforts to crystallise wild type Cd.SrtB and informed by the 
structure Cd.SrtB C226A, it would seem worthwhile to investigate other variants of SrtB. By 
abolishing the contacts which are observed in SrtB C226A, but may be sub-optimal in SrtB, other 
contact surfaces may be favoured, some of which may be more conducive to crystallisation. 
Abolition of the interactions around the active site could be achieved very easily by N-terminally 
truncating the protein by removing residues 39 to 44 to eliminate the unstructured region which 
precedes H1. A more advanced method to alter the other interface between the SrtB dimers would 
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be to engineer the loops which form the other surface of dimerisation, β7-β8 and β6-H5. In 
particular, residues which are listed in Table 5.4.2 as participating in hydrogen bonding via their 
side chains. As a structure is available for Cd.SrtB C226A, PISA could be utilised to test loop 
mutants in silico for their potential to dimerise. Assessment of correct folding of such mutants 
would also be necessary, eg. by circular dichroism (CD) spectroscopy, a technique used to analyse 
secondary structure of proteins by the manner in which they interact with polarised light. 
6.5.3 Limitations and Further Work 
As with any X-ray structure determined from diffraction of only moderate resolution, vast 
improvements to the model could be by made by analysis of higher resolution data. Improving 
resolution is often achieved by further optimising crystallisation conditions or seeking new 
conditions which yield better performing crystals. Alternatively, a fragment of the protein may be 
crystallised in place of the whole protein, removing domains which may be disordered while 
retaining the areas of most biological significance. In addition, there are several methods for 
improving the diffraction of existing crystals, including annealing and removal of solvent from the 
crystal by dehydration (Heras and Martin, 2005). Both of these techniques aim to reduce disorder 
in the crystal and often reduce mosaicity as well as increasing resolution.  
However, the major shortcoming of this work is not the quality of the structure but the reliance on a 
modelled cysteine residue for analysis of active site co-ordination. The side chain of the substituted 
alanine gives a good indication of main chain geometry of the cysteine, but the side chain dihedral 
angle was modelled by comparison with Sa.SrtB and Ba.SrtB. Serine is often chosen as a substitute 
for cysteine as it is viewed as the closest structural analog of cysteine, but it would be an 
inadvisable substitution in the case of a sortase enzyme, as a Cys to Ser substitution results in 
residual activity in SrtA (Frankel et al., 2007b). Clearly, the solution to this problem is to 
crystallise the wild type SrtB protein, as previously discussed in Section 6.5.2 
Another worthwhile experiment (which would not depend upon successful crystallisation of wild 
type Cd.SrtB) would be determine how Cd.SrtB interacts with its CWSS substrate and confirm the 
putative binding region in β6-H5. Introduction of ligands is frequently performed for X-ray 
crystallography, either before or after crystallisation (Danley, 2006) . The former requires that the 
ligand does not inhibit crystallisation and that the enzyme has sufficient affinity for the substrate 
that occupancy of the active site is high enough for the ligand to be visible in the electron density. 
There are no literature of a Kd for any sortase and its CWSS peptide substrate, but given that KM of 
SrtA enzymes for such peptides tend to be in the millimolar range, it is likely that their affinity is 
poor. An additional concern is the accessibility of the active site, which is a particular concern for 
Cd.SrtB due to its dimerisation interfaces in the region of the active site. If a non covalent complex 
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is to be formed, the latter approach of post-crystallisation is therefore more likely to be successful 
because very high concentrations of peptide can be achieved without inhibiting crystallisation. In 
the case of Cd.SrtB, the use of the C226A mutant would be preferred over the wild type due to the 
risk of hydrolysis of the peptide by the wild type enzyme. A peptide was obtained for this purpose, 
but no sufficiently large SrtB C226A crystals were obtained subsequent to the crystals for which 
diffraction is described in this chapter.  
Another approach to obtain an enzyme-substrate complex is to modify the wild type enzyme 
covalently. In the case of the SrtA-CWSS structure (Suree et al., 2009) this was achieved by the 
use of a LPAT* peptide, where T* is a threonine modified with a CH2-SH moeity in place of its 
carbonyl group. Disulphide formation between the T* residue and the active site cysteine results in 
a modification which mimics the acyl intermediate and is non-hydrolysable. Heterogeneity due to 
non-specific adduction would not be a concern, as Cd.SrtB contains no cysteines other than the 
active site residue. Such a method is likely to result in a robust level of incorporation which could 
be evaluated and quantified by mass spectroscopy. However, this is neither a true enzyme-substrate 
complex or an acyl intermediate. Such structures may be misleading, because it is possible that the 
initial enzyme-substrate interactions differ from those subsequent to formation of the acyl 
intermediate – they may be considerably weaker, since the substrate is now covalently attached to 
the enzyme there is less of a requirement to bind it with high affinity, while flexibility within the 
active site may be of benefit to allow the reaction to progress. 
Structures of many enzymes have been obtained in acyl intermediate states, although this is a 
challenging task because such states are often inherently unstable. In cases where X-ray 
crystallography is to be employed, success is often possible if crystallisation and data collection 
can be performed rapidly, as has been possible in the case of trypsin (Mangel et al., 1990) . 
Another approach is to halt the reaction by using a mutant enzyme incapable of resolving the 
intermediate state, as in the case of the Mycobacterium tuberculosis β-lactamase (Tremblay et al., 
2010). The presence of a hydrolytic shunt in the sortase mechanism rules out the latter approach, as 
interfering with the transpeptidation reaction will not necessarily favour accumulation of the 
intermediate. NMR spectroscopy is perhaps more suited to for examination of intermediates 
because it is possible to conduct whole experiments in the short timescales during which the 
intermediate is stable. 
There is some evidence, presented later in this work, that quantities of acyl intermediate Cd.SrtB 
accumulate during reaction with an SPKTG peptide, presumably due to inefficiency of hydrolysis 
or transpeptidation reactions and indicating that the Cd.SrtB acyl intermediate may be relatively 
stable. Repurification of this product may represent a method to obtain a genuine intermediate for 
 121 
crystallisation and provision of a sortase acyl intermediate structure. Other sortases may exhibit 
even more stable intermediates which again may be useful for determination of acyl intermediate 
structures. 
A wider appraisal of sortase structures reveals significant gaps in the structural knowledge of 
sortase enzymes, perhaps not surprising for a class of enzyme discovered only 14 years ago. There 
is only one convincing structure of a Srt-CWSS complex structure, of a class A enzyme, and one 
structure of a sortase transpepdiation substrate complex, of a class B enzyme. Ideally, three 
structures would be determined for each class – an apo form, a complex with a CWSS peptide and 
a double complex with a CWSS and transpeptidation acceptor molecule. A single complex with the 
transpeptidation acceptor is of limited interest as the ping pong reaction mechanism does not favour 
such a complex in vivo.  
Structures of sortases complexed with CWSS peptides may provide more information on enzyme-
substrate interactions, but because the CWSS peptides which are commonly utilised only represent 
a very small portion of the target protein, questions remain regarding whether the enzyme interacts 
more widely with the target protein. Similarly with regard to the transpeptidation substrate, it is 
unclear whether enzyme interacts more widely with the peptidoglycan? As discussed in Section 
8.4.3, the poor performance of sortase enzymes in vitro suggests that the short CWSS-mimic 
peptides are poor mimics of the in vivo substrates. It may therefore of benefit to explore larger 
fragments of CWSS-bearing proteins, to determine whether the enzyme engages in any other 
specific interactions with its in vivo substrates. 
With respect to the transpeptidation substrate, a more ambitious but worthwhile experiment would 
be to obtain the structure of a complex with a larger peptidoglycan fragment. Such structures are 
available for other classes of enzyme – for example, several structures are available of complexes 
of bacterial peptidoglycan carboxypeptidases with their cognate peptidoglycan tetrapeptide stem 
(Chen et al., 2009; McDonough et al., 2002). In the case of C. difficile, synthesis of peptidoglycan 
fragments could prove prohibitively expensive due to the presence of meso-DAPA, but purification 






6.6 - Conclusions 
An active site cysteine mutant of the Sortase B enzyme of C. difficile has been crystallised and its 
structure solved to a resolution of 2.55Å. This novel structure represents the fourth class B sortase 
structure to be solved, and the first structure of any sortase from the genus Clostridium. It exhibits a 
similar fold to other class B sortases, being composed of a core β-barrel flanked by several helices. 
Two putative substrate binding regions, for the CWSS peptide and the transpeptidation substrate, 
have been identified and analysed.  
Plans for potential future work to gain more information from the SrtB structure have been 
outlined, including crystallisation of enzyme-substrate complexes and reaction intermediates. In 
light of the failure to crystallise a wild type C. difficile SrtB, a structurally-informed plan has been 

















Chapter 7 – Crystallisation and Test Diffraction of CD0386 
7.1 Introduction 
C. difficile CD0386 is a 111kDa protein which, as described in Chapter 5, is anchored to the C. 
difficile peptidoglycan by the sortase SrtB. Its annotation in the genome is ‘Putative collagen-
binding surface protein’, an automatic annotation based upon sequence homology with domain B 
of the S. aureus collagen binding protein Cna. However, the N-terminal domain of CD0386 shows 
no sequence homology to any characterised proteins, and structural studies were planned to aid in 
ascribing its function.  
Due to the large size of the protein, a fragment-based approach was determined most appropriate, 
as crystallising such large proteins can prove challenging. Secondary structure prediction and 
homology modelling were performed to provide speculative information on the structure of 
CD0386, which informed the design of a fragment of CD0386 for structural studies. This 61kDa 
fragment, CD0386N, was crystallised and test diffraction performed. 
7.2 Methods 
7.2.1 Secondary Structure Prediction and Modelling 
The amino acid sequence of CD0386 was submitted to the Phyre2 Protein Fold Recognition server 
hosted by Imperial College, London (Kelley and Sternberg, 2009). 
7.2.2 Crystallisation and test diffraction of CD0386N 
CD0386N was purified as described in Section 4.3.6. Initial crystallisation conditions for 
CD0386N were determined by high throughput screening using a Phoenix robotic crystallisation 
system (Art Robbins Industries). Reservoir volumes of 50µl were dispensed into Intelliplate 
crystallisation plates (Art Robbins Industries) and sitting drops of 200nl assembled by dispensing 
protein and reservoir solution in ratios of 1:2, 1:1 and 2:1. Plates were sealed, incubated at 16°C 
and drops inspected microscopically after one week, then monthly. Seven commercially available 
screens were tested - Structure Screen I and II HT96, Clear Strategy Screen I HT96, Clear Strategy 
Screen II HT96, PACT Premier HT96, JCSGplus HT96, Morpheus HT96 and Heavy and Light 
HT96 (all obtained from Molecular Dimensions) . 
Manual optimisation of the condition 0.2M KSCN, 0.1M sodium cacodylate pH6.5 and 15% PEG 
4k was performed by the hanging drop method in a 16 well tissue culture plate with a reservoir 
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volume of 1mL, sealed with greased 20mm siliconised glass cover slips. Variables optimised were 
pH of crystallisation solution (pH 5.5-7.0), and KSCN concentration (175-300mM). 
Test diffraction was performed at beamline I-04 of the Diamond Light Source and diffraction 
recorded with an ADSC Q315 CCD detector. 
7.3 Results 
7.3.1 Secondary Structure Predication and Phyre2 modelling of CD0386 










Species Description Reference 
1 3KPT B .cereus BcpA, major pilin (Budzik et al., 2009) 
2 2WW8 S. pneumoniae RrgA, pilus adhesin (Izoré et al., 2010) 
3 2XIC S. pyogenes SPY0125, pilus adhesin (Pointon et al., 2010) 
4 3HTL C. diptheriae SpaA, major pilin (Kang et al., 2009) 
5 3UXF A. oris FimP, Fimbral pilin (Persson et al., 2012) 
6 2PZ4 S. agalactiae GBS52, minor pilin, adhesin (Krishnan et al., 2007) 
7 3RPK S. pneumoniae RrgB, major pilin (Paterson and Baker, 
2011) 
8 2XTL S. agalactiae BP-2a, major pilin (Necchi et al., 2011) 
9 2X9Y S. pneumoniae RrgB, major pilin (Spraggon et al., 2010) 
10 2X5P S. pyogenes Fbab-B (Oke et al., 2010) 
 
 
Figure 7.3.1 – Phyre2 Analysis of CD0386 - Alignment of the 10 highest scoring profile-
profile matches 
Rank                                                       Alignment Schematic  
N C 
Table 7.3.1 – Phyre2 Analysis of CD0386 - Details of the 10 highest scoring profile-profile 
matches 
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Models  of CD0386 produced by Phyre2 based upon the four highest-scoring profile-profile 



















7.3.2 – Design of CD0386N 
CD0386N was designed to encompass the area with predicted structural homology to bacterial 
pilins and the N-terminal region with no detected structural homologues. Its amino acid sequence is 
detailed in Appendix A. Cloning, expression and purification of CD0386N was as described in 
Chapter 4 (Section 4.3.6). 
7.3.2 – In silico Modelling of CD0386. Homology/threading models of CD0386 
produced by Phyre2 based upon (A) B. cereus BcpA (B) S. pyogenes SPY0125 (C) C. 
diptheriiae SpaA (D) S. pneumoniae RrgA 











7.3.3 Crystallisation and test diffraction of CD0386N 
Crystals were observed in well C11 of the Clear Strategy Screen 1, a condition composed of 0.2M 
KSCN, 0.1M sodium cacodylate pH6.5 and 15% PEG 4k (Figure 7.3.3 A). Optimisation to pH 5.5 
yielded larger clusters of crystals (Figure 7.3.3 B) which were broken and subject to X-ray 
diffraction at Beamline I-04 of the Diamond Light Source on 30
th























Figure 7.3.3 – Crystallisation and Test Diffraction of CD0386N. (A) Crystals grown in 
0.2M KSCN, 0.1M sodium cacodylate pH6.5 and 15% PEG 4k. (B) 0.2M KSCN, 0.1M 
sodium cacodylate pH5.5 and 15% PEG 4k. (C) Test diffraction of crystals shown in 
panel B (the hatched circle represents a resolution of 8Å). 
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7.4 Analysis and Discussion 
7.4.1 Secondary Structure Predication and in silico Modelling of CD0386 
The Phyre2 program performs prediction of protein structures based upon secondary structure 
prediction, homology modelling and threading. At the core of the system is a ‘fold library’ 
constructed by analysis of solved structures deposited in the Structural Classifications of Proteins 
(SCOP) database (Murzin et al., 1995). Upon submission of a protein sequence to Phyre2, the 
server uses three separate programs to predict the secondary structure of the query protein. This 
secondary structure profile is combined with a PSI-BLAST search of the fold library to identify 
distant sequence homologues. The combined secondary structure and PSI-BLAST profile of the 
query protein is then used to search the fold library by profile-profile matching, identifying and 
scoring proteins with predicted structural homology. Homology modelling and threading is then 
performed including modelling of insertions and deletions. 
Phyre2 identified with high confidence several structural homologues of CD0386N. All of the 
highest scoring matches are with structures of bacterial pilins, either major structural pilins or 
minor functional pilins. However, it is noteworthy that CD0386 does not appear to be pilus-
associated in C. difficile, as it is monomeric when isolated from cell walls (see Section 5.3.5) and 
does not contain the characteristic ‘YPKN’ motif which acts as transpeptidation acceptor 
nucleophile in the pilus-associated sortase reaction (Budzik et al., 2008a)  
Two of the structures identified as putative homologues of CD0386 exhibit unusual structural 
features – the BcpA pilin of B.cereus contains two intramolecular amide (‘isopeptide’) bonds, 
while the S. pyogenes contains two isopeptide bonds and an intramolecular thioester bond. These 
features are presumably required for stabilisation of the proteins to fulfil their functions. The 
formation of amide bonds results in a loss of mass of 18Da corresponding to elimination of a water 
molecule – such a mass change is not observed in CD0386 (see Section 4.3.6) but may be masked 
by other modifications. 
Modelling of CD0386 by Phyre2 produces structures which appear superficially similar, each 
featuring an overall linear structure composed of two or three β-fold domains. However, closer 
inspection reveals significant differences in the domain arrangement, with the linear structure 
formed by either a contiguous (eg. Fig. 7.3.2 A) or non-contiguous (eg. Fig. 7.3.2 C) arrangement 
of the β fold domains. This highlights a particular shortcoming of in silico modelling, as the 
program has confidently identified the folds of discrete domains, but is not able to predict how 
these domains are arranged to form the whole protein.  
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Based upon this in silico analysis, a 61kDa fragment was designed (CD0386N) encompassing both 
the pilin-like domain and the N-terminal domain for which Phyre2 did not detect any fold 
homology. 
7.4.2 Crystallisation and Test Diffraction of CD0386 
CD0386N crystallised readily in the conditions of 0.2M KSCN, 0.1M sodium cacodylate pH5.5 
and 15% PEG 4k. X-ray diffraction was performed, but diffraction was poor, with a low number of 
reflections and with a maximum resolution of <8Å. However, the observed diffraction pattern was 
characteristic of protein diffraction.  
Having established that the crystals grown under these conditions are proteinaceous, further 
optimisation is required  - general discussion on the optimisation of crystallisation was provided 
previously, in Section 6.5.2.  
7.5 Conclusions 
Preliminary in silico analysis of the sortase-anchored protein CD0386 suggests that it possesses 
homology to several bacterial pilins, several of which perform adhesin functions. A 61kDa N-
terminal fragment of CD0386 (named CD0386N) has been crystallised and subjected to test 
diffraction. Further optimisation of crystallisation is very likely to lead to solution of a structure of 












Chapter 8 – Biochemical Characterisation of the C. difficile 
SrtB reaction 
8.1 Introduction 
8.1.1 Sortase Assay Methodologies 
Initial investigations of sortase activity (eg. Ton-That et al., 1999) employed a detection technique 
based on Förster Resonance Energy Transfer (FRET). The principle of FRET is based upon the 
observation that if a fluorescent molecule emits light at a wavelength overlapping the excitation 
wavelength of a sufficiently proximal acceptor fluorophore, the acceptor molecule will be 
stimulated to fluoresce (Gadella, 2009). The transfer of energy is via a ‘virtual photon’ rather than 
emitted light, hence why the commonly-used description of ‘Fluorescence Resonance Energy 
Transfer’ is considered potentially misleading. 
As the efficiency of energy transfer between the donor and acceptor pair depends upon the distance 
between them, FRET can be used as a dynamic ‘molecular ruler’. Indeed, the first proof-of 
principle implementation of FRET in a biological context was to measure the lengths of polyprolyl 
peptides ranging from 12Å to 46Å in length, confirming that FRET efficiency is a function of the 
inverse sixth power of the distance between the donor and acceptor (Stryer and Haugland, 1967). In 
its simplest implementations, FRET can be used as a purely qualitative indicator of whether two 
molecules are in close proximity. This is particularly useful for peptide cleavage assays – the length 
of a typical peptidase probe is typically short enough for FRET to occur between fluorophores 
coupled to the N- and C-termini of the peptide. Cleavage of the probe separates the two 
fluorophores, and as they diffuse in the reaction solvent, FRET is lost and fluorescence of the 
acceptor is lost. With the availability of fluorimetric microtitre plate readers, the approach is highly 









Figure 8.1 – FRET as a technique for assaying cleavage of a peptide probe. (1) Donor and 
acceptor are held in close proximity by the probe molecule. (2) Upon excitiation of the donor, 
FRET results in fluorescence of the acceptor molecule. (3) Cleavage of the probe results in a loss 
of FRET coupling and hence a reduction in fluorescence of the acceptor. 
Donor Acceptor 
1                                             2                                                3 
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There is, however, an inherent weakness in the use of FRET for the study of enzymes. At the very 
high substrate concentrations which are often necessary in KM  determination experiments, probe 
molecules engage in non-specific absorption, whereby the donor moiety of one peptide engages in 
FRET with the acceptor of another discrete molecule. These ‘inner filter effects’ severely limit the 
utility of FRET for quantitative kinetic studies but it remains a very useful tool for qualitative 
studies, eg. probing substrate specificity and for inhibitor studies where a high throughput 
methodology is required. An additional limitation of FRET in the context of sortase enzymes is that 
it only assays cleavage of the CWSS-mimic probe – formation of the transpeptidation product 
cannot be assessed. 
Early kinetic characterisation of S. aureus SrtA activity was performed by FRET in spite of the 
above limitations. Using a probe mimicking the ‘LPETG’ SrtA CWSS coupled to Dabcyl and 





(Ton-That et al., 2000). However, when this work was repeated using a High 
Performance Liquid Chromatography (HPLC) method to robustly quantify the reaction products, it 
was found that the parameters reported by the FRET experiments were substantially erroneous, 
confirmed by the observation of quenching effects at fluorescent substrate concentrations above 
25µM. The revised KM was 5.5mM while the true kcat was determined to be 0.27 s
-1
 (Kruger et al., 
2004c). Both parameters represent remarkable increases from the initially reported figures. 
8.1.2  - Introduction to Liquid Chromatography Coupled Mass Spectroscopy (LC-MS) 
Liquid chromatography coupled mass spectroscopy (LC-MS) has rapidly become a standard 
technique in analytical laboratories  and is now finding wide and varied applications in research. 
Mass spectroscopy is not well suited to analysing complex samples, but by separating samples via 
HPLC directly prior to analysis, this weakness is overcome by the extraordinary ability of HPLC to 
separate molecules. Typically, the HPLC step is performed on an ultra high performance (uHPLC) 
reverse phase column with a bore of <1mm. On exiting the column, the sample flow passes directly 
into the electrospray ionisation source of a mass spectrometer which may be of the time of flight 
(TOF) type for determination of mass/charge ratio or a more complex multiple-quadropole 
equipped instruments (LC-MS/MS) where further structural information is acquired. UV detection 
between the column and MS instrument is very common, providing even more information on the 
analytes. The limitations of LC-MS are essentially those of its constituent technologies – HPLC is 
unable to separate highly similar molecules such as enanantiomers, while MS is unable to 
discriminate isobaric molecues or to analyse compounds which cannot be efficiently ionised. 
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8.1.3 Aims of the work Described in this Chapter 
This chapter describes characterisation of the activity of C. difficile SrtB in vitro. The aims were to:  
1. Confirm that C. difficile SrtB cleaves an SPKTG signal as suggested by Comfort and 
Clubb (2004) and to confirm or exclude the cleavage of an NVQTG signal as speculatively 
proposed by Tulli et al (2013).  
2. Demonstrate that the enzyme is a functional sortase, capable of the whole transpeptidation 
reaction with meso-diaminopimelic acid (mDAP), the diamino acid which forms the cross-
link of the C. difficile peptidoglycan.  
3. Characterise the kinetics of the C. difficile SrtB reaction (although this was ultimately 
limited to provisional experiments). 
 
8.2 - Methods 
8.2.2 – Forster Resonance Energy Transfer (FRET) Assay of C. difficile SrtB 










SDSPKTGSD Dabcyl Edans 1392.46 
SDNVQTGDS Dabcyl Edans 1421.45 






Peptides were diluted to 50µM in reaction buffer (50mM HEPES pH7.5, 250mM NaCl). Enzyme 
(SrtB or SrtB C226A) was added to achieve a final concentration of 5µM in a reaction volume 
100µL. Reactions were assembled in the wells of a black, non-fluorescent 96-well plate and 
incubated at 37ºC. 
Fluorescence readings were taken at 0hrs and after 16hrs incubation, using a fluorimetric plate 
reader (BMG Fluostar) which was configured with an excitation wavelength of 320nm and 
detection wavelength range of 500-540nm. The fluorescence readings from the ‘buffer only’ wells 
were subtracted from all other wells, following which the increase in fluorescence was calculated 
by subtracting the values of the 0hrs plate from those after 16hr of incubation. 
Table 8.2.1 – Peptides used in FRET Sortase Assays.  Dabcyl = 4(dimethylaminoazo) 
benzene-4-carboxylic acid. Edans =  5-((2-Aminoethyl)amino) naphthalene-1-sulfonic acid 
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8.2.3 Development of a HPLC Assay for C. difficile SrtB 
A range of probe peptides (Table 8.2.2) were synthesised by Peptide Protein Research Ltd by the 
Fmoc solid phase method. 
N-terminus Sequence C-terminus 
Molecular 
Mass 
Abz SPKTG Dap(Dnp) 860 
- G Dap(Dnp) 327 
Abz SPKT - 550 
Abz NVQTG Dap(Dnp) 803 
- YSSSPKTGSSY - 1162 





High Performance Liquid Chromatography (HPLC) was performed using an Akta purifier system 
(GE Healthcare) coupled to a Supelco octadecyl silica reversed phase column of the dimensions 
4.6mm x 250mm and a particle size of 3µm. Throughout chromatographic operations, flow rate 
was 1ml/min and absorbance was recorded at 320nm, 370nm and where indicated, 280nm. Peak 
areas were calculated by integration using the evaluation module of the Akta unicorn suite and with 
subtraction of a zero baseline. Mobile phases were composed of H2O, 0.1% TFA (Buffer A) and 
ACN, 0.01% TFA (Buffer B). Two chromatographic programmes were developed: 
 
Short Program: The column was equilibrated with 20% Buffer B, 80% Buffer A. A 100µL sample 
loop was flushed with Buffer A then loaded with sample in a volume of 40uL. The injection valve 
was actuated and after flushing of the loop with 1ml of mobile phase, a gradient from 20% to 32% 
Buffer B was initiated over 12 minutes. Following the gradient endpoint, the column was flushed 
with 1 column volume of 100% Buffer B.  
 
Long Program: The column was equilibrated with 5% Buffer B, 95% Buffer A. A 100uL sample 
loop was flushed with Buffer A then loaded with sample in a volume of 40uL. The injection valve 
was actuated and after flushing of the loop with 1ml of mobile phase, a gradient from 5% to 40% 
Buffer B was initiated over 30 minutes. Following the gradient endpoint, the column was flushed 
with 1 column volume of 100% Buffer B. 
 
Table 8.2.2 – Peptides used in HPLC Sortase Assays.  
Where Abz = Aminobenzoic Acid, and Dap(Dnp) = Diaminoproprionic 
dinitrophenol. 
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8.2.4 Validation of Chromatographic Method for HPLC Assay of C. difficile SrtB 
To determine a) the linearity of the relationship between Abz-SPKTG-(Dap)Dnp and peak area and 
b) the reproducibility of the HPLC analysis, a range of standards from 1000-100µM were prepared 
and analysed in triplicate by the ‘short’ method. 
 
8.2.5 – HPLC Sortase Assay General Methods 
Reactions were performed in a buffer of 50mM Tris pH7.5, 150mM NaCl. Peptide stocks (100mM) 
stored at -80°C were thawed and diluted to the appropriate concentration in chilled reaction buffer. 
Where mDAP was required in a reaction to mimic the cell wall transpeptidation substrate, it was 
diluted to the appropriate concentration in the peptide solution. The appropriate volume of SrtB 
stock, an equivalent mass of SrtB C226A or an equivalent volume of buffer was added to chilled 
reaction tubes. Where MTSET was required in the final reaction, this was added to the buffer 
immediately before the addition of SrtB to ensure rapid inactivation of the enzyme in spite of the 
instability of MTSET in aqueous conditions. Reactions were mixed by vortexing, centrifuged for 
10s, then incubated at 37°C in a thermostatic water bath. Sampling was performed by removal of 
20µl aliquots from the reaction tubes and quenching by rapid mixing with 25mM HCl. Samples 
were frozen at -80°C until analysis. 
 
8.2.6 Generation of Progress Curves 
Abz-SPKTG-Dap(Dnp) at a concentration of 250µM was incubated with SrtB at concentrations of 
50µM, 100µM and 200µM. For each timepoint, three negative control samples were prepared, 
containing buffer only, SrtB C226A or SrtB C226A. Samples were taken at 1, 2, 3, 5, 8, 12 and 
24hrs and analysed by the short method.  
 
8.2.7 Effect of Metal Ions on SrtB Activity 
A range of of aqueous salts solutions were prepared at 500mM concentration - NaCl, KCl, CaCl2, 
MgCl, MnCl2, ZnCl2 and FeCl3 and (NH4)2SO4, in addition to a 50mM solution of 
ethylenediaminetetraacetic acid (EDTA). Assays were performed in a volume of 70µL, where the 
final concentration of the additive salt was 50mM, Abz-SPKTG-(Dap)Dnp of 250µM and a SrtB 






8.2.8 Analysis of C. difficile SrtB Reactions by LC-MS 
Liquid Chromatography Mass Spectrosopy (LC-MS) was performed by Dr Anneke Lubben of the 
Chemical Characterisation and Analysis Facility, University of Bath. 
Ultra High Performance Liquid Chromatography (uHPLC) was performed with a Dionex Ultimate 
3000 system coupled to an octadecyl uHPLC column of the dimensions 5mm x 2.1mm (ACE 
HPLC), at a flow rate of 1ml/min and a column temperature of 30°C. Mobile phases were Buffer A 
H2O, 0.1% formic acid (Buffer A) and ACN, 0.1% formic acid (Buffer B). Gradient elution was 
performed from 2-40% Buffer B over 19mins. 
UV Detection of analytes was performed at 320nm for Abz-SPKTG-Dap(Dnp) and 280nm for 
YSSSPKTGSSY. Subsequent to UV detection, flow splitting was performed to reduce the flow rate 
entering the to 0.2ml/min, following which the eluate flow was analysed by ElectroSpray 
Ionisation Mass Spectroscopy (ESI-MS) using a Bruker Microtof Q instrument in full scan mode 
(+/- 50-1500 m/z). Calibration of the ESI-MS instrument with sodium formate was performed prior 
to analysis of the samples. Analysis of spectra was performed using Bruker Compass suite. 
8.3 Results 
8.3.1 – Preliminary FRET assay of C. difficile SrtB 
Peptides Dabcyl-SPKTG-Edans, Dabcyl-TKSGP-Edans and Dabcyl-NVQTG-Edans were 
incubated for 16hrs in the presence of either SrtB or SrtB C226A. An increase in fluorescence 
relative to the SrtB C226A mutant was observed for SPKTG only. As shown, the results exhibited 
unacceptably high deviations from the mean. For this reason, and to avoid potential inner filter 









Figure 8.3.1 – Forster Resonance Energy Transfer (FRET) Assay of C. difficile 
SrtB.  Mean increase in fluorescence upon incubation of self quenching peptides with 
SrtB or SrtB C226A.  
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8.3.2 Development of a HPLC Assay for C. difficile SrtB 
To select appropriate wavelengths for monitoring of Abz-SPKTG-Dap(Dnp) and its cleavage 
products, UV spectra were obtained for Abz-SPKTG-Dap(Dnp) and its predicted cleavage products 
SPKTG-Dap(Dnp) and G-Dap(Dnp). On the basis of this analysis, 320nm was selected for 
detection of Abz-SPKT and 370nm for detection of Abz-SPKTG-Dap(Dnp) and G-Dap(Dnp). 
HPLC method development was performed empirically using the method of (Kruger et al., 2004b) 
as a starting guideline. A chromatographic method was developed to resolve all three analytes. 
However, the run time (including column equilibration) was ~40mins, which was deemed 
unacceptably lengthy considering the quantity of samples envisaged. The ‘short’ method was 
therefore developed, to capture only Abz-SPKTG-Dap(Dnp) and G-Dap(Dnp) with a run time of 
~20mins. 
Example separations of a mixture of standards corresponding to the expected cleavage products of 















Figure 8.3.2 – UV/Visible Spectra of Abz-SPKTG-Dap(Dnp) and Cleavage Product 
Standards. The absorbance of a 7mM solution of each peptide was determined at 














































































































































































































































































































































































































































































































































































































































































































































































8.3.3 Standard Curve for Quantification of Abz-SPKTG-Dap(Dnp) 
To confirm the linearity of the relationship between Abz-SPKTG-Dap(Dnp) concentration and peak 
area and the reproducibility of the analysis, a range of standards from 100-1000µM were analysed 













The slope of the standard curve show in Figure 8.3.5 represents the peak area per nanomole of 




 was used for all 









Mean Standard Deviation 












Figure 8.3.5 – Quantification of Abz-SPKTG-Dap(Dnp) by HPLC. The HPLC 
method facilitates reproducible, linear quantification in the range of 4nmol to 40nmol. 
Mean values are shown (n=3) with error bars representing +/- 1SD. 
Table 8.3.1 – Chromatographic Analysis of Abz-SPKTG-Dap(Dnp) standards. 
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8.3.4 Incubation of SPKTG and NVQTG peptides with SrtB 
Abz-SPKTG-Dap(Dnp) and Abz-NVQTG-Dap(Dnp) peptides were incubated at a concentration of 
250µM with either 100µM SrtB, 100µM SrtB C226A or 100µM SrtB treated with 1mM MTSET. 
After 16hrs incubation at 37°C, reactions were quenched with an equal volume of 25mM HCl and 
analysed by HPLC using the ‘short’ method. Molar quantities of product per reaction were 
calculated by multiplying the peak area corresponding to G-Dap(Dnp) by 8.24 and scaled to the 















Quantity of G-Dap(Dnp) Formed (nmol) 
Rpt 1 Rpt 2 Rpt 3 Mean Stdev 
SPKTG 
SrtB 4.296 3.786 3.313 3.799 0.401 
SrtB C226A 0.291 0.328 0.328 0.316 0.017 
SrtB + 1mM MTSET 0.364 0.400 0.291 0.352 0.045 
NVQTG 
SrtB 0.364 0.364 0.400 0.376 0.017 
SrtB C226A 0.328 0.255 0.291 0.291 0.030 
SrtB + 1mM MTSET 0.328 0.364 0.364 0.352 0.017 
 
 
Figure 8.3.6 – Cleavage of SPKTG and NVQTG Peptides by SrtB over 16hrs.  
Mean values (n=3) are plotted with error bars representing +/- 1SD. Asterisks (*) 
and (**) indicate a p value of <0.01 as determined by Student’s T-test. 





8.3.5 Cleavage of Abz-SPKTG-Dap(Dnp)/YSSSPKTGSSY at various concentrations of SrtB 
To select an optimum enzyme concentration for subsequent experiments, Abz-SPKTG-Dap(Dnp) 
was incubated with SrtB at a range of concentrations from 0-200µM. Cleavage of YSSSPKTGSSY 
was also tested. As shown, substantial cleavage of Abz-SPKTG-Dap(Dnp) was achieved in a dose 























Figure 8.3.7 – Cleavage of Abz-SPKTG-Dap(Dnp) (A) and YSSSPKTGSSY (B) 
Peptides by SrtB. Peptides at a concentration of 250µM were incubated for 16hrs with 
0, 50µM, 100µM or 200µM SrtB.  
 






8.3.6 Preliminary Progress Curves of SrtB cleavage of Abz-SPKTG-Dap(Dnp)  
To obtain provisional information on the kinetics of SrtB cleavage of the CWSS-mimetic peptide, 
Abz-SPKTG-Dap(Dnp) was incubated with SrtB at a concentration of 50µM, 100µM and 200µM 
in the presence or absence of 1mM mDAP. Due to the necessity to conserve enzyme stocks, it was 





















Figure 8.3.8 - Progress Curves of Cleavage of Abz-SPKTG-Dap(Dnp) by SrtB at 
50µM and 100µM. The open circles (SrtB) are fitted with a second order 













At all SrtB concentrations, addition of 1mM mDAP resulted in a greater total quantity of G-
Dap(Dnp) formed at 24hrs. At concentrations of 50µM and 100µM, formation of G-Dap(Dnp) was 
linear throughout the assay in the presence of mDAP, wheras in the absence of mDAP, activity 
reduced after around 8hrs, resulting in a flattening of the progress curve. 
At the enzyme concentration of 200µM, a reduction in enzyme activity was observed after 6hrs in 









Figure 8.3.9 - Progress Curves of Cleavage of Abz-SPKTG-Dap(Dnp) by SrtB 
at 200µM. Mean values are plotted (n=3), with error bars indicating +/- 1SD. 
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8.3.7 – Effect of Metal Ions and Salts on cleavage of Abz-SPKTG-Dap(Dnp) 
As the S. aureus SrtB enzyme is calcium dependent, it was considered whether low activity of C. 
difficile SrtB was due to absence of a metal cofactor.  To provide provisional information on the 
effect of various ions on activity of SrtB, Abz-SPKTG-Dap(Dnp) at a concentration of 250µM was 











Velocities of the reactions are shown in Table 8.3.3.  Addition of any divalent metal salt reduced 
velocity, as did addition of EDTA, wheras addition of ammonium sulphate resulted in a modest 
increase. Addition of KCl did not affect velocity. Of the metal salts, MnCl2 exhibited the greatest 
inhibitory effect. 
Salt Added Velocity (nmol.hr
-1
) 
Velocity (% of 
SrtB only) 
None 0.242 100% 
50mM KCl 0.236 98% 
50mM CaCl2 0.145 60% 
50mM MgCl2 0.178 74% 
50mM MnCl2 0.050 21% 
1M NH2SO4 0.334 138% 
5mM EDTA 0.178 74% 
Figure 8.3.10 - Progress Curves of Abz-SPKTG-Dap(Dnp) Cleavage in the 
Presence of Various Salts. Trend lines are drawn for a linear fit. 
Table 8.3.3 – Velocity of SrtB in the presence of various salts.  
 144 
8.3.8 LC-MS analysis Mass Spectroscopy of SrtB Reactions 
To provide mass spectroscopic confirmation of the products of the reaction between SrtB and the 
CWSS-mimetic peptides, reaction samples were analysed by LC-MS as described in Section 8.2.9. 







1 Abz-SPKTG-Dap(Dnp) 100 0 8.3.11 
2 Abz-SPKTG-Dap(Dnp) 100 1 8.3.12 
3 YSSSPKTGSSY 100 0 8.313 
4 YSSSPKTGSSY 100 1 8.3.14 
 
 
Annotated Extracted Ion Chromatographs (EICs) are shown for each of these reactions over the 
subsequent pages. Tabulated summaries of the EICs are shown in Tables 8.3.5 and 8.3.6.  
Analyte Mass 
Detection of Analyte 
Rxn 1 Rxn 2 
Abz-SPKT 550 + + 
G-Dap(Dnp) 327 + + 
Abz-SPKTG-Dap(Dnp) 860 + + 
mDAP 190  + 




 Detection of Analyte 
Mass Rxn 3 Rxn 4 
YSSSPKTGSSY 1162 + + 
YSSSPKT 768 + + 
GSSY 412 + + 
mDAP 190  + 




Table 8.3.4 – Summary of reactions analysed by LC-MS. 
Table 8.3.5 – Summary of EICs for reactions with Abz-SPKTG-Dap(Dnp). 







Figure 8.3.11 - Extracted Ion Chromatographs for Abz-SPKTG-Dap(Dnp) cleavage by 
SrtB in absence of mDAP. The UV chromatograph is shown (top) followed by EICs for 
each of the analytes. The mass of each analyte is shown at the top right of the EIC and its 














Figure 8.3.12 - Extracted Ion Chromatographs for Abz-SPKTG-Dap(Dnp) cleavage 
by SrtB in the presence of mDAP. The UV chromatograph is shown (top) followed by 
EICs for each of the analytes. The mass of each analyte is shown at the top right of the EIC 



















Figure 8.3.13 - Extracted Ion Chromatographs for YSSSPKTGSSY cleavage by SrtB 
in the absence of mDAP. The UV chromatograph is shown (top) followed by EICs for 
each of the analytes. The mass of each analyte is shown at the top right of the EIC and its 













Figure 8.3.14 - Extracted Ion Chromatographs for YSSSPKTGSSY cleavage by SrtB 
in the presence of mDAP. The UV chromatograph is shown (top) followed by EICs for 
each of the analytes. The mass of each analyte is shown at the top right of the EIC and its 
putative assignment at the bottom left. Note that intensity scales are not equivalent 
between EICs. 
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8.3.9 - Identification of a SrtB Acyl Intermediate Species by UV-HPLC and LC-MS 
Upon extended HPLC analysis of reactions between SrtB and Abz-SPKTG-Dap(Dnp), a 320nm 
absorbance peak was observed, eluting after Abz-SPKTG-Dap(Dnp) (Figure 8.3.15). This peak 
was significantly diminished when the reaction was performed in the presence of 1mM mDAP 
(Figure 8.3.16) and was not present in reactions where SrtB had been treated with the sulphydryl-
reactive inhibitor MTSET (Figure 8.3.17). Analysis of these reactions while recording absorbance 
at 280nm in addition to 320nm and 370nm revealed that the 320nm absorbance co-eluted with the 
sortase enzyme as indicated by the sole absorbance peak at 280nm. As absorption at 320nm is 
characteristic of the Abz moiety of the probe, the absorption of the sortase enzyme at 320nm is 
consistent with the formation of a stable acyl intermediate (Abz-SPKT-SrtB). 
To confirm this hypothesis, LC-MS spectra of reactions between SrtB and the two SPKTG peptides 
described in Section 8.2.3 were re-examined. For both peptides, the ion peak series corresponding 
to the mass of SrtB was accompanied by a minor peak series which was overlooked in the original 
automated analysis. Deconvolution of this minor peak series revealed a mass consistent with an 
acyl-enzyme (Figures 8.3.13). 
Unfortunately, the poor absorbance of Abz precludes quantification of either the Abz-SPKT 
peptide or the acyl species, so it is not possible to estimate the proportion of enzyme in a stable acyl 
state. However, it is notable that for the SrtB reaction, the 320nm absorbance peak for the acyl 
intermediate is significant while that for Abz-SPKT is below the limit of detection, suggesting that 
‘stalling’ of the reaction at the acyl state is favoured over the hydrolysis reaction. Addition of 


























































































































































































































































































































































































































































































































































































































































































































Peak Assignment Theoretical Mass Observed Mass 
1 SrtB 28308 28306 
2 Abz-SPKT-SrtB 28840 28838 
Peak Assignment Theoretical Mass Observed Mass 
1 SrtB 28308 28307 
2 Abz-SPKT-SrtB 29058 29055 
Figure 8.3.18  - LC-MS detection of Acyl SrtB. Positive mode mass spectra of SrtB after 
reaction with (A) Abz-SPKTG-Dap(Dnp) and (B) YSSSPKTGSSY. Results of peak 




























8.4 - Discussion 
8.4.1 Preliminary Characterisation of SrtB activity by a FRET-based Assay 
The cleavage of SPKTG, TKSGP and NVQTG peptides was assessed using a FRET based assay. 
The C226A mutant was employed as a negative control, as this mutation has been demonstrated to 
abolish all activity in other sortases (Mazmanian et al., 1999). A statistically significant increase in 
fluorescence over the course of the assay was observed only when the SPKTG peptide was 
incubated with SrtB. For other peptides and for an SPKTG peptide incubated with SrtB C226A, 
modest increases were observed, presumably due to degradation of the probe during incubation 
period. 
The error in the FRET assay was very high, with standard deviations approaching the value of the 
mean for samples in which no specific cleavage was detected. This is likely attributable to the high 
gain values required in quantification of fluorescence, resulting in a low signal:noise ratio. With the 
benefit of knowledge from later quantitative experiments, it is clear that the requirement for high 
gain values was due to the poor activity of the enzyme resulting in minimal product formation. As 
the assay was intended to be purely qualitative, no efforts were made to quantify the extent of 
cleavage. This could be achieved by preparation of a standard curve, but  due to inner filter 
quenching effects discussed in Section 8.1.1, such a standard curve would not be reliable for 
quantification. 
Despite the severe shortcomings described above, the data are suggestive that SrtB cleaves SPKTG 
but not NVQTG or TKSGP, and that SrtB C226A is inactive as expected. To confirm these results 
in a more robust manner and to quantify product without interference from inner filter effects, the 
FRET assay was abandoned in preference for a HPLC-based assay. 
8.4.2 Assay of SrtB Activity by the HPLC method 
In order to provide quantitative data on the cleavage of peptides by SrtB, a HPLC-based SrtB assay 
was established, with UV detection enabled by modification of the SPKTG and NVQTG peptides 
with Abz and Dap(Dnp) at the N- and C- termini respectively. To allow robust quantification of the 
reaction participants, a set of standards was synthesised corresponding to the products of cleavage 
of the probe at the threonyl-glycl bond.  
The ‘long’ HPLC method described in Section 8.3.2 resolves both of the hydrolysis products plus 
residual intact substrate. However, the poor absorption characteristics of Abz-SPKTG render its 
quantification impractical, so resolution of this peak is not strictly necessary. A shorter method was 
therefore developed which would allow more rapid quantification of G-Dap(Dnp) and Abz-
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SPKTG-Dap(Dnp) only. Progress of the reaction could therefore be monitored either by 
appearance of the G-Dap(Dnp) or disappearance of Abz-SPKTG-Dap(Dnp). The elution order of 
standards was Abz-SPKT, G-Dap(Dnp) then Abz-SPKTG-Dap(Dnp), indicating that the Dap(Dnp) 
moiety was the major contributor to retention rather than the peptide probe. As shown in Figure 
8.3.5, detection of Abz-SPKTG-Dap(Dnp) was linear over the range from 100-1000µM and 
accuracy of injection was also good. Cleavage of an SPKTG but not NVQTG motif confirms the 
predictions of Comfort and Clubb (2004) and disproves the speculative suggestion of Tulli et al 
(2013) that the C. difficile collagen adhesin CbpA may be anchored by the C. difficile sortase via its 
NVQTG motif. 
Upon observation of poor hydrolysis of Abz-SPKTG-Dap(Dnp), it was proposed that the poor 
activity was due to steric hindrance by the relatively bulky modifications at the N- and C-termini. 
A new set of peptides was therefore synthesised, with diserine spacers at either side of the 
tetrapeptide CWSS, and tyrosine residues at the N- and C- termini to allow detection by UV 
spectroscopy at 280nm. However, as shown in Figure 8.3.7, hydrolysis of this peptide was even 
poorer than of Abz-SPKTG-Dap(Dnp). The Ser-Ser-Tyr is a significantly polar moiety relative to 
the aromatic Abz and Dnp, this may indicate that Abz-SPKTG-Dap(Dnp) participates in 
hydrophobic interactions with SrtB outside of the core pentapeptide motif. 
At sortase concentrations of 50µM and 100µM, reactions progress in a linear fashion throughout 
the assay in the presence of mDAP, whereas in the absence of mDAP product formation departs 
from the linear trend after around 6 hrs. Initial rates are similar regardless of whether mDAP is 
present or absent, but by 24hrs, the extent of cleavage is significantly greater in the presence of 
mDAP. Flattening of enzyme progress curves (reflecting a reduction in reaction rate over time), is 
generally ascribed to either exhaustion of substrate or inactivation of the enzyme. Since it is known 
that the substrate was in excess throughout the experiment, it is more likely that in this case it is 
due to changes in the enzyme. Taken in combination with the evidence of acyl intermediate 
formation presented in Section 8.3.8, it is tentatively suggested that the observed differences in 
activity in the later phases of the assay are due to accumulation of acyl (and therefore inactive) 
SrtB in the absence of mDAP. 
Given the observation of in vitro poor activity of SrtB (which will be discussed in Section 8.4.5), 
SrtB activity was assayed in the presence of metal ions to exclude the possibility of dependence 
upon metal ions for activity, as is the case in S. aureus SrtA. The opposite effect was observed, 
with SrtB inhibited by divalent cations. This result is consistent with those of Race et al (2009), 
who observed that the S. pyogenes SrtA was inhibited by Ca
2+
. In that case, the authors did not 
report testing of other metal ions or investigate the phenomenon any further. Given that the active 
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site of sortase enzymes contains a conserved histidine, a tentative mechanism for inhibition could 
be aberrant ion coordination distorting the active site. To determine whether SrtB does bind metal 
ions, a technique such as isothermal titration calorimetry could be employed. 
8.4.3 Discussion on the Poor Activity of SrtB 
Poor activity of sortase enzymes has been widely commented upon in the literature. Indeed, assay 
of S. pyogenes SrtB by a FRET based method failed to detect any in vitro activity at all (Kang et 
al., 2011). Wiener et al (2010) detected cleavage of a CWSS peptide by B. anthracis SrtB, but a 
transpeptidation reaction with mDAP could not be detected. These observations of poor activity are 
significantly at odds with observations of sortase activity in vivo. Pulse-chase experiments indicate 
that in S. aureus, SpA is anchored to the cell wall by SrtA within 2-3 min of its expression 
(Mazmanian et al., 1999). More generally, it is unlikely that an enzyme with such a low turnover 
rate would be of any benefit to an organism with a generation time of around 30mins. 
To understand this disparity between in vivo and in vitro activity, it is necessary to consider that the 
in vitro assays are very poor simulations of what occurs in vivo. Most importantly, in vitro sortase 
assays are performed in solution, wheras in vivo sorting is surface localised by definition and 
appears to occur at distinct foci co-localised with the Sec apparatus (Hu et al., 2008; Raz and 
Fischetti, 2008). This co-localisation of enzyme and substrate increases effective substrate 
concentrations in a way which is poorly represented by experiments performed in solution. 
Another consideration is the suitability of the substrates used for in vitro assays. A short peptide 
mimicking the CWSS may not be a realistic surrogate for the CWSS motif of wall-sorted substrate, 
which is part of a large protein, with the associated secondary and tertiary structure. Interactions of 
sortase enzymes with their substrates may be significantly more extensive than is currently known, 
with current structural knowledge of enzyme-substrate interactions limited to that gleaned from 
structures of sortases complexed with the same short peptides as used for kinetic studies. Indeed, 
the differences in SrtB activity towards YSSSPKTGSSY and Abz-SPKTG-Dap(Dnp) reported in 
this work indicate that interactions outside of the pentapeptide CWSS motif may be important for 
substrate recognition. 
It is notable that for convenience of soluble expression, the characterisation described in this work 
(in common with all published characterisations of sortase activity), utilised a truncated enzyme 
omitting its N-terminal hydrophobic anchor region. Wiener et al (2010) investigated kinetic 
properties of two variants with truncations of varying length, discovering that N-terminal 
truncation of the enzyme to remove the unstructured region before the short H1 increased kcat by 
20%. To explain this phenomenon, the authors offered a hypothesis that the N-terminus may 
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transiently occupy the active site and prevent substrate binding. However, this was in a class A 
sortase where a the absence of a long H1 helix places the N-terminus much closer to the active site 
than in a class B sortase. Given its spatial separation from the active site, it seems unlikely that the 
N-terminus of a class B sortase would significantly affect enzyme activity independently of its role 
in surface localisation. 
It is quite possible that the particularly poor performance of C. difficile SrtB described in this work 
is due specifically to the method by which it was prepared. Loss of activity during purification is a 
well documented phenomenon, and can occur for many reasons including aggregation, exposure to 
high temperatures and exposure to inhibitory compounds. 
The apparent inhibition of SrtB by divalent cations is a particular concern given that the 
purification method included a nickel affinity step. While addition of EDTA did not increase 
enzyme activity (indicating that no inhibitory metal ions were bound to the enzyme) it is still of 
concern that purification of the enzyme exposes it to high concentrations of a potentially inhibitory 
molecule. It would be therefore be worthwhile to assay SrtB enzyme purified by a different 
method. Hydrophobic interaction chromatography would be worthy of investigation as a first 
chromatographic step, as it performs very well as a second step in the purification of SrtB as 
described in Chapter 4. 
8.4.4 LC-MS analysis of SrtB products 
Due to its very strong ion suppression activity, TFA is not suitable as a mobile phase buffer for 
chromatography where mass spectroscopy is to be performed. However, MS compatible buffers 
such as acetic acid and formic acid often result in poor chromatography due to low ion pairing 
performance. In this experiment, replacement of TFA with formic acid did not impair resolution. 
 
The first aim of the LC-MS analysis was to confirm the identity of the cleavage products identified 
in the HPLC assay and hence confirm that cleavage occurred at the thronyl-glycyl bond of the 
peptide, as would be expected from a sortase-mediated hydrolysis reaction. Comparison of elution 
profiles with those of the standards was not sufficiently robust because, as previously discussed, the 
major contribution to retention appears to be the modifications rather than the peptides, so cleavage 
at a different position in the peptide may not significantly alter the elution profile of the probe. The 
observed product masses corresponded unequivocally with the theoretical masses of the expected 
cleavage products, confirming that cleavage was at the threonyl-glycyl bond. 
The second aim of the LC-MS analysis was to detect transpeptidation products resulting from 
reaction of the acyl enzyme with meso-diaminopimelic acid (mDAP). This was a key experiment in 
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order to definitively characterise C. difficile SrtB as a true sortase capable of a full transpeptidation 
reaction. When either of the SPKTG peptides was incubated with SrtB in the presence of mDAP, 
mass spectroscopy indicated the presence of species with masses corresponding to the expected 
transpeptidation products YSSSPKT-mDAP (939 Da) and Abz-SPKT-mDAP (721 Da). Notably, 
the hydrolysis products ‘Abz-SPKT’ and YSSSPKT were still present in reactions where mDAP 
was in molar excess, indicating that hydrolysis occurs even where a transpeptidation substrate is 
available. This may reflect the unavoidable fact that due to the reaction being performed in an 
aqueous solution, water was always in excess relative to mDAP. In vivo, hydrolysis is an 
undesirable outcome for the bacterium because it results in secretion, and hence loss, of proteins 
which were intended for surface anchoring. However, in the tightly surface-localised environment 
in which sortases operate, it is likely that the effective concentration of the transpeptidation 
substrate is sufficiently high to favour transpeptidation over hydrolysis. 
8.4.5 Identification of an Acyl SrtB Intermediate 
Although there are several proposed models for the reaction mechanism of sortase enzymes (as 
reviewed in Chapter 2), all of these mechanisms lead to a covalent intermediate state. Cleavage of 
the CWSS peptide at the threonyl-glycyl bond creates an acyl enzyme, with a thioester bond 
formed between the active site cysteine of the enzyme and the carboxyl of the P4 threonine. 
Previously, it has been demonstrated that this acyl state is detectable by mass spectroscopy (Huang 
et al., 2003).  
In this work, both chromatographic and mass spectroscopic evidence is presented for an acyl 
complex between C. difficile SrtB and an SPKT peptide. It is also observed that in the absence of 
the transpeptidation substrate mDAP (where hydrolysis reaction is the only means of returning the 
enzyme to its resting state), the extent of acylation is qualitatively higher. This may indicate that 
mDAP is a better nucleophile than water with regard to attack on the acyl enzyme. However, the 
generally poor performance of SrtB prevents any firm conclusions from being drawn, as it is clear 
that the enzyme is not active in a physiologically relevant manner. 
8.4.6 Limitations and Further Work 
The work described in this chapter is subject to several limitations, most of which result from the 
low in vitro activity of the enzyme. Most notably, it was not possible to determine standard 
enzymatic parameters such as Vmax and KM; doing so would have consumed vast quantities of 
enzyme and would have been entirely inappropriate, since it is clear that the in vitro activity of the 
enzyme is seriously impaired and unlikely to bear any relevance to its in vivo activity. On a more 
practical level, difficulties and delays encountered in preparing sufficient active SrtB resulted in the 
provisional kinetic data being collected in a short space of time. Without access to an automatic 
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sample loader and with an analysis time of around 30mins including sample preparation, the 
amount of work which could be performed in the available time was very limited. The use of 
higher performance chromatography methods could reduce analysis time significantly – Kruger et 
al (2004) report an analysis time of 5mins. 
Poor absorption by the aminobenzoic acid moiety which tagged the N-terminus of the CWSS 
peptide prevented quantification of either the Abz-SPKT hydrolysis product, the Abz-SPKT-
mDAP transpeptidation product or the Abz-SPKT-SrtB acyl enzyme. This could be effected by 
replacement of Abz with a more strongly absorbing chromophore – alternatively, a fluorescence 
detection method for aminobenzoic acid could be employed, as has been described previously 
(Kruger et al., 2004c). 
Future work must focus on determining whether the low activity exhibited by SrtB in this work is 
an inherent property of the enzyme when in vitro, due to reasons described in Section 8.4.5, or 
whether the enzyme is becoming inactivated during purification. Proper kinetic characterisation 
may then be performed for comparison with other sortase enzymes.  
8.5 - Summary 
Due to the low activity of the enzyme as well as practical limitations, kinetic information described 
in this chapter is limited in its scope. However, development and evaluation of the highly sensitive 
HPLC and LC-MS methods as described in this chapter will be of great value for further 
investigation of the reaction. 
The results presented in this chapter support the hypothesis that the C. difficile SrtB enzyme 
cleaves an SPKTG motif rather than an NVQTG motif, and that it is capable of a transpeptidation 
reaction with meso-diaminopimelic acid (mDAP), the diamino acid which forms the cross links of 
the C. difficile peptidoglycan. Additionally, an acyl enzyme intermediate state was identified by 







Chapter 9 – General Discussion 
9.1 Clostridium difficile – Current Situation and Future Challenges 
Clostridium difficile is an archetypal opportunistic pathogen, generally living within us as a 
harmless commensal organism and only causing disease in very specific circumstances. The 
iatrogenic depletion of gut flora which leads to C. difficile infection has only occurred on a large 
scale very recently, as an ironic consequence of the development of potent broad-spectrum 
antibiotics. While C. difficile was well known to clinicians from the 1970s onwards, it was not until 
the dramatic change in its epidemiology in the early 2000s that it became a pathogen of widespread 
public concern. The notoriety of nosocomial pathogens and their effect on the confidence of 
patients  cannot be underestimated - a poll of 1,040 people in 2008 revealed that hospital infections 
were the primary concern of NHS patients, with 40% of respondents most concerned about 
infection risk, more than those concerned about waiting lists, understaffing or poor quality of care 
(ICM/BBC, 2008). 
While it is encouraging to observe the current downward trend in C. difficile cases since the peak 
epidemic years (Figure 1.1.3), there is good reason to remain vigilant. There are growing reports of 
C. difficile infection in the wider community, including those with no exposure to antimicrobial 
therapy and in persons of much lower age than traditionally associated with nosocomial C. difficile 
infection (Khanna et al., 2012; Kutty et al., 2010). C. difficile cannot, therefore, be regarded purely 
as a healthcare associated infection. Just as its epidemiology changed abruptly with the introduction 
of clindamycin in the 1970s, future changes in human health may precipitate similar shifts in 
susceptibility. Even without expanding its reach into new populations, C. difficile is likely to be a 
growing problem over future decades due to the continuing expansion of the traditional at-risk 
populations, most notably the elderly and particularly those requiring prolonged hospitalisation or 
residential care. 
One of the cornerstones of the management of C. difficile outbreaks is ‘antibiotic stewardship’, the 
reservation of certain antibiotics for specific infections and heavy regulation of the 
fluoroquinolones and third generation cephalosporins. However, C. difficile also poses a major 
challenge to the concept of antibiotic stewardship, as vancomycin is an antibiotic of last resort for 
Enterococcus sp. and Staphylococcus sp. yet it is the ‘gold standard’ for  treatment for C. difficile 
infection. This is a particular concern given that patients at risk of C. difficile are also more likely 
to be at risk of developing other nosocomial infections due to advanced age and higher rates of co-
morbidity (Loo et al., 2011). 
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Current therapies for C. difficile are inadequate. While effective in killing C. difficile, vancomycin 
and metronidazole both suppress the glut flora even further, a ‘fighting fire with fire’ approach that 
leads to multiple relapses, ongoing misery for patients and serious financial consequences for 
healthcare providers; it has been estimated that 94% of the cost of C. difficile infection is related to 
increased duration of hospital stay (Wilcox et al., 1996). The recently introduced antibiotic 
Fidaxomycin is a promising development, especially with regard to prevention of relapse, but it 
continues to rely upon the principle of treating an antibiotic-associated infection with further 
antibiotics. The case for novel, non-antibiotic therapies is perhaps stronger for C. difficile than for 
any other organism.  
9.2 The Imperative for Novel Therapeutics 
Arguably one of the greatest achievements of the 20
th
 century was the conquering of bacterial 
pathogens through improved sanitation, vaccination and development of antibiotics. To the casual 
observer in the late 20
th
 century, it could have appeared that bacteria were no longer a threat to 
human health in the developed world. With the exception of rapidly fulminating infections such as 
those of B. anthracis and N. meningitidis, there are few infections which cannot be successfully 
treated with currently available antibiotics. As well as their therapeutic applications, the 
prophylactic use of antibiotics has facilitated countless other advances in medicine, allowing 
development of modern surgery and the treatment of patients who are immunocomprimised. 
Despite this apparent progress, we are undoubtedly heading towards a major microbial challenge in 
the 21
st
 century. Of the 13 classes of antibiotics, all but four were discovered before 1960. While 
the discovery of antibiotics has stalled, the evolution of antibiotic resistance in bacteria has 
continued unabated, rapidly depleting the treatment options available to clinicians. It is quite 
remarkable that in a period of less than 100 years, a minute fraction of human history, humankind 
has conquered bacterial pathogens, only to face a return to the widespread occurrence of 
untreatable infections, the so-called ‘post-antibiotic era’. The first portents of this era are already 
upon us, with the emergence of several pathogens which are resistant to their traditional ‘last 
resort’ antibiotic, among them the Vancomycin Resistant Enterococcus spp. (VRE), the 
Carbepenam Resistant Enterobacteriaceae (CRE) and Totally Drug Resistant M. tuberculosis 
(TDR-TB) (Courvalin, 2006; Migliori, 2007). 
With regard to C. difficile, acquisition of antibiotic resistance presents unusually complex 
consequences. Not only does resistance to a particular antibiotic rule out its use for treatment of 
CDI, it can also trigger CDI in C. difficile-carrying patients who are given the antibiotic for 
treatment of an unrelated infection. Indeed, increasing resistance to the quinolones is one of the 
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factors implicated in the changes in C. difficile epidemiology in the early 2000s, including the 
emergence of the epidemic 027 strains, which are quinolone resistant (Pepin et al., 2005a). 
While the phenomenon of declining antibiotic discovery is often cited as an example of market 
failure, with pharmaceutical companies preferring development of more profitable drugs, a 
downward trend in discovery has been observed across all classes of drug in spite of year-on-year 
increase in research spending (Powers, 2004). It is therefore simplistic to assume that the solution 
to the antibiotic crisis is to increase funding for traditional antibiotic discovery programmes. New 
approaches to the problem are clearly required in addition to intensification of current efforts. 
The majority of existing antibiotics target either cell wall synthesis, protein synthesis or nucleic 
acid synthesis, and as these antibiotics were mostly developed from secondary metabolites of other 
microorganisms, the choices of target were largely a result of nature. In the era of genomics, 
proteomics, systems biology and high throughput structural biology, the potential exists to reverse 
engineer the metabolic and pathogenic processes of bacteria and create ‘designer antibiotics’ based 
upon novel targets that nature may have overlooked. Strutural biology provides particular 
opportunities for development of ‘designer drugs’ with the emerging technology of structure-based 
drug design. 
The principle of targeting bacterial virulence rather than bacterial metabolism is currently limited 
to treatment of toxin-mediated disease – anti-toxin therapy is routinely used for treatment of 
botulinum toxin poisoning, was used historically for the treatment of Clostridium tetani infection 
and has been demonstrated for the experimental treatment of C. difficile infection (Roberts et al., 
2012). However, there have also been several experimental demonstrations of therapies targeting 
non-toxin virulence factors. For example, the small molecule Virstatin has been shown to protect 
infant mice from infection with Vibrio cholera by inhibiting the dimerisation of a transcriptional 
regulator ToxT and consequently inhibiting the expression of the toxin-coregulated pili (Hung et 
al., 2005; Shakhnovich et al., 2007). In another example, inhibitory autoinducing peptides which 
interfere with quorum sensing in S. aureus have been shown to inhibit abscess formation in a 
mouse model (Wright et al., 2005). It is noteworthy that even if these strategies prove to be poorly 
efficacious in comparison with current antibiotic therapies, virulence factors may seem much more 
attractive as therapeutic targets in the post-antibiotic era. For example, virulence-targeted therapies 
could be used for mild infections, while the antibiotics which remain effective could be reserved 
for severe infections. 
One of the most interesting yet challenging aspects of targeting bacterial virulence is that such 
therapies would not be bactericidal, but merely inhibit the organism’s ability to cause disease. A 
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considerable advantage of this is that a drug which does not kill bacteria is unlikely to exert a 
strong selective pressure for resistance (Since the pathogen gains considerable advantage from 
inhabiting the host, it would be incorrect to assume that there would be no selective pressure). 
Unfortunately, merely inhibiting pathogenesis leaves the patient’s immune system to clear the 
infection. This is a particular problem because many infected patients are immunocomprimised, 
either as a consequence of their infection or due to their underlying poor health. Again, it is likely 
that bactericidal antibiotics would be preferred for such patients. 
9.3 Sortase Enzymes as Targets of Novel Therapeutics 
Sortase enzymes offer an intriguing target for treatment of bacterial infection by inhibition of 
virulence. One of the difficulties of targeting virulence is that it is often highly multifactorial – S. 
aureus is an extraordinary example of this, possessing a vast array of virulence factors ranging 
from adhesion and immunoevasion factors to siderophores and toxins (Liu, 2009). Because sortase 
enzymes are at the centre of a pathway which processes multiple virulence factors, targeting a 
sortase enzyme could effectively target a large number of virulence factors simultaneously. Also, 
as with many antibiotic targets, sortases are an exclusively bacterial family of enzymes, so a 
specific sortase inhibitor is unlikely to exhibit off-target effects. The closest functional homologues 
of sortase enzymes in humans are likely to be the structurally unrelated cysteine proteases such as 
the calpains, caspases and selected cathepsins. 
For an organism to be a viable target for an anti-sortase therapy, several conditions must be met. 
The organism must possess a sortase, the sortase must anchor proteins which are essential for 
virulence, and inhibition of the sortase must abolish functional presentation of the essential 
proteins.  
The discovery that the S. aureus sortase is essential for virulence in a mouse model (Mazmanian et 
al., 2000) led to much interest in sortase inhibitors as therapeutics. The sole report of in vivo testing 
of a sortase inhibitor for treatment of S. aureus infection offers some encouraging results – 
administration of (Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile (DMMA) 
reduced mortality in mouse models of kidney infection and joint infection, and while the authors 
noted some evidence of toxicity at high doses, the drug remained effective at a non-toxic dose. (Oh 
et al., 2010).  
It is disappointing that no further in vivo testing of sortase inhibitors has been reported, given the 
number of S. aureus sortase inhibitors which have been identified in vitro.  It is not clear whether 
this is due to a genuine lack of experiments or a consequence of non-disclosure of results, positive 
or otherwise.  
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9.4 Contribution of This Work to the Field. 
This work represents the first investigation of any kind into the sortase enzyme of Clostridium 
difficile, representing a valuable contribution to the fields of both sortase biology and the biology of 
the C. difficile cell surface. The major shortcomings of the work are the lack of a genetically 
complemented C. difficile 630 srtB::erm mutant and the reliance upon a C226A mutant C. difficile 
SrtB for structural studies. Detailed discussions on these points have been made in the relevant 
chapter discussions, along with plans for remedy of the shortcomings. 
Adhesion is thought to be a key step for C. difficile infection, as histological investigations 
demonstrate clear association of bacteria with the mucosa (Goulding et al., 2009). As seen in other 
toxigenic bacteria such as C.diptheriae, adhesion is likely to provide a twofold advantage to C. 
difficile, securing the bacterium’s colonisation of its niche while ensuring that its toxins are 
delivered directly to the host. Although several investigations have identified proteins which appear 
to play a role in adhesion in vitro eg. Fbp68 (Hennequin et al., 2003) and CbpA (Tulli et al., 2013), 
no ‘essential’ C. difficile adhesin has yet been discovered. It is likely that in C. difficile, as in 
organisms such as S. aureus, adhesion is multifactorial. Multifactorial adhesion is an ideal case for 
sortase enzymes as targets of anti-infectives, because in the case of a species with multiple sortase-
anchored adhesins, inactivating the sortase can prevent surface localisation of several adhesins 
simultaneously. The rationale of investigating the C. difficile sortase was to determine whether, as 
is clearly the case in S. aureus, the C. difficile sortase is required for virulence and therefore 
represents a novel target for a therapeutic.  
At the time of conception of the work, it was a widely-held belief among many investigators that 
the sortase was an essential gene in C. difficile (Wren, 2011, Personal Communications via Dr Jon 
Kirby, Public Health England), based upon many unsuccessful attempts to inactivate the srtB gene 
using the Clostron system. However, such a hypothesis is not consistent with current knowledge of 
sortases in other species, as no sortase has yet been characterised as essential. It is also not 
consistent with the in silico predicted repertoire of the C. difficile sortase, as none of the predicted 
wall-sorted proteins possess putative functions of an essential nature. The results presented in 
Chapter 5 clearly contradict any suggestion that the C. difficile sortase is essential for survival of 
the organism – in fact, the rate of growth is identical in the wild type and sortase mutant. 
The demonstration that the surface protein CD0386 is anchored to the peptidoglycan by SrtB 
provides a proof of principle that a sortase-mediated wall anchoring system operates in C. difficile. 
An opportunity now exists to comprehensively characterise the repertoire of the C. difficile sortase. 
The ideal approach would be comparative proteomic characterisation of the peptidoglycan-
anchored proteome of the wild type and sortase knockout to definitively identify a population of 
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surface proteins, followed by biochemical, biophysical and structural investigation of those 
proteins identified as being anchored by the sortase. 
The finding that the C. difficile srtB::erm mutant retains full virulence in the Syrian hamster model 
casts serious doubt upon the role of SrtB in pathogenesis. However, as discussed in Section 5.4.9, 
the hamster model is limited it its scope, and investigation of the sortase in an alternate model may 
be of merit if comprehensive studies on the phenotype of the mutant and in vitro characterisation of 
the sortase repertoire suggest that there are species-specific factors which may be poorly replicated 
in the hamster model. 
Biochemical characterisation of SrtB, as described in Chapter 8, indicates a preference for an 
SPKTG sorting signal over an NVQTG signal, confirming the prediction of Comfort and Clubb 
(2004) and casting doubt upon the assertion of Tulli et al (2013) that the NVQTG-bearing collagen 
binding protein CbpA may be a sortase substrate. In addition, LC-MS analysis of the reaction 
products of SrtB and an SPKTG peptide clearly demonstrates that SrtB is a functional sortase 
capable of cleaving the peptide at the threonyl-glycyl bond and subsequently catalysing a 
transpeptidation with mDAP, the cross linking amino acid of the C. difficile peptidoglycan. 
As discussed in Section 6.5.3, there are significant gaps in knowledge of the structure/function 
relationships of the sortase enzymes, particularly regarding recognition of their two substrates. The 
limited number of available sortase structures hampers interpretation, making it more difficult to 
identify structural elements which are conserved across all sortases or conserved within sortase 
classes. Once published, the C. difficile SrtB structure will be only the fourth SrtB structure and the 
third SrtB not associated with pilus biogenesis. By adding to the pool of SrtB structures, the C. 
difficile SrtB will aid in the general interpretation of sortases of all classes. As further experiments 
are performed in other species, re-interpretation of the structure of C. difficile SrtB may yield yet 
more information, and conversely further experiments regarding substrate recognition by the C. 
difficile SrtB will aid in interpretation of other sortases. 
Early characterisations of the class B sortases of S. aureus, B. anthracis and L. monocytogenes led 
to the general classification of the class B subfamily as fulfilling a specialised role in iron 
regulation. The discovery that the S. pyogenes pilus-associated sortase is a class B enzyme 
provided the first indication that this generalisation may not be of value. Solving the structure of 
the C. difficile sortase has allowed its clear classification as a class B sortase, despite its putative 
repertoire lacking any association with iron acquisition or regulation. This casts clear doubt upon 
the paradigm. Indeed, the list of putative sortase-anchored proteins identified in C. difficile (see 
Section 5.3.2) is more suggestive of a ‘housekeeping’ sortase such as S. aureus SrtA. 
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While it is clear why bacteria such as S. aureus and L. monocytogenes have a regulatory necessity 
to segregate housekeeping sortase activity from specialised iron-associated anchoring, it is not clear 
why these enzymes are structurally different, since segregation is achieved by differences in the 
CWSS, and the regions of structural divergence (namely the additional helices) are not placed to 
directly interact with the substrates. Differences may be purely topological – the additional helix at 
the N-terminus of SrtB enzymes places the active site facing towards the cell surface, whereas in 
SrtA it faces away from the cell surface. Another hypothesis is that the differences in structure 
between SrtA and SrtB reflect wider differences in the cellular distribution or localisation of the 
enzymes. Studies into localisation of class A sortases in S. mutans and S. pyogenes (Hu et al., 2008; 
Raz and Fischetti, 2008) have produced some very interesting results, and it would be very 
interesting to expand these investigations in other species and other sortase classes. 
9.5 - Concluding Remarks 
Within this thesis is described the first investigations into the sortase enzyme of the opportunistic 
pathogen C. difficile, comprised of in vitro and in vivo studies on a sortase gene knockout strain, 
structural characterisation of the sortase by X-ray crystallography, preliminary analysis of its 
reaction by biochemical techniques and crystallisation of one of the putative sortase-anchored 
proteins.  
These results represent a novel contribution to the field of C. difficile cell biology and more 
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A1.2 Amino Acid Sequences  
 






Theoretical Mass =  28307.6 





Theoretical Mass = 28275.5 














Theoretical Mass = 110589.3 
Theoretical Mass following thrombin cleavage = 109622.3 
 
 















Theoretical Mass = 110010.8 
 









Theoretical mass = 62630.9 
Theoretical mass following thrombin cleavage = 61111 
 
 
